[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fYHDdQlqWo0FHc0zucsj-L-8L4Y0dgJAE236_M6QFooM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"University of British Columbia",[4],1308,false,208,78,1902130,48,1037,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Stroke",23,{"name":18,"count":19},"Spinal Cord Injuries",22,{"name":21,"count":22},"Healthy",21,{"name":24,"count":25},"Pregnancy",19,{"name":27,"count":28},"Type 2 Diabetes",18,{"name":30,"count":31},"Cystic Fibrosis",16,{"name":33,"count":31},"Pain",{"name":35,"count":36},"Depression",15,[38,43,48,52,57,62,67,71,76,81],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04234191","Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine\u002FNaloxone for Treatment of Opioid Use Disorder","2025-01","Buprenorphine\u002Fnaloxone",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04342039","Epigenetic Health Benefits of Budesonide","2025-12-31","Budesonide Nasal",{"nctId":49,"briefTitle":50,"date":46,"intervention":51},"NCT03615742","Diesel Exhaust Induces Glucocorticoid Resistance","Budesonide",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05089604","Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations","2026-01-01","Tacrolimus, Immediate Release,",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT03941132","Clinical Phase II\u002FIII Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)","2026-02-01","Ustekinumab",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05261321","Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure","2026-03","Cannabis oil with a high ratio of THC to CBD",{"nctId":68,"briefTitle":69,"date":65,"intervention":70},"NCT05786599","Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy","methadone",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06124976","Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma","2026-04","ST-02",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04812366","Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer","2026-04-01","Apalutamide 60mg Tab",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT05193227","Sustained Release Lidocaine for the Treatment of Postoperative Pain","2026-04-27","ST-01",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,124,148,175,203,221,246,264,286,312,340,373,420,453,479,501,519,543,566,584,609,636,654,680,698,716,734,752,770,802,820,840,858,917,946,992,1018,1042,1068,1086,1104,1129,1153,1181,1199,1217,1235,1260,1287,1334,1393,1433,1469,1505,1538,1560,1595,1625,1649,1673,1698,1723,1741,1759,1777,1795,1820,1845,1872,1890,1908,1926,1951,1976,2004,2022,2046,2071,2093,2118,2140,2166,2191,2216,2234,2258,2283,2301,2325,2350,2376,2399,2421,2445,2469,2493,2521,2544,2566,2584,2608,2631,2649,2672,2696,2741,2778,2810,2846,2869,2892,2919,2944,2970,2995,3017,3041,3067,3085,3111,3138,3161,3184,3210,3228,3246,3273,3291,3309,3327,3356,3379,3402,3427,3445,3470,3488,3511,3537,3555,3582,3600,3625,3643,3661,3679,3697,3715,3733,3751,3777,3795,3818,3836,3859,3884,3902,3924,3942,3965,3991,4009,4033,4058,4076,4094,4119,4150,4183,4206,4233,4251,4269,4292,4314,4339,4362,4385,4407,4430,4457,4480,4505,4532,4555,4580,4598,4621,4645,4663,4688,4713,4739,4757,4775,4799,4822,4844,4870,4888,4910,4932,4959,4981,5003,5027,5052,5075,5101,5119,5137,5160,5178,5204,5222,5248,5279,5297,5319,5344,5362,5388,5406,5427,5449,5473,5491,5514,5537,5614,5673,5725,5765,5791,5835,5882,5912,5948,5979,6010,6040,6062,6090,6116,6150,6180,6207,6240,6265,6295,6313,6331,6349,6371,6396,6418,6441,6465,6483,6505,6523,6546,6568,6593,6616,6639,6660,6682,6706,6728,6750,6771,6795,6813,6838,6863,6885,6908,6930,6953,6976,6994,7012,7035,7056,7074,7097,7119,7145,7170,7199,7217,7235,7268,7286,7304,7322,7340,7363,7389,7407,7425,7443,7461,7479,7501,7525,7546,7570,7588,7606,7624,7646,7664,7687,7708],{"intervention":95,"totalTrials":96,"cells":97},"Pharmacological Rate Control",1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":122},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"NCT07238452","Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial","NOT_YET_RECRUITING",[91],"2032-12-01","2033-01-01","2025-12-01",1056,[119,120],"Heart Failure With Reduced Ejection Fraction","Atrial Fibrillation (AF)",[95],{"trials":123,"activeCount":100},[],{"intervention":47,"totalTrials":96,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":146},{"trials":127,"activeCount":100},[],{"trials":129,"activeCount":100},[],{"trials":131,"activeCount":100},[],{"trials":133,"activeCount":100},[],{"trials":135,"activeCount":96,"soonestReadout":46},[136],{"nctId":44,"briefTitle":45,"status":137,"phases":138,"primaryCompletion":46,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":145},"ACTIVE_NOT_RECRUITING",[91],"2027-12-31","2021-01-07",20,[143,144],"Epigenetic Effects of Intranasal Steroids","Environmental Exposure",[47],{"trials":147,"activeCount":100},[],{"intervention":149,"totalTrials":96,"cells":150},"Nerandomilast 18 mg - adult formulation",{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":173},{"trials":152,"activeCount":100},[],{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":100},[],{"trials":160,"activeCount":96,"soonestReadout":165},[161],{"nctId":162,"briefTitle":163,"status":112,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":172},"NCT07570888","This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.",[91],"2027-06","2027-07","2026-06",120,[170,171],"Pulmonary Fibrosis","Interstitial Lung Disease (ILD)",[149],{"trials":174,"activeCount":100},[],{"intervention":56,"totalTrials":96,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":201},{"trials":178,"activeCount":100},[],{"trials":180,"activeCount":100},[],{"trials":182,"activeCount":100},[],{"trials":184,"activeCount":100},[],{"trials":186,"activeCount":96,"soonestReadout":55},[187],{"nctId":53,"briefTitle":54,"status":188,"phases":189,"primaryCompletion":55,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":199},"RECRUITING",[91],"2026-12-31","2023-01-09",124,[194,195,196,197,198],"Liver Transplantation","Immunosuppression","Neurotoxicity","Tremor","Tacrolimus",[56,200],"Tacrolimus Extended Release Oral",{"trials":202,"activeCount":100},[],{"intervention":200,"totalTrials":96,"cells":204},{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":211,"PHASE4":213,"NA":219},{"trials":206,"activeCount":100},[],{"trials":208,"activeCount":100},[],{"trials":210,"activeCount":100},[],{"trials":212,"activeCount":100},[],{"trials":214,"activeCount":96,"soonestReadout":55},[215],{"nctId":53,"briefTitle":54,"status":188,"phases":216,"primaryCompletion":55,"completion":190,"start":191,"enrollment":192,"conditions":217,"interventions":218},[91],[194,195,196,197,198],[56,200],{"trials":220,"activeCount":100},[],{"intervention":222,"totalTrials":96,"cells":223},"LABA+LAMA",{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":232,"NA":244},{"trials":225,"activeCount":100},[],{"trials":227,"activeCount":100},[],{"trials":229,"activeCount":100},[],{"trials":231,"activeCount":100},[],{"trials":233,"activeCount":96,"soonestReadout":190},[234],{"nctId":235,"briefTitle":236,"status":112,"phases":237,"primaryCompletion":190,"completion":238,"start":239,"enrollment":11,"conditions":240,"interventions":242},"NCT06552364","Air Pollution and Inhaled Corticosteroids in COPD",[91],"2028-12-31","2025-04-01",[241],"COPD",[222,243],"LABA+LAMA+ICS",{"trials":245,"activeCount":100},[],{"intervention":243,"totalTrials":96,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":262},{"trials":249,"activeCount":100},[],{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":100},[],{"trials":255,"activeCount":100},[],{"trials":257,"activeCount":96,"soonestReadout":190},[258],{"nctId":235,"briefTitle":236,"status":112,"phases":259,"primaryCompletion":190,"completion":238,"start":239,"enrollment":11,"conditions":260,"interventions":261},[91],[241],[222,243],{"trials":263,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":284},{"trials":267,"activeCount":100},[],{"trials":269,"activeCount":100},[],{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":100},[],{"trials":275,"activeCount":96,"soonestReadout":46},[276],{"nctId":49,"briefTitle":50,"status":188,"phases":277,"primaryCompletion":46,"completion":46,"start":278,"enrollment":279,"conditions":280,"interventions":283},[91],"2018-12-01",30,[281,282],"Exposure to Pollution","Glucocorticoid Resistance",[51],{"trials":285,"activeCount":100},[],{"intervention":287,"totalTrials":96,"cells":288},"Tranexamic Acid",{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":310},{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":100},[],{"trials":294,"activeCount":100},[],{"trials":296,"activeCount":100},[],{"trials":298,"activeCount":96,"soonestReadout":303},[299],{"nctId":300,"briefTitle":301,"status":188,"phases":302,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT06356948","Rate of Tranexamic Acid Administration on Blood Pressure (RateTXA) Study.",[91],"2027-07-30","2027-12-30","2024-03-30",110,[308],"Healthy Participants",[287],{"trials":311,"activeCount":100},[],{"intervention":313,"totalTrials":96,"cells":314},"Nonavalent HPV vaccine",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":338},{"trials":316,"activeCount":100},[],{"trials":318,"activeCount":100},[],{"trials":320,"activeCount":100},[],{"trials":322,"activeCount":100},[],{"trials":324,"activeCount":96,"soonestReadout":329},[325],{"nctId":326,"briefTitle":327,"status":188,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":337},"NCT05495906","A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV",[91],"2026-08","2028-01","2023-07-27",275,[334,335,336],"HPV","Human Papilloma Virus","Human Immunodeficiency Virus",[313],{"trials":339,"activeCount":100},[],{"intervention":42,"totalTrials":341,"cells":342},2,{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":357,"PHASE4":369,"NA":371},{"trials":344,"activeCount":100},[],{"trials":346,"activeCount":100},[],{"trials":348,"activeCount":96,"soonestReadout":41},[349],{"nctId":39,"briefTitle":40,"status":188,"phases":350,"primaryCompletion":41,"completion":41,"start":351,"enrollment":352,"conditions":353,"interventions":355},[89],"2021-08-18",50,[354],"Opioid Use Disorder",[42,356],"Hydromorphone",{"trials":358,"activeCount":96,"soonestReadout":363},[359],{"nctId":360,"briefTitle":361,"status":188,"phases":362,"primaryCompletion":363,"completion":165,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT04893525","Evaluating Buprenorphine\u002FNaloxone Microdosing vs. Standard Dosing in Emergency Departments",[89,90],"2026-12","2021-07-23",658,[367],"Opioid-use Disorder",[42],{"trials":370,"activeCount":100},[],{"trials":372,"activeCount":100},[],{"intervention":70,"totalTrials":374,"cells":375},3,{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":416,"NA":418},{"trials":377,"activeCount":100},[],{"trials":379,"activeCount":100},[],{"trials":381,"activeCount":100},[],{"trials":383,"activeCount":96,"soonestReadout":65},[384,391,403],{"nctId":68,"briefTitle":69,"status":188,"phases":385,"primaryCompletion":65,"completion":65,"start":386,"enrollment":352,"conditions":387,"interventions":389},[89,90],"2025-03-21",[388],"Chemotherapy-induced Peripheral Neuropathy",[70,390],"duloxetine",{"nctId":392,"briefTitle":393,"status":394,"phases":395,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":401},"NCT02502175","Comparing Opium Tincture (OT) With Methadone for Medication-assisted Treatment of Opioid Use Disorder","COMPLETED",[90],"2018-03-08","2017-06-22",204,[400],"Opioid Dependence",[402,70],"opium",{"nctId":404,"briefTitle":405,"status":394,"phases":406,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":413},"NCT00175357","NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction",[90],"2007-04","2009-04","2005-03",192,[412],"Opiate Addiction",[414,415],"Methadone","Diamorphine hydrochloride",{"trials":417,"activeCount":100},[],{"trials":419,"activeCount":100},[],{"intervention":61,"totalTrials":341,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":439,"PHASE4":449,"NA":451},{"trials":423,"activeCount":100},[],{"trials":425,"activeCount":100},[],{"trials":427,"activeCount":100},[428],{"nctId":429,"briefTitle":430,"status":431,"phases":432,"primaryCompletion":433,"completion":434,"start":435,"enrollment":141,"conditions":436,"interventions":438},"NCT02117765","Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D","UNKNOWN",[88,89],"2017-02","2017-06","2015-03",[437],"Type 1 Diabetes",[61],{"trials":440,"activeCount":96,"soonestReadout":60},[441],{"nctId":58,"briefTitle":59,"status":137,"phases":442,"primaryCompletion":60,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},[89,90],"2026-11-01","2021-01-04",66,[447],"Type 1 Diabetes Mellitus",[61],{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":100},[],{"intervention":454,"totalTrials":96,"cells":455},"Cannabidiol",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":475,"NA":477},{"trials":457,"activeCount":100},[],{"trials":459,"activeCount":100},[],{"trials":461,"activeCount":100},[],{"trials":463,"activeCount":96,"soonestReadout":468},[464],{"nctId":465,"briefTitle":466,"status":188,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":474},"NCT05867849","Cannabidiol for Bipolar Depression (CBD-BD)",[90],"2029-12","2030-12","2023-10-15",360,[473],"Bipolar Disorder",[454],{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"intervention":75,"totalTrials":96,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":497,"NA":499},{"trials":482,"activeCount":100},[],{"trials":484,"activeCount":100},[],{"trials":486,"activeCount":100},[],{"trials":488,"activeCount":96,"soonestReadout":74},[489],{"nctId":72,"briefTitle":73,"status":188,"phases":490,"primaryCompletion":74,"completion":74,"start":491,"enrollment":492,"conditions":493,"interventions":496},[89,90],"2024-06-19",70,[494,495],"Urothelial Carcinoma of the Renal Pelvis and Ureter","Transitional Cell Cancer of the Renal Pelvis and Ureter",[75],{"trials":498,"activeCount":100},[],{"trials":500,"activeCount":100},[],{"intervention":390,"totalTrials":96,"cells":502},{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":509,"PHASE4":515,"NA":517},{"trials":504,"activeCount":100},[],{"trials":506,"activeCount":100},[],{"trials":508,"activeCount":100},[],{"trials":510,"activeCount":96,"soonestReadout":65},[511],{"nctId":68,"briefTitle":69,"status":188,"phases":512,"primaryCompletion":65,"completion":65,"start":386,"enrollment":352,"conditions":513,"interventions":514},[89,90],[388],[70,390],{"trials":516,"activeCount":100},[],{"trials":518,"activeCount":100},[],{"intervention":520,"totalTrials":96,"cells":521},"Apo-levocarb",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":523,"activeCount":100},[],{"trials":525,"activeCount":100},[],{"trials":527,"activeCount":96,"soonestReadout":532},[528],{"nctId":529,"briefTitle":530,"status":188,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":352,"conditions":534,"interventions":536},"NCT06626152","Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial",[89],"2026-05-30","2024-08-15",[535],"Major Depressive Disorder",[520],{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"trials":542,"activeCount":100},[],{"intervention":85,"totalTrials":96,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":560,"PHASE4":562,"NA":564},{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":100},[],{"trials":550,"activeCount":96,"soonestReadout":84},[551],{"nctId":82,"briefTitle":83,"status":188,"phases":552,"primaryCompletion":84,"completion":553,"start":554,"enrollment":168,"conditions":555,"interventions":558},[89],"2026-05-27","2021-10-27",[556,557],"Postoperative Pain","Postsurgical Pain",[85,559],"Control",{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":100},[],{"intervention":559,"totalTrials":96,"cells":567},{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":569,"activeCount":100},[],{"trials":571,"activeCount":100},[],{"trials":573,"activeCount":96,"soonestReadout":84},[574],{"nctId":82,"briefTitle":83,"status":188,"phases":575,"primaryCompletion":84,"completion":553,"start":554,"enrollment":168,"conditions":576,"interventions":577},[89],[556,557],[85,559],{"trials":579,"activeCount":100},[],{"trials":581,"activeCount":100},[],{"trials":583,"activeCount":100},[],{"intervention":585,"totalTrials":96,"cells":586},"Psilocybin-assisted Psychotherapy",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":588,"activeCount":100},[],{"trials":590,"activeCount":100},[],{"trials":592,"activeCount":96,"soonestReadout":597},[593],{"nctId":594,"briefTitle":595,"status":188,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":602},"NCT05585229","Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication",[89],"2026-08-31","2025-10-27",10,[400,601],"Chronic Pain",[585],{"trials":604,"activeCount":100},[],{"trials":606,"activeCount":100},[],{"trials":608,"activeCount":100},[],{"intervention":610,"totalTrials":96,"cells":611},"Indomethacin",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":613,"activeCount":100},[],{"trials":615,"activeCount":100},[],{"trials":617,"activeCount":96,"soonestReadout":238},[618],{"nctId":619,"briefTitle":620,"status":112,"phases":621,"primaryCompletion":238,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":629},"NCT06572917","Single-dose Prophylactic INdomethacin in Extremely Preterm Infants",[89],"2031-03-31","2025-11-01",500,[626,627,628],"Extreme Prematurity","Intraventricular Hemorrhage","Morbidity;Newborn",[610],{"trials":631,"activeCount":100},[],{"trials":633,"activeCount":100},[],{"trials":635,"activeCount":100},[],{"intervention":356,"totalTrials":96,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":639,"activeCount":100},[],{"trials":641,"activeCount":100},[],{"trials":643,"activeCount":96,"soonestReadout":41},[644],{"nctId":39,"briefTitle":40,"status":188,"phases":645,"primaryCompletion":41,"completion":41,"start":351,"enrollment":352,"conditions":646,"interventions":647},[89],[354],[42,356],{"trials":649,"activeCount":100},[],{"trials":651,"activeCount":100},[],{"trials":653,"activeCount":100},[],{"intervention":80,"totalTrials":96,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":674,"PHASE4":676,"NA":678},{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[],{"trials":661,"activeCount":96,"soonestReadout":79},[662],{"nctId":77,"briefTitle":78,"status":188,"phases":663,"primaryCompletion":79,"completion":79,"start":664,"enrollment":665,"conditions":666,"interventions":668},[89],"2021-09-21",315,[667],"Prostate Cancer",[80,669,670,671,672,673],"Abiraterone Acetate 250mg","Prednisone 5mg Tab","Docetaxel","Niraparib 100mg Oral","Atezolizumab",{"trials":675,"activeCount":100},[],{"trials":677,"activeCount":100},[],{"trials":679,"activeCount":100},[],{"intervention":669,"totalTrials":96,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":692,"PHASE4":694,"NA":696},{"trials":683,"activeCount":100},[],{"trials":685,"activeCount":100},[],{"trials":687,"activeCount":96,"soonestReadout":79},[688],{"nctId":77,"briefTitle":78,"status":188,"phases":689,"primaryCompletion":79,"completion":79,"start":664,"enrollment":665,"conditions":690,"interventions":691},[89],[667],[80,669,670,671,672,673],{"trials":693,"activeCount":100},[],{"trials":695,"activeCount":100},[],{"trials":697,"activeCount":100},[],{"intervention":670,"totalTrials":96,"cells":699},{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":701,"activeCount":100},[],{"trials":703,"activeCount":100},[],{"trials":705,"activeCount":96,"soonestReadout":79},[706],{"nctId":77,"briefTitle":78,"status":188,"phases":707,"primaryCompletion":79,"completion":79,"start":664,"enrollment":665,"conditions":708,"interventions":709},[89],[667],[80,669,670,671,672,673],{"trials":711,"activeCount":100},[],{"trials":713,"activeCount":100},[],{"trials":715,"activeCount":100},[],{"intervention":671,"totalTrials":96,"cells":717},{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":728,"PHASE4":730,"NA":732},{"trials":719,"activeCount":100},[],{"trials":721,"activeCount":100},[],{"trials":723,"activeCount":96,"soonestReadout":79},[724],{"nctId":77,"briefTitle":78,"status":188,"phases":725,"primaryCompletion":79,"completion":79,"start":664,"enrollment":665,"conditions":726,"interventions":727},[89],[667],[80,669,670,671,672,673],{"trials":729,"activeCount":100},[],{"trials":731,"activeCount":100},[],{"trials":733,"activeCount":100},[],{"intervention":672,"totalTrials":96,"cells":735},{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":737,"activeCount":100},[],{"trials":739,"activeCount":100},[],{"trials":741,"activeCount":96,"soonestReadout":79},[742],{"nctId":77,"briefTitle":78,"status":188,"phases":743,"primaryCompletion":79,"completion":79,"start":664,"enrollment":665,"conditions":744,"interventions":745},[89],[667],[80,669,670,671,672,673],{"trials":747,"activeCount":100},[],{"trials":749,"activeCount":100},[],{"trials":751,"activeCount":100},[],{"intervention":673,"totalTrials":96,"cells":753},{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":764,"PHASE4":766,"NA":768},{"trials":755,"activeCount":100},[],{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":96,"soonestReadout":79},[760],{"nctId":77,"briefTitle":78,"status":188,"phases":761,"primaryCompletion":79,"completion":79,"start":664,"enrollment":665,"conditions":762,"interventions":763},[89],[667],[80,669,670,671,672,673],{"trials":765,"activeCount":100},[],{"trials":767,"activeCount":100},[],{"trials":769,"activeCount":100},[],{"intervention":771,"totalTrials":96,"cells":772},"Lemborexant 5 mg",{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":774,"activeCount":100},[],{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":96,"soonestReadout":783},[779],{"nctId":780,"briefTitle":781,"status":112,"phases":782,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":794},"NCT06648681","Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients",[89],"2027-04-30","2025-05-01",60,[787,788,789,790,791,792,793],"Delirium - Postoperative","Cardiac Surgery","Cardiac Surgery Subjects","Orexin Antagonist","Feasibility Studies","Sleep","In-hospital Mortality",[771,795],"Control (placebo) group",{"trials":797,"activeCount":100},[],{"trials":799,"activeCount":100},[],{"trials":801,"activeCount":100},[],{"intervention":795,"totalTrials":96,"cells":803},{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":814,"PHASE4":816,"NA":818},{"trials":805,"activeCount":100},[],{"trials":807,"activeCount":100},[],{"trials":809,"activeCount":96,"soonestReadout":783},[810],{"nctId":780,"briefTitle":781,"status":112,"phases":811,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":812,"interventions":813},[89],[787,788,789,790,791,792,793],[771,795],{"trials":815,"activeCount":100},[],{"trials":817,"activeCount":100},[],{"trials":819,"activeCount":100},[],{"intervention":66,"totalTrials":96,"cells":821},{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":832,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":823,"activeCount":100},[],{"trials":825,"activeCount":96,"soonestReadout":65},[826],{"nctId":63,"briefTitle":64,"status":137,"phases":827,"primaryCompletion":65,"completion":65,"start":828,"enrollment":141,"conditions":829,"interventions":830},[88],"2022-10-15",[21],[66,831],"Cannabis oil with a high ratio of CBD to THC",{"trials":833,"activeCount":100},[],{"trials":835,"activeCount":100},[],{"trials":837,"activeCount":100},[],{"trials":839,"activeCount":100},[],{"intervention":831,"totalTrials":96,"cells":841},{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":843,"activeCount":100},[],{"trials":845,"activeCount":96,"soonestReadout":65},[846],{"nctId":63,"briefTitle":64,"status":137,"phases":847,"primaryCompletion":65,"completion":65,"start":828,"enrollment":141,"conditions":848,"interventions":849},[88],[21],[66,831],{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":100},[],{"trials":855,"activeCount":100},[],{"trials":857,"activeCount":100},[],{"intervention":859,"totalTrials":860,"cells":861},"Salbutamol",4,{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":895},{"trials":863,"activeCount":100},[],{"trials":865,"activeCount":100},[],{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":100},[],{"trials":871,"activeCount":100},[872,885],{"nctId":873,"briefTitle":874,"status":394,"phases":875,"primaryCompletion":876,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":884},"NCT01903785","Salbutamol, Pharmacogenetics and Breathing Mechanics",[91],"2014-12","2016-08","2013-05",94,[881,882,883],"Bronchoconstriction","Inhaled Salbutamol","Cycling Performance",[859],{"nctId":886,"briefTitle":887,"status":394,"phases":888,"primaryCompletion":889,"completion":889,"start":890,"enrollment":28,"conditions":891,"interventions":894},"NCT05087693","Salbutamol Use in Ozone Air Pollution by People With Asthma and\u002For Exercise Induced Bronchoconstriction (EIB)",[91],"2023-08-31","2021-11-01",[892,893],"Asthma and\u002For Exercise Induced Bronchoconstriction","Ozone Air Pollution",[859],{"trials":896,"activeCount":341,"soonestReadout":139},[897,909],{"nctId":898,"briefTitle":899,"status":188,"phases":900,"primaryCompletion":901,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":908},"NCT07037511","Effects of Salbutamol in Athletes and Implications for Screening and Sports",[92],"2029-12-31","2030-12-31","2025-10-30",64,[906,21,907],"Asthma","Effect of Drug",[859],{"nctId":910,"briefTitle":911,"status":137,"phases":912,"primaryCompletion":139,"completion":139,"start":913,"enrollment":141,"conditions":914,"interventions":916},"NCT03522831","CF Bronchodilation",[92],"2018-05-01",[915,30],"Lung Diseases",[859],{"intervention":918,"totalTrials":341,"cells":919},"Trikafta",{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":926,"PHASE4":928,"NA":930},{"trials":921,"activeCount":100},[],{"trials":923,"activeCount":100},[],{"trials":925,"activeCount":100},[],{"trials":927,"activeCount":100},[],{"trials":929,"activeCount":100},[],{"trials":931,"activeCount":341,"soonestReadout":936},[932,940],{"nctId":933,"briefTitle":934,"status":188,"phases":935,"primaryCompletion":936,"completion":936,"start":937,"enrollment":141,"conditions":938,"interventions":939},"NCT05279040","Trikafta Exercise Study in Cystic Fibrosis",[],"2027-01","2021-11-10",[30,915],[918],{"nctId":941,"briefTitle":942,"status":188,"phases":943,"primaryCompletion":139,"completion":139,"start":890,"enrollment":624,"conditions":944,"interventions":945},"NCT05200429","Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF",[],[30],[918],{"intervention":947,"totalTrials":374,"cells":948},"Prednisone",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":980},{"trials":950,"activeCount":100},[],{"trials":952,"activeCount":100},[],{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":100},[],{"trials":958,"activeCount":100},[959,970],{"nctId":960,"briefTitle":961,"status":431,"phases":962,"primaryCompletion":963,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":969},"NCT02534402","Prednisone Administration in Quiescent COPD Patients to Determine the Effect on Gene Expression",[91],"2016-12","2021-12","2015-08",40,[968],"Chronic Obstructive Pulmonary Disease",[947],{"nctId":971,"briefTitle":972,"status":394,"phases":973,"primaryCompletion":974,"completion":877,"start":975,"enrollment":976,"conditions":977,"interventions":979},"NCT01981889","Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease",[91],"2016-05","2013-10",53,[978],"Inflammatory Bowel Disease 11",[947],{"trials":981,"activeCount":96,"soonestReadout":986},[982],{"nctId":983,"briefTitle":984,"status":188,"phases":985,"primaryCompletion":986,"completion":166,"start":987,"enrollment":966,"conditions":988,"interventions":991},"NCT06453447","Prednisone for CRPS in Distal Radius Fracture",[92],"2027-05","2024-10-10",[989,990],"Complex Regional Pain Syndromes","Distal Radius Fractures",[947],{"intervention":993,"totalTrials":96,"cells":994},"Prevention of Allosensitization",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[],{"trials":1002,"activeCount":100},[],{"trials":1004,"activeCount":100},[],{"trials":1006,"activeCount":96,"soonestReadout":1011},[1007],{"nctId":1008,"briefTitle":1009,"status":112,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":41,"enrollment":1012,"conditions":1013,"interventions":1017},"NCT06802822","Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART)",[92],"2027-12",96,[1014,1015,1016],"Kidney Transplant","Kidney Transplant Failure","Immunosuppresion",[993],{"intervention":1019,"totalTrials":96,"cells":1020},"Diphenhydramine hydrochloride",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1022,"activeCount":100},[],{"trials":1024,"activeCount":100},[],{"trials":1026,"activeCount":100},[],{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":100},[],{"trials":1032,"activeCount":96,"soonestReadout":329},[1033],{"nctId":1034,"briefTitle":1035,"status":188,"phases":1036,"primaryCompletion":329,"completion":329,"start":1037,"enrollment":141,"conditions":1038,"interventions":1041},"NCT07285031","Histamines and Central Hemodynamics",[92],"2025-12",[1039,1040],"Histamine","Exercise",[1019],{"intervention":1043,"totalTrials":96,"cells":1044},"Local Anesthetic at the Umbilical Port Site",{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":1046,"activeCount":100},[],{"trials":1048,"activeCount":100},[],{"trials":1050,"activeCount":100},[],{"trials":1052,"activeCount":100},[],{"trials":1054,"activeCount":100},[],{"trials":1056,"activeCount":96,"soonestReadout":84},[1057],{"nctId":1058,"briefTitle":1059,"status":1060,"phases":1061,"primaryCompletion":84,"completion":84,"start":784,"enrollment":1062,"conditions":1063,"interventions":1065},"NCT06945263","Comparing Pain Relief Between Two Methods of Freezing Injections in Children Having Their Appendix Removed","ENROLLING_BY_INVITATION",[92],32,[1064],"Laparoscopic Appendectomy",[1043,1066,1067],"Intravenous Dexamethasone","Local Anesthetic at the Incision Site",{"intervention":1066,"totalTrials":96,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1071,"activeCount":100},[],{"trials":1073,"activeCount":100},[],{"trials":1075,"activeCount":100},[],{"trials":1077,"activeCount":100},[],{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":96,"soonestReadout":84},[1082],{"nctId":1058,"briefTitle":1059,"status":1060,"phases":1083,"primaryCompletion":84,"completion":84,"start":784,"enrollment":1062,"conditions":1084,"interventions":1085},[92],[1064],[1043,1066,1067],{"intervention":1067,"totalTrials":96,"cells":1087},{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1089,"activeCount":100},[],{"trials":1091,"activeCount":100},[],{"trials":1093,"activeCount":100},[],{"trials":1095,"activeCount":100},[],{"trials":1097,"activeCount":100},[],{"trials":1099,"activeCount":96,"soonestReadout":84},[1100],{"nctId":1058,"briefTitle":1059,"status":1060,"phases":1101,"primaryCompletion":84,"completion":84,"start":784,"enrollment":1062,"conditions":1102,"interventions":1103},[92],[1064],[1043,1066,1067],{"intervention":1105,"totalTrials":96,"cells":1106},"Vaginal DNA swab, microbiome swab and pH test",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1115,"NA":1117},{"trials":1108,"activeCount":100},[],{"trials":1110,"activeCount":100},[],{"trials":1112,"activeCount":100},[],{"trials":1114,"activeCount":100},[],{"trials":1116,"activeCount":100},[],{"trials":1118,"activeCount":96,"soonestReadout":329},[1119],{"nctId":1120,"briefTitle":1121,"status":188,"phases":1122,"primaryCompletion":329,"completion":1123,"start":1124,"enrollment":279,"conditions":1125,"interventions":1128},"NCT07194551","Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire",[92],"2027-04","2025-08-29",[1126,1127],"Endometrial Cancer","Lynch Syndrome",[1105],{"intervention":1130,"totalTrials":96,"cells":1131},"COVID-19 vaccines",{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1133,"activeCount":100},[],{"trials":1135,"activeCount":100},[],{"trials":1137,"activeCount":100},[],{"trials":1139,"activeCount":100},[],{"trials":1141,"activeCount":100},[],{"trials":1143,"activeCount":96,"soonestReadout":363},[1144],{"nctId":1145,"briefTitle":1146,"status":188,"phases":1147,"primaryCompletion":363,"completion":363,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1152},"NCT05212792","Genomics and COVID-19 Vaccine Adverse Events",[],"2022-06-24",6325,[1151],"Vaccine Adverse Reaction",[1130],{"intervention":1154,"totalTrials":96,"cells":1155},"GnRH antagonist",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1157,"activeCount":100},[],{"trials":1159,"activeCount":100},[],{"trials":1161,"activeCount":100},[],{"trials":1163,"activeCount":100},[],{"trials":1165,"activeCount":100},[],{"trials":1167,"activeCount":96,"soonestReadout":190},[1168],{"nctId":1169,"briefTitle":1170,"status":112,"phases":1171,"primaryCompletion":190,"completion":139,"start":79,"enrollment":352,"conditions":1172,"interventions":1177},"NCT07212712","The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans",[92],[1173,1174,1175,1040,1176],"Cerebral Blood Flow","Cerebral Blood Flow Regulation","Sex Differences","Vascular",[1154,1178,1179,1180],"Estradiol","Testosterone","Anastrozole",{"intervention":1178,"totalTrials":96,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1189,"PHASE4":1191,"NA":1193},{"trials":1184,"activeCount":100},[],{"trials":1186,"activeCount":100},[],{"trials":1188,"activeCount":100},[],{"trials":1190,"activeCount":100},[],{"trials":1192,"activeCount":100},[],{"trials":1194,"activeCount":96,"soonestReadout":190},[1195],{"nctId":1169,"briefTitle":1170,"status":112,"phases":1196,"primaryCompletion":190,"completion":139,"start":79,"enrollment":352,"conditions":1197,"interventions":1198},[92],[1173,1174,1175,1040,1176],[1154,1178,1179,1180],{"intervention":1179,"totalTrials":96,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1209,"NA":1211},{"trials":1202,"activeCount":100},[],{"trials":1204,"activeCount":100},[],{"trials":1206,"activeCount":100},[],{"trials":1208,"activeCount":100},[],{"trials":1210,"activeCount":100},[],{"trials":1212,"activeCount":96,"soonestReadout":190},[1213],{"nctId":1169,"briefTitle":1170,"status":112,"phases":1214,"primaryCompletion":190,"completion":139,"start":79,"enrollment":352,"conditions":1215,"interventions":1216},[92],[1173,1174,1175,1040,1176],[1154,1178,1179,1180],{"intervention":1180,"totalTrials":96,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1220,"activeCount":100},[],{"trials":1222,"activeCount":100},[],{"trials":1224,"activeCount":100},[],{"trials":1226,"activeCount":100},[],{"trials":1228,"activeCount":100},[],{"trials":1230,"activeCount":96,"soonestReadout":190},[1231],{"nctId":1169,"briefTitle":1170,"status":112,"phases":1232,"primaryCompletion":190,"completion":139,"start":79,"enrollment":352,"conditions":1233,"interventions":1234},[92],[1173,1174,1175,1040,1176],[1154,1178,1179,1180],{"intervention":1236,"totalTrials":96,"cells":1237},"MI-Coach: ED Mobile App",{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[],{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":96,"soonestReadout":165},[1250],{"nctId":1251,"briefTitle":1252,"status":188,"phases":1253,"primaryCompletion":165,"completion":1254,"start":1255,"enrollment":1256,"conditions":1257,"interventions":1259},"NCT06801197","Impact of a Mobile App-Based Waitlist Intervention on Readiness for Eating Disorder Treatment",[92],"2027-09","2025-10-21",74,[1258],"Eating Disorders",[1236],{"intervention":1261,"totalTrials":96,"cells":1262},"Hyperoxia",{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1264,"activeCount":100},[],{"trials":1266,"activeCount":100},[],{"trials":1268,"activeCount":100},[],{"trials":1270,"activeCount":100},[],{"trials":1272,"activeCount":100},[],{"trials":1274,"activeCount":96,"soonestReadout":190},[1275],{"nctId":1276,"briefTitle":1277,"status":188,"phases":1278,"primaryCompletion":190,"completion":190,"start":1279,"enrollment":966,"conditions":1280,"interventions":1286},"NCT03800017","Skeletal Muscle Function in Interstitial Lung Disease",[92],"2024-08-07",[1281,1282,1283,1284,1285],"Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis","Hypersensitivity Pneumonitis","Scleroderma","Nonspecific Interstitial Pneumonia",[1261],{"intervention":1288,"totalTrials":374,"cells":1289},"Lidocaine",{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1305,"PHASE4":1318,"NA":1332},{"trials":1291,"activeCount":100},[],{"trials":1293,"activeCount":100},[],{"trials":1295,"activeCount":100},[1296],{"nctId":1297,"briefTitle":1298,"status":394,"phases":1299,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":1302,"conditions":1303,"interventions":1304},"NCT04026945","Sustained Release Lidocaine for Treatment of Scrotal Pain",[88,89],"2021-03-24","2019-10-31",12,[601],[1288],{"trials":1306,"activeCount":100},[1307],{"nctId":1308,"briefTitle":1309,"status":394,"phases":1310,"primaryCompletion":1311,"completion":1311,"start":1312,"enrollment":11,"conditions":1313,"interventions":1316},"NCT04069169","IV Lidocaine Analgesia in Pediatric Scoliosis Surgery",[90],"2024-05-10","2019-12-18",[1314,1315],"Scoliosis; Adolescence","Anesthesia Recovery Period",[1288,1317],"Saline Solution",{"trials":1319,"activeCount":100},[1320],{"nctId":1321,"briefTitle":1322,"status":394,"phases":1323,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1330},"NCT01751347","Bupivacaine Versus Lidocaine Local Anesthesia",[91],"2015-12","2013-02",135,[1328,1329],"Carpal Tunnel Syndrome","Trigger Finger",[1331,1288],"Bupivacaine",{"trials":1333,"activeCount":100},[],{"intervention":1335,"totalTrials":374,"cells":1336},"Losartan",{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1355,"PHASE4":1376,"NA":1391},{"trials":1338,"activeCount":100},[],{"trials":1340,"activeCount":100},[],{"trials":1342,"activeCount":100},[1343],{"nctId":1344,"briefTitle":1345,"status":394,"phases":1346,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1353},"NCT00593710","Losartan Versus Atenolol for the Treatment of Marfan Syndrome",[89],"2010-10","2011-12","2008-01",17,[1352],"Marfan Syndrome",[1335,1354],"Atenolol",{"trials":1356,"activeCount":100},[1357],{"nctId":1358,"briefTitle":1359,"status":1360,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1368},"NCT04606563","Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?","TERMINATED",[90],"2022-04-22","2020-10-09",341,[1366,1367],"Covid19","SARS-CoV Infection",[1335,1369,1370,1371,1372,1373,1374,1375],"Valsartan","Azilsartan","Candesartan","Eprosartan","Irbesartan","Olmesartan","Telmisartan",{"trials":1377,"activeCount":100},[1378],{"nctId":1379,"briefTitle":1380,"status":394,"phases":1381,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1390},"NCT03335904","AT1R Blockade and Periodic Breathing During Sleep in Hypoxia",[91],"2019-08-01","2018-01-01",14,[1386,1387,1388,1389],"Sleep Disordered Breathing","Hypoxia","Respiration; Sleep Disorder","Chemoreceptor Apnea",[1335],{"trials":1392,"activeCount":100},[],{"intervention":1394,"totalTrials":341,"cells":1395},"Dexamethasone",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1415,"NA":1431},{"trials":1397,"activeCount":100},[],{"trials":1399,"activeCount":100},[],{"trials":1401,"activeCount":100},[],{"trials":1403,"activeCount":100},[1404],{"nctId":1405,"briefTitle":1406,"status":394,"phases":1407,"primaryCompletion":1408,"completion":1409,"start":1410,"enrollment":1411,"conditions":1412,"interventions":1414},"NCT01297686","Exercise Versus Corticosteroid Randomized Clinical Trial for Plantar Fasciitis",[89,90],"2012-02","2012-04","2011-05",56,[1413],"Fasciitis, Plantar",[1394],{"trials":1416,"activeCount":100},[1417],{"nctId":1418,"briefTitle":1419,"status":394,"phases":1420,"primaryCompletion":963,"completion":963,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1425},"NCT02798835","Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty",[91],"2016-07",180,[1424],"Total Knee Arthroplasty",[1426,1427,1428,1331,1429,1430,1394],"Adductor canal block","Adductor canal block with dexamethasone","Adductor canal catheter","Fentanyl","Ropivacaine 0.5% Injectable Solution",{"trials":1432,"activeCount":100},[],{"intervention":1434,"totalTrials":341,"cells":1435},"Varenicline",{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1467},{"trials":1437,"activeCount":100},[],{"trials":1439,"activeCount":100},[1440],{"nctId":1441,"briefTitle":1442,"status":394,"phases":1443,"primaryCompletion":1444,"completion":1444,"start":1349,"enrollment":1445,"conditions":1446,"interventions":1448},"NCT00832806","Smoke-Free Living Study",[88],"2011-11",100,[1447],"Additional, Effective Methods to Stop Smoking",[1434],{"trials":1450,"activeCount":100},[],{"trials":1452,"activeCount":100},[],{"trials":1454,"activeCount":100},[1455],{"nctId":1456,"briefTitle":1457,"status":1458,"phases":1459,"primaryCompletion":1460,"completion":1460,"start":1461,"enrollment":100,"conditions":1462,"interventions":1466},"NCT00702793","Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)","WITHDRAWN",[91],"2012-05","2008-04",[1463,1464,1465],"Schizophrenia","Schizoaffective","Psychosis",[1434],{"trials":1468,"activeCount":100},[],{"intervention":1470,"totalTrials":341,"cells":1471},"carbetocin",{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1476,"PHASE3":1478,"PHASE4":1480,"NA":1503},{"trials":1473,"activeCount":100},[],{"trials":1475,"activeCount":100},[],{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":100},[1482,1492],{"nctId":1483,"briefTitle":1484,"status":394,"phases":1485,"primaryCompletion":1486,"completion":1486,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1491},"NCT02636816","Cardiovascular Effects of Carbetocin Given During Elective Cesarean",[91],"2016-06","2016-03",57,[1490,24],"Effect of Carbetocin on Cardiovascular System",[1470],{"nctId":1493,"briefTitle":1494,"status":394,"phases":1495,"primaryCompletion":1496,"completion":1497,"start":1498,"enrollment":352,"conditions":1499,"interventions":1501},"NCT03716076","Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study",[91],"2019-06-15","2020-04-24","2018-11-01",[1500],"Cardiac Arrythmias",[1502],"Carbetocin",{"trials":1504,"activeCount":100},[],{"intervention":1506,"totalTrials":341,"cells":1507},"Acetazolamide",{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1514,"PHASE4":1516,"NA":1536},{"trials":1509,"activeCount":100},[],{"trials":1511,"activeCount":100},[],{"trials":1513,"activeCount":100},[],{"trials":1515,"activeCount":100},[],{"trials":1517,"activeCount":100},[1518,1527],{"nctId":1519,"briefTitle":1520,"status":394,"phases":1521,"primaryCompletion":877,"completion":877,"start":974,"enrollment":1384,"conditions":1522,"interventions":1525},"NCT02760121","AZ, MZ, and the Pulmonary System Response to Hypoxia",[91],[1523,1524],"Altitude Sickness","Hypertension, Pulmonary",[1506,1526],"Methazolamide",{"nctId":1528,"briefTitle":1529,"status":394,"phases":1530,"primaryCompletion":1531,"completion":1531,"start":1532,"enrollment":1533,"conditions":1534,"interventions":1535},"NCT02758470","Muscle Fatigue and Carbonic Anhydrase Inhibitors",[91],"2017-06-30","2016-11",13,[1387],[1506,1526],{"trials":1537,"activeCount":100},[],{"intervention":1526,"totalTrials":341,"cells":1539},{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1546,"PHASE4":1548,"NA":1558},{"trials":1541,"activeCount":100},[],{"trials":1543,"activeCount":100},[],{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":100},[],{"trials":1549,"activeCount":100},[1550,1554],{"nctId":1519,"briefTitle":1520,"status":394,"phases":1551,"primaryCompletion":877,"completion":877,"start":974,"enrollment":1384,"conditions":1552,"interventions":1553},[91],[1523,1524],[1506,1526],{"nctId":1528,"briefTitle":1529,"status":394,"phases":1555,"primaryCompletion":1531,"completion":1531,"start":1532,"enrollment":1533,"conditions":1556,"interventions":1557},[91],[1387],[1506,1526],{"trials":1559,"activeCount":100},[],{"intervention":1561,"totalTrials":341,"cells":1562},"Vitamin D",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1578,"PHASE4":1580,"NA":1593},{"trials":1564,"activeCount":100},[],{"trials":1566,"activeCount":100},[],{"trials":1568,"activeCount":100},[1569],{"nctId":1570,"briefTitle":1571,"status":394,"phases":1572,"primaryCompletion":1573,"completion":1573,"start":1574,"enrollment":966,"conditions":1575,"interventions":1577},"NCT01150877","High Dose Vitamin D Study",[88,89],"2014-04-23","2011-01",[1576],"Colorectal Cancer",[1561],{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[1582],{"nctId":1583,"briefTitle":1584,"status":394,"phases":1585,"primaryCompletion":1586,"completion":1325,"start":1587,"enrollment":1588,"conditions":1589,"interventions":1591},"NCT01112891","Vitamin D in Pregnancy and Lactation",[91],"2012-08","2010-03",225,[1590],"Vitamin D Deficiency",[1561,1592,1561],"Vitamin D3",{"trials":1594,"activeCount":100},[],{"intervention":1596,"totalTrials":96,"cells":1597},"Botulinum Toxin-A",{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1623},{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":100},[],{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[1608],{"nctId":1609,"briefTitle":1610,"status":431,"phases":1611,"primaryCompletion":963,"completion":1612,"start":1613,"enrollment":1614,"conditions":1615,"interventions":1621},"NCT01427400","The Use of Botulinum Toxin A in Two-Stage Tissue Expander\u002F Implant Breast Reconstruction",[91],"2017-12","2011-10",128,[1616,1617,1618,1619,1620],"Breast Neoplasms","Neoplasms by Site","Neoplasms","Breast Diseases","Skin Diseases",[1596,1622],"Saline",{"trials":1624,"activeCount":100},[],{"intervention":1626,"totalTrials":96,"cells":1627},"Melatonin",{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1634,"PHASE4":1636,"NA":1647},{"trials":1629,"activeCount":100},[],{"trials":1631,"activeCount":100},[],{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[],{"trials":1637,"activeCount":100},[1638],{"nctId":1639,"briefTitle":1640,"status":1458,"phases":1641,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":100,"conditions":1644,"interventions":1646},"NCT02282241","Melatonin for Delirium Prophylaxis",[91],"2021-09","2016-02",[1645],"Delirium",[1626],{"trials":1648,"activeCount":100},[],{"intervention":1650,"totalTrials":96,"cells":1651},"Progestin",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1658,"PHASE4":1660,"NA":1671},{"trials":1653,"activeCount":100},[],{"trials":1655,"activeCount":100},[],{"trials":1657,"activeCount":100},[],{"trials":1659,"activeCount":100},[],{"trials":1661,"activeCount":100},[1662],{"nctId":1663,"briefTitle":1664,"status":1458,"phases":1665,"primaryCompletion":1666,"completion":1324,"start":975,"enrollment":100,"conditions":1667,"interventions":1670},"NCT01966575","Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate",[91],"2015-09",[1668,1669],"Polycystic Ovary Syndrome","Infertility",[1650],{"trials":1672,"activeCount":100},[],{"intervention":1674,"totalTrials":96,"cells":1675},"oral anti-acid treatment",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1682,"PHASE4":1684,"NA":1696},{"trials":1677,"activeCount":100},[],{"trials":1679,"activeCount":100},[],{"trials":1681,"activeCount":100},[],{"trials":1683,"activeCount":100},[],{"trials":1685,"activeCount":100},[1686],{"nctId":1687,"briefTitle":1688,"status":394,"phases":1689,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1445,"conditions":1692,"interventions":1695},"NCT03920306","A Prospective Evaluation of Non-Operative Treatments for Gastrocutaneous Fistulae in Children",[91],"2024-09-01","2019-04-01",[1693,1694],"Gastrocutaneous Fistula","Gastrostomy Complications",[1674],{"trials":1697,"activeCount":100},[],{"intervention":1699,"totalTrials":96,"cells":1700},"tenofovir",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1709,"NA":1721},{"trials":1702,"activeCount":100},[],{"trials":1704,"activeCount":100},[],{"trials":1706,"activeCount":100},[],{"trials":1708,"activeCount":100},[],{"trials":1710,"activeCount":100},[1711],{"nctId":1712,"briefTitle":1713,"status":394,"phases":1714,"primaryCompletion":1715,"completion":1715,"start":1716,"enrollment":279,"conditions":1717,"interventions":1720},"NCT00358696","Antiretroviral Switch From Didanosine to Tenofovir in HIV\u002FHCV Co-infected Patients",[91],"2009-10","2006-07",[1718,1719],"HIV","HIV Infections",[1699],{"trials":1722,"activeCount":100},[],{"intervention":1426,"totalTrials":96,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1733,"NA":1739},{"trials":1726,"activeCount":100},[],{"trials":1728,"activeCount":100},[],{"trials":1730,"activeCount":100},[],{"trials":1732,"activeCount":100},[],{"trials":1734,"activeCount":100},[1735],{"nctId":1418,"briefTitle":1419,"status":394,"phases":1736,"primaryCompletion":963,"completion":963,"start":1421,"enrollment":1422,"conditions":1737,"interventions":1738},[91],[1424],[1426,1427,1428,1331,1429,1430,1394],{"trials":1740,"activeCount":100},[],{"intervention":1427,"totalTrials":96,"cells":1742},{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1749,"PHASE4":1751,"NA":1757},{"trials":1744,"activeCount":100},[],{"trials":1746,"activeCount":100},[],{"trials":1748,"activeCount":100},[],{"trials":1750,"activeCount":100},[],{"trials":1752,"activeCount":100},[1753],{"nctId":1418,"briefTitle":1419,"status":394,"phases":1754,"primaryCompletion":963,"completion":963,"start":1421,"enrollment":1422,"conditions":1755,"interventions":1756},[91],[1424],[1426,1427,1428,1331,1429,1430,1394],{"trials":1758,"activeCount":100},[],{"intervention":1428,"totalTrials":96,"cells":1760},{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1769,"NA":1775},{"trials":1762,"activeCount":100},[],{"trials":1764,"activeCount":100},[],{"trials":1766,"activeCount":100},[],{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":100},[1771],{"nctId":1418,"briefTitle":1419,"status":394,"phases":1772,"primaryCompletion":963,"completion":963,"start":1421,"enrollment":1422,"conditions":1773,"interventions":1774},[91],[1424],[1426,1427,1428,1331,1429,1430,1394],{"trials":1776,"activeCount":100},[],{"intervention":1430,"totalTrials":96,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1787,"NA":1793},{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[],{"trials":1784,"activeCount":100},[],{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":100},[1789],{"nctId":1418,"briefTitle":1419,"status":394,"phases":1790,"primaryCompletion":963,"completion":963,"start":1421,"enrollment":1422,"conditions":1791,"interventions":1792},[91],[1424],[1426,1427,1428,1331,1429,1430,1394],{"trials":1794,"activeCount":100},[],{"intervention":1796,"totalTrials":96,"cells":1797},"Ketamine",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1818},{"trials":1799,"activeCount":100},[],{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[],{"trials":1805,"activeCount":100},[],{"trials":1807,"activeCount":100},[1808],{"nctId":1809,"briefTitle":1810,"status":394,"phases":1811,"primaryCompletion":1812,"completion":1812,"start":1813,"enrollment":168,"conditions":1814,"interventions":1816},"NCT02753114","Prehospital Analgesia With Intra-Nasal Ketamine",[91],"2018-05-24","2017-11-06",[33,1815],"Acute Pain",[1796,1817],"Normal Saline",{"trials":1819,"activeCount":100},[],{"intervention":1821,"totalTrials":96,"cells":1822},"Lamivudine",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1831,"NA":1843},{"trials":1824,"activeCount":100},[],{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[1833],{"nctId":1834,"briefTitle":1835,"status":1836,"phases":1837,"primaryCompletion":1838,"completion":1838,"start":1839,"enrollment":1840,"conditions":1841,"interventions":1842},"NCT00143728","3TC or No 3TC for HIV With 3TC Resistance","SUSPENDED",[91],"2010-05","2004-01",152,[1719],[1821],{"trials":1844,"activeCount":100},[],{"intervention":1846,"totalTrials":96,"cells":1847},"Agriflu",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1854,"PHASE4":1856,"NA":1870},{"trials":1849,"activeCount":100},[],{"trials":1851,"activeCount":100},[],{"trials":1853,"activeCount":100},[],{"trials":1855,"activeCount":100},[],{"trials":1857,"activeCount":100},[1858],{"nctId":1859,"briefTitle":1860,"status":394,"phases":1861,"primaryCompletion":1348,"completion":1460,"start":1862,"enrollment":1863,"conditions":1864,"interventions":1866},"NCT01368796","Comparison of 4 Influenza Vaccines in Seniors",[91],"2011-07",953,[1865],"Influenza Vaccine",[1846,1867,1868,1869],"Fluad","Intanza","Vaxigrip",{"trials":1871,"activeCount":100},[],{"intervention":1867,"totalTrials":96,"cells":1873},{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1888},{"trials":1875,"activeCount":100},[],{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":100},[],{"trials":1881,"activeCount":100},[],{"trials":1883,"activeCount":100},[1884],{"nctId":1859,"briefTitle":1860,"status":394,"phases":1885,"primaryCompletion":1348,"completion":1460,"start":1862,"enrollment":1863,"conditions":1886,"interventions":1887},[91],[1865],[1846,1867,1868,1869],{"trials":1889,"activeCount":100},[],{"intervention":1868,"totalTrials":96,"cells":1891},{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1906},{"trials":1893,"activeCount":100},[],{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":100},[],{"trials":1899,"activeCount":100},[],{"trials":1901,"activeCount":100},[1902],{"nctId":1859,"briefTitle":1860,"status":394,"phases":1903,"primaryCompletion":1348,"completion":1460,"start":1862,"enrollment":1863,"conditions":1904,"interventions":1905},[91],[1865],[1846,1867,1868,1869],{"trials":1907,"activeCount":100},[],{"intervention":1869,"totalTrials":96,"cells":1909},{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1918,"NA":1924},{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"trials":1919,"activeCount":100},[1920],{"nctId":1859,"briefTitle":1860,"status":394,"phases":1921,"primaryCompletion":1348,"completion":1460,"start":1862,"enrollment":1863,"conditions":1922,"interventions":1923},[91],[1865],[1846,1867,1868,1869],{"trials":1925,"activeCount":100},[],{"intervention":1927,"totalTrials":96,"cells":1928},"NeisVac C vaccine",{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1937,"NA":1949},{"trials":1930,"activeCount":100},[],{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[1939],{"nctId":1940,"briefTitle":1941,"status":394,"phases":1942,"primaryCompletion":1943,"completion":1943,"start":1944,"enrollment":1945,"conditions":1946,"interventions":1948},"NCT00936962","Evaluation of Meningococcal C Vaccine Programmes in Canadian Children",[91],"2015-06","2009-07",452,[1947],"Meningococcal Sero-type C Infection",[1927],{"trials":1950,"activeCount":100},[],{"intervention":1952,"totalTrials":96,"cells":1953},"Pantoprazole",{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1960,"PHASE4":1962,"NA":1974},{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":100},[1964],{"nctId":1965,"briefTitle":1966,"status":1458,"phases":1967,"primaryCompletion":1968,"completion":1968,"start":1969,"enrollment":100,"conditions":1970,"interventions":1973},"NCT02213887","Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications",[91],"2020-11-02","2014-09",[1971,1972],"Psychotic Disorders","Gastroesophageal Reflux",[1952,1952],{"trials":1975,"activeCount":100},[],{"intervention":1977,"totalTrials":96,"cells":1978},"Tacrolimus - Prograf® twice daily formulation",{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1983,"PHASE3":1985,"PHASE4":1987,"NA":2002},{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"trials":1986,"activeCount":100},[],{"trials":1988,"activeCount":100},[1989],{"nctId":1990,"briefTitle":1991,"status":394,"phases":1992,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":1996,"conditions":1997,"interventions":2000},"NCT01334333","Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients",[91],"2014-10-30","2018-03-01","2011-11-11",46,[1998,1999],"Renal Disease","Renal Transplant",[1977,2001],"Tacrolimus - Advagraf® once daily formulation",{"trials":2003,"activeCount":100},[],{"intervention":2001,"totalTrials":96,"cells":2005},{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2012,"PHASE4":2014,"NA":2020},{"trials":2007,"activeCount":100},[],{"trials":2009,"activeCount":100},[],{"trials":2011,"activeCount":100},[],{"trials":2013,"activeCount":100},[],{"trials":2015,"activeCount":100},[2016],{"nctId":1990,"briefTitle":1991,"status":394,"phases":2017,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":1996,"conditions":2018,"interventions":2019},[91],[1998,1999],[1977,2001],{"trials":2021,"activeCount":100},[],{"intervention":2023,"totalTrials":96,"cells":2024},"Provera",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2033,"NA":2044},{"trials":2026,"activeCount":100},[],{"trials":2028,"activeCount":100},[],{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"trials":2034,"activeCount":100},[2035],{"nctId":2036,"briefTitle":2037,"status":394,"phases":2038,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":1012,"conditions":2041,"interventions":2043},"NCT05651282","Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer",[91],"2025-11-30","2023-03-15",[2042],"Endometrium Cancer",[2023],{"trials":2045,"activeCount":100},[],{"intervention":2047,"totalTrials":96,"cells":2048},"Bupivacaine 0.08% - fentanyl 2mcg",{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2055,"PHASE4":2057,"NA":2069},{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[2059],{"nctId":2060,"briefTitle":2061,"status":394,"phases":2062,"primaryCompletion":2063,"completion":2063,"start":2064,"enrollment":2065,"conditions":2066,"interventions":2068},"NCT03712735","Programmed Intermittent Epidural Bolus For Laboring Obstetrical Women",[91],"2021-03-02","2018-10-23",390,[2067],"Labor Pain",[2047],{"trials":2070,"activeCount":100},[],{"intervention":2072,"totalTrials":96,"cells":2073},"Cranberry",{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2080,"PHASE4":2082,"NA":2091},{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[],{"trials":2079,"activeCount":100},[],{"trials":2081,"activeCount":100},[],{"trials":2083,"activeCount":100},[2084],{"nctId":2085,"briefTitle":2086,"status":1458,"phases":2087,"primaryCompletion":1324,"completion":1487,"start":1969,"enrollment":100,"conditions":2088,"interventions":2090},"NCT01881165","Cranberry on Urinary Tract Infections",[91],[2089],"Urinary Tract Infection",[2072],{"trials":2092,"activeCount":100},[],{"intervention":2094,"totalTrials":96,"cells":2095},"Arm 1 Oral Cortico Steroids",{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2100,"PHASE3":2102,"PHASE4":2104,"NA":2116},{"trials":2097,"activeCount":100},[],{"trials":2099,"activeCount":100},[],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":100},[2106],{"nctId":2107,"briefTitle":2108,"status":394,"phases":2109,"primaryCompletion":1460,"completion":2110,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2115},"NCT01326494","Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia",[91],"2021-05","2011-04",92,[2114,906],"Upper Respiratory Tract Infection",[2094],{"trials":2117,"activeCount":100},[],{"intervention":2119,"totalTrials":96,"cells":2120},"Clozapine",{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2127,"PHASE4":2129,"NA":2138},{"trials":2122,"activeCount":100},[],{"trials":2124,"activeCount":100},[],{"trials":2126,"activeCount":100},[],{"trials":2128,"activeCount":100},[],{"trials":2130,"activeCount":100},[2131],{"nctId":2132,"briefTitle":2133,"status":1458,"phases":2134,"primaryCompletion":1612,"completion":1612,"start":2135,"enrollment":100,"conditions":2136,"interventions":2137},"NCT02286206","Study of the Effect of Dosing on Clozapine Levels",[91],"2015-01",[1971,1463],[2119],{"trials":2139,"activeCount":100},[],{"intervention":2141,"totalTrials":96,"cells":2142},"Arepanrix",{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2149,"PHASE4":2151,"NA":2164},{"trials":2144,"activeCount":100},[],{"trials":2146,"activeCount":100},[],{"trials":2148,"activeCount":100},[],{"trials":2150,"activeCount":100},[],{"trials":2152,"activeCount":100},[2153],{"nctId":2154,"briefTitle":2155,"status":394,"phases":2156,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":2160,"conditions":2161,"interventions":2163},"NCT01002040","Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV",[91],"2010-07","2010-08","2010-02",150,[1719,2162],"H1N1 Influenza",[2141,2141],{"trials":2165,"activeCount":100},[],{"intervention":2167,"totalTrials":96,"cells":2168},"Hepatitis B vaccine",{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2175,"PHASE4":2177,"NA":2189},{"trials":2170,"activeCount":100},[],{"trials":2172,"activeCount":100},[],{"trials":2174,"activeCount":100},[],{"trials":2176,"activeCount":100},[],{"trials":2178,"activeCount":100},[2179],{"nctId":2180,"briefTitle":2181,"status":394,"phases":2182,"primaryCompletion":2183,"completion":2183,"start":2184,"enrollment":31,"conditions":2185,"interventions":2188},"NCT03083158","Immunity to Hepatitis B Vaccine",[91],"2018-02-01","2017-03-06",[2186,2187],"Hepatitis B","Immunization; Infection",[2167],{"trials":2190,"activeCount":100},[],{"intervention":2192,"totalTrials":96,"cells":2193},"Polyethylene Glycol (PEG) and 15 mg Bisacodyl",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2200,"PHASE4":2202,"NA":2214},{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[],{"trials":2199,"activeCount":100},[],{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[2204],{"nctId":2205,"briefTitle":2206,"status":394,"phases":2207,"primaryCompletion":1324,"completion":1643,"start":2208,"enrollment":2209,"conditions":2210,"interventions":2212},"NCT01865916","2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation",[91],"2013-04",309,[2211],"Colonoscopy",[2192,2213],"Polyethylene Glycol (PEG) + ascorbic acid",{"trials":2215,"activeCount":100},[],{"intervention":2213,"totalTrials":96,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2226,"NA":2232},{"trials":2219,"activeCount":100},[],{"trials":2221,"activeCount":100},[],{"trials":2223,"activeCount":100},[],{"trials":2225,"activeCount":100},[],{"trials":2227,"activeCount":100},[2228],{"nctId":2205,"briefTitle":2206,"status":394,"phases":2229,"primaryCompletion":1324,"completion":1643,"start":2208,"enrollment":2209,"conditions":2230,"interventions":2231},[91],[2211],[2192,2213],{"trials":2233,"activeCount":100},[],{"intervention":2235,"totalTrials":96,"cells":2236},"intravenous corticosteroids",{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2241,"PHASE3":2243,"PHASE4":2245,"NA":2256},{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[],{"trials":2242,"activeCount":100},[],{"trials":2244,"activeCount":100},[],{"trials":2246,"activeCount":100},[2247],{"nctId":2248,"briefTitle":2249,"status":431,"phases":2250,"primaryCompletion":2251,"completion":2252,"start":2135,"enrollment":1445,"conditions":2253,"interventions":2255},"NCT02339142","Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease",[91],"2018-12","2019-12",[2254],"Graves Ophthalmopathy",[2235],{"trials":2257,"activeCount":100},[],{"intervention":2259,"totalTrials":96,"cells":2260},"Advair",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2265,"PHASE3":2267,"PHASE4":2269,"NA":2281},{"trials":2262,"activeCount":100},[],{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[],{"trials":2268,"activeCount":100},[],{"trials":2270,"activeCount":100},[2271],{"nctId":2272,"briefTitle":2273,"status":431,"phases":2274,"completion":2275,"start":2276,"enrollment":2277,"conditions":2278,"interventions":2279},"NCT00120978","Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial",[91],"2006-08","2004-12",250,[968],[2259,2280],"Flovent",{"trials":2282,"activeCount":100},[],{"intervention":2280,"totalTrials":96,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2291,"PHASE4":2293,"NA":2299},{"trials":2286,"activeCount":100},[],{"trials":2288,"activeCount":100},[],{"trials":2290,"activeCount":100},[],{"trials":2292,"activeCount":100},[],{"trials":2294,"activeCount":100},[2295],{"nctId":2272,"briefTitle":2273,"status":431,"phases":2296,"completion":2275,"start":2276,"enrollment":2277,"conditions":2297,"interventions":2298},[91],[968],[2259,2280],{"trials":2300,"activeCount":100},[],{"intervention":2302,"totalTrials":96,"cells":2303},"Treatment simplification",{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2310,"PHASE4":2312,"NA":2323},{"trials":2305,"activeCount":100},[],{"trials":2307,"activeCount":100},[],{"trials":2309,"activeCount":100},[],{"trials":2311,"activeCount":100},[],{"trials":2313,"activeCount":100},[2314],{"nctId":2315,"briefTitle":2316,"status":394,"phases":2317,"primaryCompletion":2318,"completion":2318,"start":2319,"enrollment":599,"conditions":2320,"interventions":2322},"NCT02199613","Elvitegravir\u002FCobicistat\u002FTenofovir DF\u002FEmtricitabine With Darunavir Treatment Simplification Strategy",[91],"2017-02-14","2014-10",[2321],"HIV Infection",[2302],{"trials":2324,"activeCount":100},[],{"intervention":2326,"totalTrials":96,"cells":2327},"inhaled fluticasone 500 mcg b.i.d.",{"EARLY_PHASE1":2328,"PHASE1":2330,"PHASE2":2332,"PHASE3":2334,"PHASE4":2336,"NA":2348},{"trials":2329,"activeCount":100},[],{"trials":2331,"activeCount":100},[],{"trials":2333,"activeCount":100},[],{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":100},[2338],{"nctId":2339,"briefTitle":2340,"status":394,"phases":2341,"completion":2342,"start":2343,"enrollment":352,"conditions":2344,"interventions":2347},"NCT00175565","Inhaled Steroid Reduces Systemic Inflammation in COPD",[91],"2003-07","2002-01",[968,2345,2346],"Emphysema","Chronic Bronchitis",[2326],{"trials":2349,"activeCount":100},[],{"intervention":2351,"totalTrials":96,"cells":2352},"Orlistat",{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2359,"PHASE4":2361,"NA":2374},{"trials":2354,"activeCount":100},[],{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[],{"trials":2360,"activeCount":100},[],{"trials":2362,"activeCount":100},[2363],{"nctId":2364,"briefTitle":2365,"status":394,"phases":2366,"primaryCompletion":2367,"completion":2367,"start":2368,"enrollment":2369,"conditions":2370,"interventions":2373},"NCT00152360","The Effect of Xenical on Weight and Risk Factors",[91],"2013-03","2005-06",25,[2371,2372],"Obesity","Heart Diseases",[2351],{"trials":2375,"activeCount":100},[],{"intervention":2377,"totalTrials":96,"cells":2378},"Oral Zinc",{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2397},{"trials":2380,"activeCount":100},[],{"trials":2382,"activeCount":100},[],{"trials":2384,"activeCount":100},[],{"trials":2386,"activeCount":100},[],{"trials":2388,"activeCount":100},[2389],{"nctId":2390,"briefTitle":2391,"status":1360,"phases":2392,"primaryCompletion":2393,"completion":2393,"start":1444,"enrollment":352,"conditions":2394,"interventions":2396},"NCT01468636","A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts",[91],"2012-01",[2395,334],"Genital Warts",[2377],{"trials":2398,"activeCount":100},[],{"intervention":2400,"totalTrials":96,"cells":2401},"EngerixB, GlaxoSmithKline Vaccines",{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2410,"NA":2419},{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"trials":2409,"activeCount":100},[],{"trials":2411,"activeCount":100},[2412],{"nctId":2413,"briefTitle":2414,"status":394,"phases":2415,"primaryCompletion":965,"completion":974,"start":1969,"enrollment":2416,"conditions":2417,"interventions":2418},"NCT02169674","Hepatitis B Booster Study in Adolescence",[91],359,[2186],[2400],{"trials":2420,"activeCount":100},[],{"intervention":2422,"totalTrials":96,"cells":2423},"TGIR",{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2428,"PHASE3":2430,"PHASE4":2432,"NA":2443},{"trials":2425,"activeCount":100},[],{"trials":2427,"activeCount":100},[],{"trials":2429,"activeCount":100},[],{"trials":2431,"activeCount":100},[],{"trials":2433,"activeCount":100},[2434],{"nctId":2435,"briefTitle":2436,"status":431,"phases":2437,"primaryCompletion":2438,"completion":2438,"start":2439,"enrollment":2440,"conditions":2441,"interventions":2442},"NCT05783193","TGIR Randomized Placebo-controlled Healthy Subject Study",[91],"2023-12","2022-11-01",24,[21],[2422],{"trials":2444,"activeCount":100},[],{"intervention":2446,"totalTrials":96,"cells":2447},"Acetaminophen",{"EARLY_PHASE1":2448,"PHASE1":2450,"PHASE2":2452,"PHASE3":2454,"PHASE4":2456,"NA":2467},{"trials":2449,"activeCount":100},[],{"trials":2451,"activeCount":100},[],{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[],{"trials":2457,"activeCount":100},[2458],{"nctId":2459,"briefTitle":2460,"status":1360,"phases":2461,"primaryCompletion":1643,"completion":1643,"start":2462,"enrollment":599,"conditions":2463,"interventions":2466},"NCT02280239","Safety and Efficacy of Acetaminophen in the Intensive Care Unit.",[91],"2015-05",[2464,2465],"Critical Illness","Fever",[2446],{"trials":2468,"activeCount":100},[],{"intervention":2470,"totalTrials":96,"cells":2471},"adjuvanted Arepanrix",{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2480,"NA":2491},{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[],{"trials":2477,"activeCount":100},[],{"trials":2479,"activeCount":100},[],{"trials":2481,"activeCount":100},[2482],{"nctId":2483,"briefTitle":2484,"status":394,"phases":2485,"primaryCompletion":2159,"completion":2159,"start":2486,"enrollment":2487,"conditions":2488,"interventions":2490},"NCT01000831","Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children",[91],"2009-11",167,[2489],"Influenza",[2470],{"trials":2492,"activeCount":100},[],{"intervention":2494,"totalTrials":96,"cells":2495},"Prucalopride",{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2502,"PHASE4":2504,"NA":2519},{"trials":2497,"activeCount":100},[],{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[],{"trials":2503,"activeCount":100},[],{"trials":2505,"activeCount":100},[2506],{"nctId":2507,"briefTitle":2508,"status":431,"phases":2509,"primaryCompletion":2510,"completion":2510,"start":1421,"enrollment":2511,"conditions":2512,"interventions":2518},"NCT02806206","Prucalopride Prior to Small Bowel Capsule Endoscopy",[91],"2017-05",122,[2513,2514,2515,2516,2517],"Gastrointestinal Hemorrhage","Crohn Disease","Celiac Disease","Intestinal Diseases","Inflammatory Bowel Diseases",[2494],{"trials":2520,"activeCount":100},[],{"intervention":2522,"totalTrials":96,"cells":2523},"ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin",{"EARLY_PHASE1":2524,"PHASE1":2526,"PHASE2":2528,"PHASE3":2530,"PHASE4":2532,"NA":2542},{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[],{"trials":2533,"activeCount":100},[2534],{"nctId":2535,"briefTitle":2536,"status":431,"phases":2537,"primaryCompletion":2438,"completion":2438,"start":435,"enrollment":2538,"conditions":2539,"interventions":2541},"NCT02375295","Struvite Stones Antibiotic Study",[91],28,[2540],"Kidney Stones",[2522],{"trials":2543,"activeCount":100},[],{"intervention":2545,"totalTrials":96,"cells":2546},"atazanavir",{"EARLY_PHASE1":2547,"PHASE1":2549,"PHASE2":2551,"PHASE3":2553,"PHASE4":2555,"NA":2564},{"trials":2548,"activeCount":100},[],{"trials":2550,"activeCount":100},[],{"trials":2552,"activeCount":100},[],{"trials":2554,"activeCount":100},[],{"trials":2556,"activeCount":100},[2557],{"nctId":2558,"briefTitle":2559,"status":394,"phases":2560,"primaryCompletion":2135,"completion":1324,"start":1862,"enrollment":352,"conditions":2561,"interventions":2562},"NCT01351740","Switch to Unboosted Atazanavir With Tenofovir Study",[91],[2321],[2545,2563],"atazanavir\u002Fritonavir",{"trials":2565,"activeCount":100},[],{"intervention":2563,"totalTrials":96,"cells":2567},{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2572,"PHASE3":2574,"PHASE4":2576,"NA":2582},{"trials":2569,"activeCount":100},[],{"trials":2571,"activeCount":100},[],{"trials":2573,"activeCount":100},[],{"trials":2575,"activeCount":100},[],{"trials":2577,"activeCount":100},[2578],{"nctId":2558,"briefTitle":2559,"status":394,"phases":2579,"primaryCompletion":2135,"completion":1324,"start":1862,"enrollment":352,"conditions":2580,"interventions":2581},[91],[2321],[2545,2563],{"trials":2583,"activeCount":100},[],{"intervention":2585,"totalTrials":96,"cells":2586},"Human Papillomavirus 9-valent Vaccine, Recombinant",{"EARLY_PHASE1":2587,"PHASE1":2589,"PHASE2":2591,"PHASE3":2593,"PHASE4":2595,"NA":2606},{"trials":2588,"activeCount":100},[],{"trials":2590,"activeCount":100},[],{"trials":2592,"activeCount":100},[],{"trials":2594,"activeCount":100},[],{"trials":2596,"activeCount":100},[2597],{"nctId":2598,"briefTitle":2599,"status":394,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":28,"conditions":2603,"interventions":2605},"NCT02968420","Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine",[91],"2019-05-15","2017-09-11",[2604],"Human Papillomavirus",[2585],{"trials":2607,"activeCount":100},[],{"intervention":2609,"totalTrials":96,"cells":2610},"Diflunisal",{"EARLY_PHASE1":2611,"PHASE1":2613,"PHASE2":2615,"PHASE3":2617,"PHASE4":2619,"NA":2629},{"trials":2612,"activeCount":100},[],{"trials":2614,"activeCount":100},[],{"trials":2616,"activeCount":100},[],{"trials":2618,"activeCount":100},[],{"trials":2620,"activeCount":100},[2621],{"nctId":2622,"briefTitle":2623,"status":1360,"phases":2624,"primaryCompletion":2625,"completion":2625,"start":2367,"enrollment":2626,"conditions":2627,"interventions":2628},"NCT01676363","Pilot Study of Diflunisal in HIV-infected Adults",[91],"2016-10-12",8,[2321],[2609],{"trials":2630,"activeCount":100},[],{"intervention":1592,"totalTrials":96,"cells":2632},{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2641,"NA":2647},{"trials":2634,"activeCount":100},[],{"trials":2636,"activeCount":100},[],{"trials":2638,"activeCount":100},[],{"trials":2640,"activeCount":100},[],{"trials":2642,"activeCount":100},[2643],{"nctId":1583,"briefTitle":1584,"status":394,"phases":2644,"primaryCompletion":1586,"completion":1325,"start":1587,"enrollment":1588,"conditions":2645,"interventions":2646},[91],[1590],[1561,1592,1561],{"trials":2648,"activeCount":100},[],{"intervention":2650,"totalTrials":96,"cells":2651},"Oxycodone Naloxone Combination",{"EARLY_PHASE1":2652,"PHASE1":2654,"PHASE2":2656,"PHASE3":2658,"PHASE4":2660,"NA":2670},{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[],{"trials":2659,"activeCount":100},[],{"trials":2661,"activeCount":100},[2662],{"nctId":2663,"briefTitle":2664,"status":394,"phases":2665,"primaryCompletion":2666,"completion":2666,"start":2667,"enrollment":96,"conditions":2668,"interventions":2669},"NCT03179475","Targin® for Chronic Pain Management in Patients With Spinal Cord Injury",[91],"2021-11-29","2019-09-05",[601],[2650],{"trials":2671,"activeCount":100},[],{"intervention":2673,"totalTrials":96,"cells":2674},"lopinavir\u002Fritonavir; nevirapine; Zidovudine; Lamivudine",{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2679,"PHASE3":2681,"PHASE4":2683,"NA":2694},{"trials":2676,"activeCount":100},[],{"trials":2678,"activeCount":100},[],{"trials":2680,"activeCount":100},[],{"trials":2682,"activeCount":100},[],{"trials":2684,"activeCount":100},[2685],{"nctId":2686,"briefTitle":2687,"status":394,"phases":2688,"primaryCompletion":2689,"completion":2689,"start":2690,"enrollment":1533,"conditions":2691,"interventions":2693},"NCT00143689","NRTI-Sparing Pilot Study",[91],"2008-02","2002-04",[1718,2692],"Mitochondrial Toxicity",[2673],{"trials":2695,"activeCount":100},[],{"intervention":2697,"totalTrials":374,"cells":2698},"Oral Micronized Progesterone",{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2703,"PHASE3":2715,"PHASE4":2737,"NA":2739},{"trials":2700,"activeCount":100},[],{"trials":2702,"activeCount":100},[],{"trials":2704,"activeCount":100},[2705],{"nctId":2706,"briefTitle":2707,"status":431,"phases":2708,"primaryCompletion":1715,"completion":2709,"start":2710,"enrollment":2711,"conditions":2712,"interventions":2714},"NCT00152438","Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone",[89],"2012-12","2005-09",125,[2713],"Menopause",[2697],{"trials":2716,"activeCount":100},[2717,2728],{"nctId":2718,"briefTitle":2719,"status":394,"phases":2720,"primaryCompletion":2721,"completion":2721,"start":1613,"enrollment":2722,"conditions":2723,"interventions":2726},"NCT01464697","Progesterone for Perimenopausal Night Sweats",[90],"2018-06-01",249,[2724,2725],"Hot Flushes","Night Sweats",[2727],"Oral micronized progesterone",{"nctId":2729,"briefTitle":2730,"status":394,"phases":2731,"primaryCompletion":2721,"completion":2721,"start":1943,"enrollment":2732,"conditions":2733,"interventions":2736},"NCT02779582","Oral Micronized Progesterone Effects on Perimenopausal Menstrual Flow",[90],59,[2734,2735],"Perimenopause","Menstrual Cramps",[2697],{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[],{"intervention":2742,"totalTrials":341,"cells":2743},"Gabapentin",{"EARLY_PHASE1":2744,"PHASE1":2746,"PHASE2":2748,"PHASE3":2762,"PHASE4":2774,"NA":2776},{"trials":2745,"activeCount":100},[],{"trials":2747,"activeCount":100},[],{"trials":2749,"activeCount":100},[2750],{"nctId":2751,"briefTitle":2752,"status":431,"phases":2753,"primaryCompletion":2754,"completion":2755,"start":2756,"enrollment":2757,"conditions":2758,"interventions":2761},"NCT04619862","Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial)",[89],"2026-03-31","2026-04-30","2021-05-15",5,[33,2759,2760],"Neuropathic Pain","Irritability",[2742],{"trials":2763,"activeCount":100},[2764],{"nctId":2765,"briefTitle":2766,"status":394,"phases":2767,"primaryCompletion":2768,"completion":2769,"start":2770,"enrollment":2538,"conditions":2771,"interventions":2773},"NCT00624455","How Does Gabapentin Affects Post-operative Tonsillectomy Pain?",[90],"2008-12","2009-08","2007-07",[2772],"Post-operative Pain",[2742],{"trials":2775,"activeCount":100},[],{"trials":2777,"activeCount":100},[],{"intervention":2779,"totalTrials":341,"cells":2780},"Sitagliptin",{"EARLY_PHASE1":2781,"PHASE1":2783,"PHASE2":2785,"PHASE3":2795,"PHASE4":2806,"NA":2808},{"trials":2782,"activeCount":100},[],{"trials":2784,"activeCount":100},[],{"trials":2786,"activeCount":100},[2787],{"nctId":2788,"briefTitle":2789,"status":1360,"phases":2790,"primaryCompletion":2791,"completion":2791,"start":2792,"enrollment":374,"conditions":2793,"interventions":2794},"NCT01257464","Sitagliptin in Cystic Fibrosis-Related Diabetes",[89],"2012-06","2010-09",[30],[2779],{"trials":2796,"activeCount":100},[2797],{"nctId":2798,"briefTitle":2799,"status":1360,"phases":2800,"primaryCompletion":2801,"completion":2801,"start":1944,"enrollment":1302,"conditions":2802,"interventions":2804},"NCT00853944","Effect of Sitagliptin on Graft Function Following Islet Transplantation",[90],"2013-11-01",[2803],"Islet Transplantation",[2805],"sitagliptin",{"trials":2807,"activeCount":100},[],{"trials":2809,"activeCount":100},[],{"intervention":2811,"totalTrials":341,"cells":2812},"Escitalopram",{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2819,"PHASE4":2842,"NA":2844},{"trials":2814,"activeCount":100},[],{"trials":2816,"activeCount":100},[],{"trials":2818,"activeCount":100},[],{"trials":2820,"activeCount":100},[2821,2830],{"nctId":2822,"briefTitle":2823,"status":1360,"phases":2824,"primaryCompletion":2825,"completion":2825,"start":2826,"enrollment":352,"conditions":2827,"interventions":2829},"NCT00488670","Escitalopram and Depression in Elderly Alzheimer's Patients",[90],"2011-06","2010-12",[2828],"Depressive Disorder",[2811],{"nctId":2831,"briefTitle":2832,"status":1360,"phases":2833,"primaryCompletion":2834,"completion":2835,"start":2836,"enrollment":2837,"conditions":2838,"interventions":2840},"NCT00958633","Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.",[90],"2020-03-31","2020-05-20","2010-11",237,[2839],"Bipolar I Disorder",[2811,2841],"Bupropion XL",{"trials":2843,"activeCount":100},[],{"trials":2845,"activeCount":100},[],{"intervention":2847,"totalTrials":96,"cells":2848},"Remifentanil",{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2855,"PHASE4":2865,"NA":2867},{"trials":2850,"activeCount":100},[],{"trials":2852,"activeCount":100},[],{"trials":2854,"activeCount":100},[],{"trials":2856,"activeCount":100},[2857],{"nctId":2858,"briefTitle":2859,"status":394,"phases":2860,"primaryCompletion":1461,"completion":1461,"start":2861,"enrollment":785,"conditions":2862,"interventions":2864},"NCT00474071","Optimum Dose of Remifentanil for Intubation in Small Children",[90],"2007-03",[2863],"Endotracheal Intubation",[2847],{"trials":2866,"activeCount":100},[],{"trials":2868,"activeCount":100},[],{"intervention":2870,"totalTrials":96,"cells":2871},"Cefazolin and Moxifloxacin",{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2876,"PHASE3":2878,"PHASE4":2888,"NA":2890},{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[],{"trials":2877,"activeCount":100},[],{"trials":2879,"activeCount":100},[2880],{"nctId":2881,"briefTitle":2882,"status":394,"phases":2883,"primaryCompletion":2709,"completion":2884,"start":1839,"enrollment":2065,"conditions":2885,"interventions":2887},"NCT00323219","Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department",[90],"2013-12",[2886],"Cellulitis",[2870],{"trials":2889,"activeCount":100},[],{"trials":2891,"activeCount":100},[],{"intervention":2893,"totalTrials":96,"cells":2894},"Paracetamol",{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2901,"PHASE4":2915,"NA":2917},{"trials":2896,"activeCount":100},[],{"trials":2898,"activeCount":100},[],{"trials":2900,"activeCount":100},[],{"trials":2902,"activeCount":100},[2903],{"nctId":2904,"briefTitle":2905,"status":431,"phases":2906,"primaryCompletion":2907,"completion":623,"start":2908,"enrollment":2909,"conditions":2910,"interventions":2914},"NCT04251351","Effect of Paracetamol on Kidney Function in Severe Malaria",[90],"2024-06-01","2021-12-13",460,[2911,2912,2913,2893],"Severe Malaria","Malaria,Falciparum","Acute Kidney Injury",[2893],{"trials":2916,"activeCount":100},[],{"trials":2918,"activeCount":100},[],{"intervention":2920,"totalTrials":96,"cells":2921},"MabCampath-1h",{"EARLY_PHASE1":2922,"PHASE1":2924,"PHASE2":2926,"PHASE3":2928,"PHASE4":2940,"NA":2942},{"trials":2923,"activeCount":100},[],{"trials":2925,"activeCount":100},[],{"trials":2927,"activeCount":100},[],{"trials":2929,"activeCount":100},[2930],{"nctId":2931,"briefTitle":2932,"status":394,"phases":2933,"primaryCompletion":2934,"completion":2934,"start":2935,"enrollment":2936,"conditions":2937,"interventions":2939},"NCT01307332","Advanced MRI Measures of Repair in Alemtuzumab Treated Patients",[90],"2018-09-28","2011-03",27,[2938],"Relapsing Remitting Multiple Sclerosis",[2920],{"trials":2941,"activeCount":100},[],{"trials":2943,"activeCount":100},[],{"intervention":2945,"totalTrials":96,"cells":2946},"Alpha Lipoic Acid 600 MG Oral",{"EARLY_PHASE1":2947,"PHASE1":2949,"PHASE2":2951,"PHASE3":2953,"PHASE4":2966,"NA":2968},{"trials":2948,"activeCount":100},[],{"trials":2950,"activeCount":100},[],{"trials":2952,"activeCount":100},[],{"trials":2954,"activeCount":100},[2955],{"nctId":2956,"briefTitle":2957,"status":431,"phases":2958,"primaryCompletion":2959,"completion":2960,"start":2961,"enrollment":2962,"conditions":2963,"interventions":2965},"NCT05009901","A Pilot Study of Antioxidant Therapy in Obstructive Sleep Apnea Patients",[89,90],"2023-08","2024-08","2022-06-01",80,[2964],"Obstructive Sleep Apnea of Adult",[2945],{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[],{"intervention":2971,"totalTrials":96,"cells":2972},"Fluoxetine",{"EARLY_PHASE1":2973,"PHASE1":2975,"PHASE2":2977,"PHASE3":2979,"PHASE4":2991,"NA":2993},{"trials":2974,"activeCount":100},[],{"trials":2976,"activeCount":100},[],{"trials":2978,"activeCount":100},[],{"trials":2980,"activeCount":100},[2981],{"nctId":2982,"briefTitle":2983,"status":394,"phases":2984,"primaryCompletion":2985,"completion":2986,"start":1715,"enrollment":2987,"conditions":2988,"interventions":2990},"NCT00958204","Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression",[90],"2014-02","2014-05",134,[2989],"Major Depressive Disorder (MDD)",[2971],{"trials":2992,"activeCount":100},[],{"trials":2994,"activeCount":100},[],{"intervention":2996,"totalTrials":96,"cells":2997},"Ketamine & hydromorphone",{"EARLY_PHASE1":2998,"PHASE1":3000,"PHASE2":3002,"PHASE3":3004,"PHASE4":3013,"NA":3015},{"trials":2999,"activeCount":100},[],{"trials":3001,"activeCount":100},[],{"trials":3003,"activeCount":100},[],{"trials":3005,"activeCount":100},[3006],{"nctId":3007,"briefTitle":3008,"status":1458,"phases":3009,"primaryCompletion":1348,"completion":1348,"start":2769,"enrollment":100,"conditions":3010,"interventions":3012},"NCT00474110","Ketamine and Hydromorphone for Patient Controlled Pain Relief in Children's Mucositis",[90],[3011],"Mucositis",[2996],{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":100},[],{"intervention":3018,"totalTrials":96,"cells":3019},"imiquimod",{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3026,"PHASE4":3037,"NA":3039},{"trials":3021,"activeCount":100},[],{"trials":3023,"activeCount":100},[],{"trials":3025,"activeCount":100},[],{"trials":3027,"activeCount":100},[3028],{"nctId":3029,"briefTitle":3030,"status":394,"phases":3031,"completion":3032,"start":3033,"enrollment":141,"conditions":3034,"interventions":3036},"NCT00175643","Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses",[90],"2005-11","2005-02",[3035],"Actinic Keratoses",[3018],{"trials":3038,"activeCount":100},[],{"trials":3040,"activeCount":100},[],{"intervention":3042,"totalTrials":96,"cells":3043},"Digoxin",{"EARLY_PHASE1":3044,"PHASE1":3046,"PHASE2":3048,"PHASE3":3050,"PHASE4":3063,"NA":3065},{"trials":3045,"activeCount":100},[],{"trials":3047,"activeCount":100},[],{"trials":3049,"activeCount":100},[],{"trials":3051,"activeCount":100},[3052],{"nctId":3053,"briefTitle":3054,"status":394,"phases":3055,"primaryCompletion":2158,"completion":3056,"start":3057,"enrollment":3058,"conditions":3059,"interventions":3061},"NCT00390546","Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia",[90],"2011-08","2006-10",72,[3060],"Supraventricular Tachycardia",[3042,3062],"Propranolol",{"trials":3064,"activeCount":100},[],{"trials":3066,"activeCount":100},[],{"intervention":3062,"totalTrials":96,"cells":3068},{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3073,"PHASE3":3075,"PHASE4":3081,"NA":3083},{"trials":3070,"activeCount":100},[],{"trials":3072,"activeCount":100},[],{"trials":3074,"activeCount":100},[],{"trials":3076,"activeCount":100},[3077],{"nctId":3053,"briefTitle":3054,"status":394,"phases":3078,"primaryCompletion":2158,"completion":3056,"start":3057,"enrollment":3058,"conditions":3079,"interventions":3080},[90],[3060],[3042,3062],{"trials":3082,"activeCount":100},[],{"trials":3084,"activeCount":100},[],{"intervention":3086,"totalTrials":96,"cells":3087},"PCV13",{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3094,"PHASE4":3107,"NA":3109},{"trials":3089,"activeCount":100},[],{"trials":3091,"activeCount":100},[],{"trials":3093,"activeCount":100},[],{"trials":3095,"activeCount":100},[3096],{"nctId":3097,"briefTitle":3098,"status":394,"phases":3099,"primaryCompletion":3100,"completion":3100,"start":3101,"enrollment":3102,"conditions":3103,"interventions":3106},"NCT03384589","CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study",[89,90],"2023-03-31","2018-08-23",248,[3104,3105],"Invasive Pneumococcal Disease, Protection Against","Streptococcus Pneumoniae Infection",[3086],{"trials":3108,"activeCount":100},[],{"trials":3110,"activeCount":100},[],{"intervention":3112,"totalTrials":96,"cells":3113},"intravenous magnesium",{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3120,"PHASE4":3134,"NA":3136},{"trials":3115,"activeCount":100},[],{"trials":3117,"activeCount":100},[],{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[3122],{"nctId":3123,"briefTitle":3124,"status":1360,"phases":3125,"primaryCompletion":3126,"completion":3127,"start":3128,"enrollment":3129,"conditions":3130,"interventions":3133},"NCT00250965","MPAACS: Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery",[90],"2008-09","2009-02","2004-07",927,[3131,3132],"Coronary Artery Disease","Valvular Heart Disease",[3112],{"trials":3135,"activeCount":100},[],{"trials":3137,"activeCount":100},[],{"intervention":3139,"totalTrials":96,"cells":3140},"Nalbuphine",{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3147,"PHASE4":3157,"NA":3159},{"trials":3142,"activeCount":100},[],{"trials":3144,"activeCount":100},[],{"trials":3146,"activeCount":100},[],{"trials":3148,"activeCount":100},[3149],{"nctId":3150,"briefTitle":3151,"status":394,"phases":3152,"primaryCompletion":2276,"completion":2276,"start":3153,"enrollment":2987,"conditions":3154,"interventions":3156},"NCT00323154","Nalbuphine for the Treatment of Opioid Induced Pruritus in Children",[90],"2004-03",[3155],"Pruritis",[3139],{"trials":3158,"activeCount":100},[],{"trials":3160,"activeCount":100},[],{"intervention":3162,"totalTrials":96,"cells":3163},"Quetiapine XR",{"EARLY_PHASE1":3164,"PHASE1":3166,"PHASE2":3168,"PHASE3":3170,"PHASE4":3180,"NA":3182},{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[],{"trials":3171,"activeCount":100},[3172],{"nctId":3173,"briefTitle":3174,"status":394,"phases":3175,"primaryCompletion":2792,"completion":2792,"start":3176,"enrollment":904,"conditions":3177,"interventions":3179},"NCT00517387","The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression",[90],"2007-09",[3178],"Unipolar Depression",[3162],{"trials":3181,"activeCount":100},[],{"trials":3183,"activeCount":100},[],{"intervention":3185,"totalTrials":96,"cells":3186},"Valproate",{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3193,"PHASE4":3206,"NA":3208},{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[3195],{"nctId":3196,"briefTitle":3197,"status":394,"phases":3198,"primaryCompletion":3056,"completion":3056,"start":3199,"enrollment":3200,"conditions":3201,"interventions":3202},"NCT01977300","Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode",[90],"2003-01",159,[2839],[3185,3203,3204,3205],"Lithium","Risperidone","Olanzapine",{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[],{"intervention":3203,"totalTrials":96,"cells":3211},{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3216,"PHASE3":3218,"PHASE4":3224,"NA":3226},{"trials":3213,"activeCount":100},[],{"trials":3215,"activeCount":100},[],{"trials":3217,"activeCount":100},[],{"trials":3219,"activeCount":100},[3220],{"nctId":3196,"briefTitle":3197,"status":394,"phases":3221,"primaryCompletion":3056,"completion":3056,"start":3199,"enrollment":3200,"conditions":3222,"interventions":3223},[90],[2839],[3185,3203,3204,3205],{"trials":3225,"activeCount":100},[],{"trials":3227,"activeCount":100},[],{"intervention":3205,"totalTrials":96,"cells":3229},{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3242,"NA":3244},{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[],{"trials":3235,"activeCount":100},[],{"trials":3237,"activeCount":100},[3238],{"nctId":3196,"briefTitle":3197,"status":394,"phases":3239,"primaryCompletion":3056,"completion":3056,"start":3199,"enrollment":3200,"conditions":3240,"interventions":3241},[90],[2839],[3185,3203,3204,3205],{"trials":3243,"activeCount":100},[],{"trials":3245,"activeCount":100},[],{"intervention":3247,"totalTrials":96,"cells":3248},"Hydromorphone, Injectable",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3255,"PHASE4":3269,"NA":3271},{"trials":3250,"activeCount":100},[],{"trials":3252,"activeCount":100},[],{"trials":3254,"activeCount":100},[],{"trials":3256,"activeCount":100},[3257],{"nctId":3258,"briefTitle":3259,"status":394,"phases":3260,"primaryCompletion":3261,"completion":1643,"start":1348,"enrollment":3262,"conditions":3263,"interventions":3265},"NCT01447212","Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)",[90],"2014-06",202,[400,3264],"Heroin Dependence",[3247,3266,3267,3268],"Diacetylmorphine, injectable","Hydromorphone, liquid","Diacetylmorphine, liquid",{"trials":3270,"activeCount":100},[],{"trials":3272,"activeCount":100},[],{"intervention":3266,"totalTrials":96,"cells":3274},{"EARLY_PHASE1":3275,"PHASE1":3277,"PHASE2":3279,"PHASE3":3281,"PHASE4":3287,"NA":3289},{"trials":3276,"activeCount":100},[],{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[3283],{"nctId":3258,"briefTitle":3259,"status":394,"phases":3284,"primaryCompletion":3261,"completion":1643,"start":1348,"enrollment":3262,"conditions":3285,"interventions":3286},[90],[400,3264],[3247,3266,3267,3268],{"trials":3288,"activeCount":100},[],{"trials":3290,"activeCount":100},[],{"intervention":3267,"totalTrials":96,"cells":3292},{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3297,"PHASE3":3299,"PHASE4":3305,"NA":3307},{"trials":3294,"activeCount":100},[],{"trials":3296,"activeCount":100},[],{"trials":3298,"activeCount":100},[],{"trials":3300,"activeCount":100},[3301],{"nctId":3258,"briefTitle":3259,"status":394,"phases":3302,"primaryCompletion":3261,"completion":1643,"start":1348,"enrollment":3262,"conditions":3303,"interventions":3304},[90],[400,3264],[3247,3266,3267,3268],{"trials":3306,"activeCount":100},[],{"trials":3308,"activeCount":100},[],{"intervention":3268,"totalTrials":96,"cells":3310},{"EARLY_PHASE1":3311,"PHASE1":3313,"PHASE2":3315,"PHASE3":3317,"PHASE4":3323,"NA":3325},{"trials":3312,"activeCount":100},[],{"trials":3314,"activeCount":100},[],{"trials":3316,"activeCount":100},[],{"trials":3318,"activeCount":100},[3319],{"nctId":3258,"briefTitle":3259,"status":394,"phases":3320,"primaryCompletion":3261,"completion":1643,"start":1348,"enrollment":3262,"conditions":3321,"interventions":3322},[90],[400,3264],[3247,3266,3267,3268],{"trials":3324,"activeCount":100},[],{"trials":3326,"activeCount":100},[],{"intervention":3328,"totalTrials":96,"cells":3329},"Vancomycin Hydrochloride",{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3334,"PHASE3":3336,"PHASE4":3352,"NA":3354},{"trials":3331,"activeCount":100},[],{"trials":3333,"activeCount":100},[],{"trials":3335,"activeCount":100},[],{"trials":3337,"activeCount":100},[3338],{"nctId":3339,"briefTitle":3340,"status":431,"phases":3341,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":3345,"conditions":3346,"interventions":3351},"NCT03221023","Intrawound Vancomycin Prophylaxis for Neural Stimulator",[89,90],"2021-09-15","2021-12-15","2017-09-15",900,[3347,3348,3349,3350],"Vancomycin","Implantable Neural Stimulator","Deep Brain Stimulation","Surgical Site Infection",[3328,1317],{"trials":3353,"activeCount":100},[],{"trials":3355,"activeCount":100},[],{"intervention":3357,"totalTrials":96,"cells":3358},"Lurasidone",{"EARLY_PHASE1":3359,"PHASE1":3361,"PHASE2":3363,"PHASE3":3365,"PHASE4":3375,"NA":3377},{"trials":3360,"activeCount":100},[],{"trials":3362,"activeCount":100},[],{"trials":3364,"activeCount":100},[],{"trials":3366,"activeCount":100},[3367],{"nctId":3368,"briefTitle":3369,"status":394,"phases":3370,"primaryCompletion":3371,"completion":3372,"start":2986,"enrollment":976,"conditions":3373,"interventions":3374},"NCT02147379","Lurasidone and Cognition in Bipolar I Disorder",[90],"2015-10","2017-01-12",[2839],[3357],{"trials":3376,"activeCount":100},[],{"trials":3378,"activeCount":100},[],{"intervention":3380,"totalTrials":96,"cells":3381},"Hydrocortisone",{"EARLY_PHASE1":3382,"PHASE1":3384,"PHASE2":3386,"PHASE3":3388,"PHASE4":3398,"NA":3400},{"trials":3383,"activeCount":100},[],{"trials":3385,"activeCount":100},[],{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[3390],{"nctId":3391,"briefTitle":3392,"status":394,"phases":3393,"primaryCompletion":1838,"completion":1838,"start":3394,"enrollment":966,"conditions":3395,"interventions":3397},"NCT00358748","Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants",[90],"2005-07",[3396],"Neonatal Hypotension",[3380],{"trials":3399,"activeCount":100},[],{"trials":3401,"activeCount":100},[],{"intervention":3403,"totalTrials":96,"cells":3404},"Sandostatin LAR",{"EARLY_PHASE1":3405,"PHASE1":3407,"PHASE2":3409,"PHASE3":3411,"PHASE4":3423,"NA":3425},{"trials":3406,"activeCount":100},[],{"trials":3408,"activeCount":100},[],{"trials":3410,"activeCount":100},[],{"trials":3412,"activeCount":100},[3413],{"nctId":3414,"briefTitle":3415,"status":1360,"phases":3416,"completion":3417,"start":3418,"enrollment":599,"conditions":3419,"interventions":3422},"NCT00175305","Prader-Willi Syndrome and Appetite",[90],"2007-10","2004-08",[3420,3421],"Hyperphagia","Prader-Willi Syndrome",[3403],{"trials":3424,"activeCount":100},[],{"trials":3426,"activeCount":100},[],{"intervention":2841,"totalTrials":96,"cells":3428},{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3435,"PHASE4":3441,"NA":3443},{"trials":3430,"activeCount":100},[],{"trials":3432,"activeCount":100},[],{"trials":3434,"activeCount":100},[],{"trials":3436,"activeCount":100},[3437],{"nctId":2831,"briefTitle":2832,"status":1360,"phases":3438,"primaryCompletion":2834,"completion":2835,"start":2836,"enrollment":2837,"conditions":3439,"interventions":3440},[90],[2839],[2811,2841],{"trials":3442,"activeCount":100},[],{"trials":3444,"activeCount":100},[],{"intervention":3446,"totalTrials":96,"cells":3447},"Boric acid",{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3452,"PHASE3":3454,"PHASE4":3466,"NA":3468},{"trials":3449,"activeCount":100},[],{"trials":3451,"activeCount":100},[],{"trials":3453,"activeCount":100},[],{"trials":3455,"activeCount":100},[3456],{"nctId":3457,"briefTitle":3458,"status":394,"phases":3459,"primaryCompletion":3460,"completion":1643,"start":3461,"enrollment":1533,"conditions":3462,"interventions":3464},"NCT00799214","BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study",[89,90],"2015-11","2014-04",[3463],"Bacterial Vaginosis",[3446,3465],"Metronidazole",{"trials":3467,"activeCount":100},[],{"trials":3469,"activeCount":100},[],{"intervention":3465,"totalTrials":96,"cells":3471},{"EARLY_PHASE1":3472,"PHASE1":3474,"PHASE2":3476,"PHASE3":3478,"PHASE4":3484,"NA":3486},{"trials":3473,"activeCount":100},[],{"trials":3475,"activeCount":100},[],{"trials":3477,"activeCount":100},[],{"trials":3479,"activeCount":100},[3480],{"nctId":3457,"briefTitle":3458,"status":394,"phases":3481,"primaryCompletion":3460,"completion":1643,"start":3461,"enrollment":1533,"conditions":3482,"interventions":3483},[89,90],[3463],[3446,3465],{"trials":3485,"activeCount":100},[],{"trials":3487,"activeCount":100},[],{"intervention":3489,"totalTrials":96,"cells":3490},"Eplerenone",{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3495,"PHASE3":3497,"PHASE4":3507,"NA":3509},{"trials":3492,"activeCount":100},[],{"trials":3494,"activeCount":100},[],{"trials":3496,"activeCount":100},[],{"trials":3498,"activeCount":100},[3499],{"nctId":3500,"briefTitle":3501,"status":1360,"phases":3502,"primaryCompletion":1532,"completion":1532,"start":2986,"enrollment":3503,"conditions":3504,"interventions":3506},"NCT01708798","Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer",[89,90],44,[3505],"Breast Cancer",[3489],{"trials":3508,"activeCount":100},[],{"trials":3510,"activeCount":100},[],{"intervention":3512,"totalTrials":96,"cells":3513},"Electrical-first",{"EARLY_PHASE1":3514,"PHASE1":3516,"PHASE2":3518,"PHASE3":3520,"PHASE4":3533,"NA":3535},{"trials":3515,"activeCount":100},[],{"trials":3517,"activeCount":100},[],{"trials":3519,"activeCount":100},[],{"trials":3521,"activeCount":100},[3522],{"nctId":3523,"briefTitle":3524,"status":394,"phases":3525,"primaryCompletion":435,"completion":3526,"start":3527,"enrollment":3528,"conditions":3529,"interventions":3531},"NCT01994070","Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation",[90],"2015-04","2013-11",86,[3530],"Atrial Fibrillation",[3512,3532],"Chemical-first",{"trials":3534,"activeCount":100},[],{"trials":3536,"activeCount":100},[],{"intervention":3532,"totalTrials":96,"cells":3538},{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3551,"NA":3553},{"trials":3540,"activeCount":100},[],{"trials":3542,"activeCount":100},[],{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":100},[3547],{"nctId":3523,"briefTitle":3524,"status":394,"phases":3548,"primaryCompletion":435,"completion":3526,"start":3527,"enrollment":3528,"conditions":3549,"interventions":3550},[90],[3530],[3512,3532],{"trials":3552,"activeCount":100},[],{"trials":3554,"activeCount":100},[],{"intervention":3556,"totalTrials":96,"cells":3557},"Placebos",{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3564,"PHASE4":3578,"NA":3580},{"trials":3559,"activeCount":100},[],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[3566],{"nctId":3567,"briefTitle":3568,"status":431,"phases":3569,"primaryCompletion":3570,"completion":3571,"start":3572,"enrollment":141,"conditions":3573,"interventions":3576},"NCT04106999","Dexmedetomidine and HIPEC",[89,90],"2024-06","2024-12","2023-03",[3574,3575],"Inflammation","Cancer",[3577,3556],"Dexmedetomidine",{"trials":3579,"activeCount":100},[],{"trials":3581,"activeCount":100},[],{"intervention":402,"totalTrials":96,"cells":3583},{"EARLY_PHASE1":3584,"PHASE1":3586,"PHASE2":3588,"PHASE3":3590,"PHASE4":3596,"NA":3598},{"trials":3585,"activeCount":100},[],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[],{"trials":3591,"activeCount":100},[3592],{"nctId":392,"briefTitle":393,"status":394,"phases":3593,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":3594,"interventions":3595},[90],[400],[402,70],{"trials":3597,"activeCount":100},[],{"trials":3599,"activeCount":100},[],{"intervention":3601,"totalTrials":96,"cells":3602},"Tacrolimus Topical 0.1% Topical Ointment",{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3607,"PHASE3":3609,"PHASE4":3621,"NA":3623},{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[],{"trials":3608,"activeCount":100},[],{"trials":3610,"activeCount":100},[3611],{"nctId":3612,"briefTitle":3613,"status":431,"phases":3614,"primaryCompletion":3615,"completion":3615,"start":3616,"enrollment":1445,"conditions":3617,"interventions":3619},"NCT03715387","Tacrolimus for Malar Edema",[89,90],"2019-07-01","2018-10-10",[3618],"Edema Face",[3601,3620],"Polysporin Ointment",{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":100},[],{"intervention":1369,"totalTrials":96,"cells":3626},{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3633,"PHASE4":3639,"NA":3641},{"trials":3628,"activeCount":100},[],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":100},[],{"trials":3634,"activeCount":100},[3635],{"nctId":1358,"briefTitle":1359,"status":1360,"phases":3636,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":3637,"interventions":3638},[90],[1366,1367],[1335,1369,1370,1371,1372,1373,1374,1375],{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":100},[],{"intervention":1370,"totalTrials":96,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3651,"PHASE4":3657,"NA":3659},{"trials":3646,"activeCount":100},[],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[3653],{"nctId":1358,"briefTitle":1359,"status":1360,"phases":3654,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":3655,"interventions":3656},[90],[1366,1367],[1335,1369,1370,1371,1372,1373,1374,1375],{"trials":3658,"activeCount":100},[],{"trials":3660,"activeCount":100},[],{"intervention":1371,"totalTrials":96,"cells":3662},{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3667,"PHASE3":3669,"PHASE4":3675,"NA":3677},{"trials":3664,"activeCount":100},[],{"trials":3666,"activeCount":100},[],{"trials":3668,"activeCount":100},[],{"trials":3670,"activeCount":100},[3671],{"nctId":1358,"briefTitle":1359,"status":1360,"phases":3672,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":3673,"interventions":3674},[90],[1366,1367],[1335,1369,1370,1371,1372,1373,1374,1375],{"trials":3676,"activeCount":100},[],{"trials":3678,"activeCount":100},[],{"intervention":1372,"totalTrials":96,"cells":3680},{"EARLY_PHASE1":3681,"PHASE1":3683,"PHASE2":3685,"PHASE3":3687,"PHASE4":3693,"NA":3695},{"trials":3682,"activeCount":100},[],{"trials":3684,"activeCount":100},[],{"trials":3686,"activeCount":100},[],{"trials":3688,"activeCount":100},[3689],{"nctId":1358,"briefTitle":1359,"status":1360,"phases":3690,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":3691,"interventions":3692},[90],[1366,1367],[1335,1369,1370,1371,1372,1373,1374,1375],{"trials":3694,"activeCount":100},[],{"trials":3696,"activeCount":100},[],{"intervention":1373,"totalTrials":96,"cells":3698},{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3703,"PHASE3":3705,"PHASE4":3711,"NA":3713},{"trials":3700,"activeCount":100},[],{"trials":3702,"activeCount":100},[],{"trials":3704,"activeCount":100},[],{"trials":3706,"activeCount":100},[3707],{"nctId":1358,"briefTitle":1359,"status":1360,"phases":3708,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":3709,"interventions":3710},[90],[1366,1367],[1335,1369,1370,1371,1372,1373,1374,1375],{"trials":3712,"activeCount":100},[],{"trials":3714,"activeCount":100},[],{"intervention":1374,"totalTrials":96,"cells":3716},{"EARLY_PHASE1":3717,"PHASE1":3719,"PHASE2":3721,"PHASE3":3723,"PHASE4":3729,"NA":3731},{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[],{"trials":3722,"activeCount":100},[],{"trials":3724,"activeCount":100},[3725],{"nctId":1358,"briefTitle":1359,"status":1360,"phases":3726,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":3727,"interventions":3728},[90],[1366,1367],[1335,1369,1370,1371,1372,1373,1374,1375],{"trials":3730,"activeCount":100},[],{"trials":3732,"activeCount":100},[],{"intervention":1375,"totalTrials":96,"cells":3734},{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3739,"PHASE3":3741,"PHASE4":3747,"NA":3749},{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[],{"trials":3742,"activeCount":100},[3743],{"nctId":1358,"briefTitle":1359,"status":1360,"phases":3744,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":3745,"interventions":3746},[90],[1366,1367],[1335,1369,1370,1371,1372,1373,1374,1375],{"trials":3748,"activeCount":100},[],{"trials":3750,"activeCount":100},[],{"intervention":3752,"totalTrials":96,"cells":3753},"Ropivacaine 0.2% Injectable Solution Bolus",{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3760,"PHASE4":3773,"NA":3775},{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[],{"trials":3761,"activeCount":100},[3762],{"nctId":3763,"briefTitle":3764,"status":431,"phases":3765,"primaryCompletion":3766,"completion":3767,"start":3768,"enrollment":2962,"conditions":3769,"interventions":3771},"NCT05054179","Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain",[89,90],"2024-01","2024-07","2022-09-07",[788,3770,1815],"Sternotomy",[3752,3772],"Ropivacaine 0.2% Injectable Solution",{"trials":3774,"activeCount":100},[],{"trials":3776,"activeCount":100},[],{"intervention":3772,"totalTrials":96,"cells":3778},{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3785,"PHASE4":3791,"NA":3793},{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[],{"trials":3784,"activeCount":100},[],{"trials":3786,"activeCount":100},[3787],{"nctId":3763,"briefTitle":3764,"status":431,"phases":3788,"primaryCompletion":3766,"completion":3767,"start":3768,"enrollment":2962,"conditions":3789,"interventions":3790},[89,90],[788,3770,1815],[3752,3772],{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[],{"intervention":3796,"totalTrials":96,"cells":3797},"Naloxone",{"EARLY_PHASE1":3798,"PHASE1":3800,"PHASE2":3802,"PHASE3":3804,"PHASE4":3814,"NA":3816},{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[],{"trials":3803,"activeCount":100},[],{"trials":3805,"activeCount":100},[3806],{"nctId":3807,"briefTitle":3808,"status":394,"phases":3809,"primaryCompletion":2208,"completion":2208,"start":2826,"enrollment":2112,"conditions":3810,"interventions":3812},"NCT01071057","Naloxone for the Treatment of Opioid-Induced Pruritus",[89,90],[3811],"Pruritus",[3796,3813],"Saline\u002FMorphine",{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[],{"intervention":3813,"totalTrials":96,"cells":3819},{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3826,"PHASE4":3832,"NA":3834},{"trials":3821,"activeCount":100},[],{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[3828],{"nctId":3807,"briefTitle":3808,"status":394,"phases":3829,"primaryCompletion":2208,"completion":2208,"start":2826,"enrollment":2112,"conditions":3830,"interventions":3831},[89,90],[3811],[3796,3813],{"trials":3833,"activeCount":100},[],{"trials":3835,"activeCount":100},[],{"intervention":3837,"totalTrials":96,"cells":3838},"Morphine",{"EARLY_PHASE1":3839,"PHASE1":3841,"PHASE2":3843,"PHASE3":3845,"PHASE4":3855,"NA":3857},{"trials":3840,"activeCount":100},[],{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[3847],{"nctId":3848,"briefTitle":3849,"status":394,"phases":3850,"primaryCompletion":3851,"completion":3851,"start":1587,"enrollment":3852,"conditions":3853,"interventions":3854},"NCT01071499","Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population Presenting for Elective Surgery",[89,90],"2012-11",43,[33],[3837,3837,3837],{"trials":3856,"activeCount":100},[],{"trials":3858,"activeCount":100},[],{"intervention":3860,"totalTrials":96,"cells":3861},"Ketofol",{"EARLY_PHASE1":3862,"PHASE1":3864,"PHASE2":3866,"PHASE3":3868,"PHASE4":3880,"NA":3882},{"trials":3863,"activeCount":100},[],{"trials":3865,"activeCount":100},[],{"trials":3867,"activeCount":100},[],{"trials":3869,"activeCount":100},[3870],{"nctId":3871,"briefTitle":3872,"status":394,"phases":3873,"primaryCompletion":434,"completion":434,"start":3874,"enrollment":279,"conditions":3875,"interventions":3878},"NCT02079090","Ketofol Versus Fentofol for Procedural Sedation in the Pediatric Emergency Department",[90],"2014-07",[3876,3877],"Emergency Department Procedural Sedation","Fracture Reduction",[3860,3879],"Fentofol",{"trials":3881,"activeCount":100},[],{"trials":3883,"activeCount":100},[],{"intervention":3879,"totalTrials":96,"cells":3885},{"EARLY_PHASE1":3886,"PHASE1":3888,"PHASE2":3890,"PHASE3":3892,"PHASE4":3898,"NA":3900},{"trials":3887,"activeCount":100},[],{"trials":3889,"activeCount":100},[],{"trials":3891,"activeCount":100},[],{"trials":3893,"activeCount":100},[3894],{"nctId":3871,"briefTitle":3872,"status":394,"phases":3895,"primaryCompletion":434,"completion":434,"start":3874,"enrollment":279,"conditions":3896,"interventions":3897},[90],[3876,3877],[3860,3879],{"trials":3899,"activeCount":100},[],{"trials":3901,"activeCount":100},[],{"intervention":3903,"totalTrials":96,"cells":3904},"luteinizing hormone-releasing hormone (LHRH) short acting or long acting",{"EARLY_PHASE1":3905,"PHASE1":3907,"PHASE2":3909,"PHASE3":3911,"PHASE4":3920,"NA":3922},{"trials":3906,"activeCount":100},[],{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[3913],{"nctId":3914,"briefTitle":3915,"status":431,"phases":3916,"primaryCompletion":2884,"completion":2884,"start":3917,"enrollment":1445,"conditions":3918,"interventions":3919},"NCT00175383","Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer",[90],"2004-06",[667],[3903],{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"intervention":415,"totalTrials":96,"cells":3925},{"EARLY_PHASE1":3926,"PHASE1":3928,"PHASE2":3930,"PHASE3":3932,"PHASE4":3938,"NA":3940},{"trials":3927,"activeCount":100},[],{"trials":3929,"activeCount":100},[],{"trials":3931,"activeCount":100},[],{"trials":3933,"activeCount":100},[3934],{"nctId":404,"briefTitle":405,"status":394,"phases":3935,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":3936,"interventions":3937},[90],[412],[414,415],{"trials":3939,"activeCount":100},[],{"trials":3941,"activeCount":100},[],{"intervention":3943,"totalTrials":96,"cells":3944},"Cephalexin",{"EARLY_PHASE1":3945,"PHASE1":3947,"PHASE2":3949,"PHASE3":3951,"PHASE4":3961,"NA":3963},{"trials":3946,"activeCount":100},[],{"trials":3948,"activeCount":100},[],{"trials":3950,"activeCount":100},[],{"trials":3952,"activeCount":100},[3953],{"nctId":3954,"briefTitle":3955,"status":431,"phases":3956,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":3528,"conditions":3959,"interventions":3960},"NCT04553419","Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF",[90],"2025-06-30","2020-07-27",[30],[3943],{"trials":3962,"activeCount":100},[],{"trials":3964,"activeCount":100},[],{"intervention":3966,"totalTrials":96,"cells":3967},"aspirin",{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3974,"PHASE4":3987,"NA":3989},{"trials":3969,"activeCount":100},[],{"trials":3971,"activeCount":100},[],{"trials":3973,"activeCount":100},[],{"trials":3975,"activeCount":100},[3976],{"nctId":3977,"briefTitle":3978,"status":394,"phases":3979,"primaryCompletion":1409,"completion":1409,"start":3980,"enrollment":3981,"conditions":3982,"interventions":3985},"NCT00059306","Secondary Prevention of Small Subcortical Strokes Trial",[90],"2003-02",3020,[3983,3984],"Cerebrovascular Accident","Hypertension",[3966,3986],"clopidogrel",{"trials":3988,"activeCount":100},[],{"trials":3990,"activeCount":100},[],{"intervention":3986,"totalTrials":96,"cells":3992},{"EARLY_PHASE1":3993,"PHASE1":3995,"PHASE2":3997,"PHASE3":3999,"PHASE4":4005,"NA":4007},{"trials":3994,"activeCount":100},[],{"trials":3996,"activeCount":100},[],{"trials":3998,"activeCount":100},[],{"trials":4000,"activeCount":100},[4001],{"nctId":3977,"briefTitle":3978,"status":394,"phases":4002,"primaryCompletion":1409,"completion":1409,"start":3980,"enrollment":3981,"conditions":4003,"interventions":4004},[90],[3983,3984],[3966,3986],{"trials":4006,"activeCount":100},[],{"trials":4008,"activeCount":100},[],{"intervention":4010,"totalTrials":96,"cells":4011},"Inhaled Budesonide 800 µg twice daily",{"EARLY_PHASE1":4012,"PHASE1":4014,"PHASE2":4016,"PHASE3":4018,"PHASE4":4029,"NA":4031},{"trials":4013,"activeCount":100},[],{"trials":4015,"activeCount":100},[],{"trials":4017,"activeCount":100},[],{"trials":4019,"activeCount":100},[4020],{"nctId":4021,"briefTitle":4022,"status":394,"phases":4023,"completion":4024,"start":4025,"enrollment":168,"conditions":4026,"interventions":4028},"NCT00175747","A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)",[89,90],"2002-12","2000-01",[4027],"Lung Cancer",[4010],{"trials":4030,"activeCount":100},[],{"trials":4032,"activeCount":100},[],{"intervention":4034,"totalTrials":96,"cells":4035},"d4T",{"EARLY_PHASE1":4036,"PHASE1":4038,"PHASE2":4040,"PHASE3":4042,"PHASE4":4054,"NA":4056},{"trials":4037,"activeCount":100},[],{"trials":4039,"activeCount":100},[],{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[4044],{"nctId":4045,"briefTitle":4046,"status":394,"phases":4047,"primaryCompletion":2275,"completion":2275,"start":4048,"enrollment":2962,"conditions":4049,"interventions":4051},"NCT00143702","D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE)",[89,90],"2001-08",[4050],"Acidosis, Lactic",[4034,4052,4053],"Abacavir","Riboflavin and Thiamine",{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"intervention":4052,"totalTrials":96,"cells":4059},{"EARLY_PHASE1":4060,"PHASE1":4062,"PHASE2":4064,"PHASE3":4066,"PHASE4":4072,"NA":4074},{"trials":4061,"activeCount":100},[],{"trials":4063,"activeCount":100},[],{"trials":4065,"activeCount":100},[],{"trials":4067,"activeCount":100},[4068],{"nctId":4045,"briefTitle":4046,"status":394,"phases":4069,"primaryCompletion":2275,"completion":2275,"start":4048,"enrollment":2962,"conditions":4070,"interventions":4071},[89,90],[4050],[4034,4052,4053],{"trials":4073,"activeCount":100},[],{"trials":4075,"activeCount":100},[],{"intervention":4053,"totalTrials":96,"cells":4077},{"EARLY_PHASE1":4078,"PHASE1":4080,"PHASE2":4082,"PHASE3":4084,"PHASE4":4090,"NA":4092},{"trials":4079,"activeCount":100},[],{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"trials":4085,"activeCount":100},[4086],{"nctId":4045,"briefTitle":4046,"status":394,"phases":4087,"primaryCompletion":2275,"completion":2275,"start":4048,"enrollment":2962,"conditions":4088,"interventions":4089},[89,90],[4050],[4034,4052,4053],{"trials":4091,"activeCount":100},[],{"trials":4093,"activeCount":100},[],{"intervention":4095,"totalTrials":96,"cells":4096},"Cesemat",{"EARLY_PHASE1":4097,"PHASE1":4099,"PHASE2":4101,"PHASE3":4103,"PHASE4":4115,"NA":4117},{"trials":4098,"activeCount":100},[],{"trials":4100,"activeCount":100},[],{"trials":4102,"activeCount":100},[],{"trials":4104,"activeCount":100},[4105],{"nctId":4106,"briefTitle":4107,"status":394,"phases":4108,"primaryCompletion":4109,"completion":1347,"start":4110,"enrollment":4111,"conditions":4112,"interventions":4114},"NCT01025700","Nabilone & Marijuana Addiction",[89,90],"2010-06","2009-06",35,[4113],"Marijuana Smoking",[4095],{"trials":4116,"activeCount":100},[],{"trials":4118,"activeCount":100},[],{"intervention":4120,"totalTrials":341,"cells":4121},"Botulinum Toxin Type A",{"EARLY_PHASE1":4122,"PHASE1":4124,"PHASE2":4134,"PHASE3":4144,"PHASE4":4146,"NA":4148},{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":100},[4126],{"nctId":4127,"briefTitle":4128,"status":431,"phases":4129,"primaryCompletion":2709,"completion":4130,"start":3056,"enrollment":785,"conditions":4131,"interventions":4133},"NCT01405482","Botulinum Toxin Injections for Thoracic Outlet Syndrome",[88],"2013-06",[4132],"Thoracic Outlet Syndrome",[4120],{"trials":4135,"activeCount":100},[4136],{"nctId":4137,"briefTitle":4138,"status":394,"phases":4139,"primaryCompletion":4140,"completion":4140,"start":4141,"enrollment":966,"conditions":4142,"interventions":4143},"NCT00444886","Treatment of Thoracic Outlet Syndrome (TOS) With Botox",[89],"2011-02","2007-05",[4132],[4120,4120],{"trials":4145,"activeCount":100},[],{"trials":4147,"activeCount":100},[],{"trials":4149,"activeCount":100},[],{"intervention":4151,"totalTrials":341,"cells":4152},"Mannitol cream",{"EARLY_PHASE1":4153,"PHASE1":4155,"PHASE2":4165,"PHASE3":4177,"PHASE4":4179,"NA":4181},{"trials":4154,"activeCount":100},[],{"trials":4156,"activeCount":100},[4157],{"nctId":4158,"briefTitle":4159,"status":394,"phases":4160,"primaryCompletion":878,"completion":4161,"start":878,"enrollment":4162,"conditions":4163,"interventions":4164},"NCT01843088","Trial of Mannitol Cream for Pain Relief After a Long Run",[88],"2013-07",170,[33],[4151],{"trials":4166,"activeCount":100},[4167],{"nctId":4168,"briefTitle":4169,"status":394,"phases":4170,"primaryCompletion":4171,"completion":4172,"start":4173,"enrollment":141,"conditions":4174,"interventions":4176},"NCT02484170","Mannitol Cream for Post Herpetic Neuralgia",[88,89],"2016-04-29","2017-04-30","2015-09-30",[4175],"Neuralgia, Postherpetic",[4151],{"trials":4178,"activeCount":100},[],{"trials":4180,"activeCount":100},[],{"trials":4182,"activeCount":100},[],{"intervention":4184,"totalTrials":96,"cells":4185},"L-theanine",{"EARLY_PHASE1":4186,"PHASE1":4188,"PHASE2":4190,"PHASE3":4200,"PHASE4":4202,"NA":4204},{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[],{"trials":4191,"activeCount":100},[4192],{"nctId":4193,"briefTitle":4194,"status":394,"phases":4195,"primaryCompletion":1716,"completion":1716,"start":4196,"enrollment":1445,"conditions":4197,"interventions":4199},"NCT00291070","Effects of L-Theanine in Boys With ADHD",[89],"2005-10",[4198],"Attention Deficit Hyperactivity Disorder",[4184],{"trials":4201,"activeCount":100},[],{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[],{"intervention":4207,"totalTrials":96,"cells":4208},"Fluticasone group",{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4227,"PHASE4":4229,"NA":4231},{"trials":4210,"activeCount":100},[],{"trials":4212,"activeCount":100},[],{"trials":4214,"activeCount":100},[4215],{"nctId":4216,"briefTitle":4217,"status":431,"phases":4218,"primaryCompletion":4219,"completion":4220,"start":4221,"enrollment":4222,"conditions":4223,"interventions":4224},"NCT02833480","A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota",[89],"2021-01","2021-06","2015-02",69,[968],[4207,4225,4226],"Budesonide group","Formoterol group",{"trials":4228,"activeCount":100},[],{"trials":4230,"activeCount":100},[],{"trials":4232,"activeCount":100},[],{"intervention":4225,"totalTrials":96,"cells":4234},{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4239,"PHASE3":4245,"PHASE4":4247,"NA":4249},{"trials":4236,"activeCount":100},[],{"trials":4238,"activeCount":100},[],{"trials":4240,"activeCount":100},[4241],{"nctId":4216,"briefTitle":4217,"status":431,"phases":4242,"primaryCompletion":4219,"completion":4220,"start":4221,"enrollment":4222,"conditions":4243,"interventions":4244},[89],[968],[4207,4225,4226],{"trials":4246,"activeCount":100},[],{"trials":4248,"activeCount":100},[],{"trials":4250,"activeCount":100},[],{"intervention":4226,"totalTrials":96,"cells":4252},{"EARLY_PHASE1":4253,"PHASE1":4255,"PHASE2":4257,"PHASE3":4263,"PHASE4":4265,"NA":4267},{"trials":4254,"activeCount":100},[],{"trials":4256,"activeCount":100},[],{"trials":4258,"activeCount":100},[4259],{"nctId":4216,"briefTitle":4217,"status":431,"phases":4260,"primaryCompletion":4219,"completion":4220,"start":4221,"enrollment":4222,"conditions":4261,"interventions":4262},[89],[968],[4207,4225,4226],{"trials":4264,"activeCount":100},[],{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[],{"intervention":4270,"totalTrials":96,"cells":4271},"Memantine",{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4273,"activeCount":100},[],{"trials":4275,"activeCount":100},[],{"trials":4277,"activeCount":100},[4278],{"nctId":4279,"briefTitle":4280,"status":394,"phases":4281,"primaryCompletion":1586,"completion":3851,"start":4282,"enrollment":25,"conditions":4283,"interventions":4285},"NCT01458470","A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease",[89],"2011-09",[4284],"Huntington Disease",[4270],{"trials":4287,"activeCount":100},[],{"trials":4289,"activeCount":100},[],{"trials":4291,"activeCount":100},[],{"intervention":4293,"totalTrials":96,"cells":4294},"Valacyclovir",{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4299,"PHASE3":4308,"PHASE4":4310,"NA":4312},{"trials":4296,"activeCount":100},[],{"trials":4298,"activeCount":100},[],{"trials":4300,"activeCount":100},[4301],{"nctId":4302,"briefTitle":4303,"status":394,"phases":4304,"primaryCompletion":4305,"completion":4305,"start":2710,"enrollment":1445,"conditions":4306,"interventions":4307},"NCT00175513","V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis",[89],"2009-09",[1465],[4293],{"trials":4309,"activeCount":100},[],{"trials":4311,"activeCount":100},[],{"trials":4313,"activeCount":100},[],{"intervention":4315,"totalTrials":96,"cells":4316},"apixaban",{"EARLY_PHASE1":4317,"PHASE1":4319,"PHASE2":4321,"PHASE3":4333,"PHASE4":4335,"NA":4337},{"trials":4318,"activeCount":100},[],{"trials":4320,"activeCount":100},[],{"trials":4322,"activeCount":100},[4323],{"nctId":4324,"briefTitle":4325,"status":1360,"phases":4326,"primaryCompletion":4327,"completion":4328,"start":4329,"enrollment":341,"conditions":4330,"interventions":4332},"NCT02749617","A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma",[89],"2018-01-03","2019-03-28","2016-08-09",[4331],"Anti-Xa Activity",[4315],{"trials":4334,"activeCount":100},[],{"trials":4336,"activeCount":100},[],{"trials":4338,"activeCount":100},[],{"intervention":4340,"totalTrials":96,"cells":4341},"Psychostimulants",{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4346,"PHASE3":4356,"PHASE4":4358,"NA":4360},{"trials":4343,"activeCount":100},[],{"trials":4345,"activeCount":100},[],{"trials":4347,"activeCount":100},[4348],{"nctId":4349,"briefTitle":4350,"status":431,"phases":4351,"primaryCompletion":3571,"completion":3571,"start":3261,"enrollment":4352,"conditions":4353,"interventions":4355},"NCT02167048","Low-dose vs. Normal-dose Psychostimulants on Executive Functions in Individuals With ADHD",[88,89],52,[4354],"Attention Deficit Hyperactivity Disorders",[4340],{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[],{"trials":4361,"activeCount":100},[],{"intervention":4363,"totalTrials":96,"cells":4364},"Resiquimod gel",{"EARLY_PHASE1":4365,"PHASE1":4367,"PHASE2":4369,"PHASE3":4379,"PHASE4":4381,"NA":4383},{"trials":4366,"activeCount":100},[],{"trials":4368,"activeCount":100},[],{"trials":4370,"activeCount":100},[4371],{"nctId":4372,"briefTitle":4373,"status":394,"phases":4374,"primaryCompletion":407,"completion":407,"start":4375,"enrollment":4376,"conditions":4377,"interventions":4378},"NCT00175435","Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator",[88,89],"2005-08",39,[2186],[4363,4363,4363],{"trials":4380,"activeCount":100},[],{"trials":4382,"activeCount":100},[],{"trials":4384,"activeCount":100},[],{"intervention":4386,"totalTrials":96,"cells":4387},"Sitagliptin 100 mg",{"EARLY_PHASE1":4388,"PHASE1":4390,"PHASE2":4392,"PHASE3":4401,"PHASE4":4403,"NA":4405},{"trials":4389,"activeCount":100},[],{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[4394],{"nctId":4395,"briefTitle":4396,"status":394,"phases":4397,"primaryCompletion":3851,"completion":3851,"start":4398,"enrollment":1302,"conditions":4399,"interventions":4400},"NCT00451113","Sitagliptin in the Elderly",[89],"2006-11",[27],[4386],{"trials":4402,"activeCount":100},[],{"trials":4404,"activeCount":100},[],{"trials":4406,"activeCount":100},[],{"intervention":4408,"totalTrials":96,"cells":4409},"Triheptanoin",{"EARLY_PHASE1":4410,"PHASE1":4412,"PHASE2":4414,"PHASE3":4424,"PHASE4":4426,"NA":4428},{"trials":4411,"activeCount":100},[],{"trials":4413,"activeCount":100},[],{"trials":4415,"activeCount":100},[4416],{"nctId":4417,"briefTitle":4418,"status":431,"phases":4419,"primaryCompletion":1643,"completion":4420,"start":3461,"enrollment":374,"conditions":4421,"interventions":4423},"NCT02000960","Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome",[89],"2016-10",[4422],"Glucose Transporter Type 1 Deficiency Syndrome",[4408],{"trials":4425,"activeCount":100},[],{"trials":4427,"activeCount":100},[],{"trials":4429,"activeCount":100},[],{"intervention":4431,"totalTrials":96,"cells":4432},"Tremelimumab",{"EARLY_PHASE1":4433,"PHASE1":4435,"PHASE2":4437,"PHASE3":4451,"PHASE4":4453,"NA":4455},{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[],{"trials":4438,"activeCount":100},[4439],{"nctId":4440,"briefTitle":4441,"status":1458,"phases":4442,"primaryCompletion":4443,"completion":4443,"start":4444,"enrollment":100,"conditions":4445,"interventions":4450},"NCT05120622","Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer",[88,89],"2022-05-01","2021-09-01",[4446,4447,4431,4448,4449],"Bladder Cancer","High-Risk Cancer","Durvalumab","Non-muscle Invasive",[4431],{"trials":4452,"activeCount":100},[],{"trials":4454,"activeCount":100},[],{"trials":4456,"activeCount":100},[],{"intervention":4458,"totalTrials":96,"cells":4459},"Botox injections",{"EARLY_PHASE1":4460,"PHASE1":4462,"PHASE2":4464,"PHASE3":4474,"PHASE4":4476,"NA":4478},{"trials":4461,"activeCount":100},[],{"trials":4463,"activeCount":100},[],{"trials":4465,"activeCount":100},[4466],{"nctId":4467,"briefTitle":4468,"status":394,"phases":4469,"primaryCompletion":2486,"completion":2486,"start":4470,"enrollment":1062,"conditions":4471,"interventions":4473},"NCT00175669","Trial of a Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking",[89],"2007-08",[4472],"Idiopathic Toe Walking",[4458],{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":100},[],{"intervention":4481,"totalTrials":96,"cells":4482},"Evolocumab",{"EARLY_PHASE1":4483,"PHASE1":4485,"PHASE2":4487,"PHASE3":4499,"PHASE4":4501,"NA":4503},{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[4489],{"nctId":4490,"briefTitle":4491,"status":431,"phases":4492,"primaryCompletion":4493,"completion":4493,"start":4494,"enrollment":4495,"conditions":4496,"interventions":4498},"NCT03869073","Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study)",[89],"2021-02-11","2019-02-11",36,[4497],"Sepsis",[4481],{"trials":4500,"activeCount":100},[],{"trials":4502,"activeCount":100},[],{"trials":4504,"activeCount":100},[],{"intervention":4506,"totalTrials":96,"cells":4507},"Flunarizine Hydrochloride",{"EARLY_PHASE1":4508,"PHASE1":4510,"PHASE2":4512,"PHASE3":4526,"PHASE4":4528,"NA":4530},{"trials":4509,"activeCount":100},[],{"trials":4511,"activeCount":100},[],{"trials":4513,"activeCount":100},[4514],{"nctId":4515,"briefTitle":4516,"status":1360,"phases":4517,"primaryCompletion":4518,"completion":4518,"start":4519,"enrollment":4520,"conditions":4521,"interventions":4525},"NCT06153186","Flunarizine for Treatment Resistant Absence Epilepsy",[89],"2023-05-26","2019-09-20",9,[4522,4523,4524],"Childhood Absence Epilepsy","Juvenile Absence Epilepsy","Juvenile Myoclonic Epilepsy",[4506],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[],{"trials":4531,"activeCount":100},[],{"intervention":4533,"totalTrials":96,"cells":4534},"Subcutaneous testosterone",{"EARLY_PHASE1":4535,"PHASE1":4537,"PHASE2":4539,"PHASE3":4549,"PHASE4":4551,"NA":4553},{"trials":4536,"activeCount":100},[],{"trials":4538,"activeCount":100},[],{"trials":4540,"activeCount":100},[4541],{"nctId":4542,"briefTitle":4543,"status":394,"phases":4544,"primaryCompletion":974,"completion":974,"start":4545,"enrollment":1384,"conditions":4546,"interventions":4548},"NCT02229617","Subcutaneous Testosterone Project",[88,89],"2015-07",[4547],"Gender Dysphoria",[4533],{"trials":4550,"activeCount":100},[],{"trials":4552,"activeCount":100},[],{"trials":4554,"activeCount":100},[],{"intervention":4556,"totalTrials":96,"cells":4557},"FMT",{"EARLY_PHASE1":4558,"PHASE1":4560,"PHASE2":4562,"PHASE3":4574,"PHASE4":4576,"NA":4578},{"trials":4559,"activeCount":100},[],{"trials":4561,"activeCount":100},[],{"trials":4563,"activeCount":100},[4564],{"nctId":4565,"briefTitle":4566,"status":1458,"phases":4567,"primaryCompletion":3571,"completion":4568,"start":4569,"enrollment":100,"conditions":4570,"interventions":4572},"NCT04202211","FMT for Remission of Active Ulcerative Colitis in Adults",[89],"2028-12","2022-03",[4571,2517],"Ulcerative Colitis",[4556,4573],"FMT enema",{"trials":4575,"activeCount":100},[],{"trials":4577,"activeCount":100},[],{"trials":4579,"activeCount":100},[],{"intervention":4573,"totalTrials":96,"cells":4581},{"EARLY_PHASE1":4582,"PHASE1":4584,"PHASE2":4586,"PHASE3":4592,"PHASE4":4594,"NA":4596},{"trials":4583,"activeCount":100},[],{"trials":4585,"activeCount":100},[],{"trials":4587,"activeCount":100},[4588],{"nctId":4565,"briefTitle":4566,"status":1458,"phases":4589,"primaryCompletion":3571,"completion":4568,"start":4569,"enrollment":100,"conditions":4590,"interventions":4591},[89],[4571,2517],[4556,4573],{"trials":4593,"activeCount":100},[],{"trials":4595,"activeCount":100},[],{"trials":4597,"activeCount":100},[],{"intervention":4599,"totalTrials":96,"cells":4600},"doxorubicin, superabsorbent polymer microspheres, embolotherapy",{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4605,"PHASE3":4615,"PHASE4":4617,"NA":4619},{"trials":4602,"activeCount":100},[],{"trials":4604,"activeCount":100},[],{"trials":4606,"activeCount":100},[4607],{"nctId":4608,"briefTitle":4609,"status":394,"phases":4610,"primaryCompletion":2393,"completion":2393,"start":4611,"enrollment":2440,"conditions":4612,"interventions":4614},"NCT01116635","Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)",[88,89],"2010-01",[4613],"Hepatocellular Carcinoma",[4599],{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"trials":4620,"activeCount":100},[],{"intervention":4622,"totalTrials":96,"cells":4623},"Spironolactone",{"EARLY_PHASE1":4624,"PHASE1":4626,"PHASE2":4628,"PHASE3":4639,"PHASE4":4641,"NA":4643},{"trials":4625,"activeCount":100},[],{"trials":4627,"activeCount":100},[],{"trials":4629,"activeCount":100},[4630],{"nctId":4631,"briefTitle":4632,"status":394,"phases":4633,"primaryCompletion":4634,"completion":4634,"start":2710,"enrollment":966,"conditions":4635,"interventions":4637},"NCT00175617","Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss",[89],"2009-03-09",[4636],"Female Pattern Hair Loss",[4622,4638],"Minoxidil",{"trials":4640,"activeCount":100},[],{"trials":4642,"activeCount":100},[],{"trials":4644,"activeCount":100},[],{"intervention":4638,"totalTrials":96,"cells":4646},{"EARLY_PHASE1":4647,"PHASE1":4649,"PHASE2":4651,"PHASE3":4657,"PHASE4":4659,"NA":4661},{"trials":4648,"activeCount":100},[],{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[4653],{"nctId":4631,"briefTitle":4632,"status":394,"phases":4654,"primaryCompletion":4634,"completion":4634,"start":2710,"enrollment":966,"conditions":4655,"interventions":4656},[89],[4636],[4622,4638],{"trials":4658,"activeCount":100},[],{"trials":4660,"activeCount":100},[],{"trials":4662,"activeCount":100},[],{"intervention":4664,"totalTrials":96,"cells":4665},"Nitric Oxide gas at 160ppm",{"EARLY_PHASE1":4666,"PHASE1":4668,"PHASE2":4670,"PHASE3":4682,"PHASE4":4684,"NA":4686},{"trials":4667,"activeCount":100},[],{"trials":4669,"activeCount":100},[],{"trials":4671,"activeCount":100},[4672],{"nctId":4673,"briefTitle":4674,"status":394,"phases":4675,"primaryCompletion":4676,"completion":4677,"start":4678,"enrollment":96,"conditions":4679,"interventions":4681},"NCT03473314","Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for Adult With Non-Tuberculous Mycobacteria Infection",[89],"2020-07-11","2020-07-21","2018-03-09",[4680],"Non-Tuberculous Mycobacterial Pneumonia",[4664],{"trials":4683,"activeCount":100},[],{"trials":4685,"activeCount":100},[],{"trials":4687,"activeCount":100},[],{"intervention":4689,"totalTrials":96,"cells":4690},"Celecoxib",{"EARLY_PHASE1":4691,"PHASE1":4693,"PHASE2":4695,"PHASE3":4707,"PHASE4":4709,"NA":4711},{"trials":4692,"activeCount":100},[],{"trials":4694,"activeCount":100},[],{"trials":4696,"activeCount":100},[4697],{"nctId":4698,"briefTitle":4699,"status":431,"phases":4700,"primaryCompletion":4701,"completion":4701,"start":4702,"enrollment":2962,"conditions":4703,"interventions":4706},"NCT04673578","Adjunctive Celecoxib in Childhood-onset OCD Study",[89],"2023-06","2021-06-01",[4704,4705],"Obsessive-Compulsive Disorder","Pediatric Psychiatric Disorder",[4689],{"trials":4708,"activeCount":100},[],{"trials":4710,"activeCount":100},[],{"trials":4712,"activeCount":100},[],{"intervention":4714,"totalTrials":96,"cells":4715},"Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab",{"EARLY_PHASE1":4716,"PHASE1":4718,"PHASE2":4720,"PHASE3":4733,"PHASE4":4735,"NA":4737},{"trials":4717,"activeCount":100},[],{"trials":4719,"activeCount":100},[],{"trials":4721,"activeCount":100},[4722],{"nctId":4723,"briefTitle":4724,"status":394,"phases":4725,"primaryCompletion":4726,"completion":4727,"start":1716,"enrollment":4495,"conditions":4728,"interventions":4730},"NCT00359164","Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.",[89],"2008-06","2008-08",[4729],"Macular Degeneration",[4714,4731,4732],"Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab","Verteporfin Photodynamic Therapy (SHAM) and bevacizumab",{"trials":4734,"activeCount":100},[],{"trials":4736,"activeCount":100},[],{"trials":4738,"activeCount":100},[],{"intervention":4731,"totalTrials":96,"cells":4740},{"EARLY_PHASE1":4741,"PHASE1":4743,"PHASE2":4745,"PHASE3":4751,"PHASE4":4753,"NA":4755},{"trials":4742,"activeCount":100},[],{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[4747],{"nctId":4723,"briefTitle":4724,"status":394,"phases":4748,"primaryCompletion":4726,"completion":4727,"start":1716,"enrollment":4495,"conditions":4749,"interventions":4750},[89],[4729],[4714,4731,4732],{"trials":4752,"activeCount":100},[],{"trials":4754,"activeCount":100},[],{"trials":4756,"activeCount":100},[],{"intervention":4732,"totalTrials":96,"cells":4758},{"EARLY_PHASE1":4759,"PHASE1":4761,"PHASE2":4763,"PHASE3":4769,"PHASE4":4771,"NA":4773},{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[],{"trials":4764,"activeCount":100},[4765],{"nctId":4723,"briefTitle":4724,"status":394,"phases":4766,"primaryCompletion":4726,"completion":4727,"start":1716,"enrollment":4495,"conditions":4767,"interventions":4768},[89],[4729],[4714,4731,4732],{"trials":4770,"activeCount":100},[],{"trials":4772,"activeCount":100},[],{"trials":4774,"activeCount":100},[],{"intervention":4776,"totalTrials":96,"cells":4777},"Acarbose",{"EARLY_PHASE1":4778,"PHASE1":4780,"PHASE2":4782,"PHASE3":4793,"PHASE4":4795,"NA":4797},{"trials":4779,"activeCount":100},[],{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[4784],{"nctId":4785,"briefTitle":4786,"status":394,"phases":4787,"primaryCompletion":4788,"completion":2986,"start":4789,"enrollment":36,"conditions":4790,"interventions":4792},"NCT02043886","Acarbose, Postprandial Hypotension and Type 2 Diabetes",[89],"2013-01","2007-06",[27,4791],"Postprandial Hypotension",[4776],{"trials":4794,"activeCount":100},[],{"trials":4796,"activeCount":100},[],{"trials":4798,"activeCount":100},[],{"intervention":4800,"totalTrials":96,"cells":4801},"Platelet Rich Plasma",{"EARLY_PHASE1":4802,"PHASE1":4804,"PHASE2":4806,"PHASE3":4816,"PHASE4":4818,"NA":4820},{"trials":4803,"activeCount":100},[],{"trials":4805,"activeCount":100},[],{"trials":4807,"activeCount":100},[4808],{"nctId":4809,"briefTitle":4810,"status":1360,"phases":4811,"primaryCompletion":2251,"completion":2251,"start":4812,"enrollment":904,"conditions":4813,"interventions":4815},"NCT02116946","Plasma Injections Plus Exercise for Patellar Tendinopathy",[89],"2014-03",[4814],"Patellar Tendinopathy",[4800],{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[],{"trials":4821,"activeCount":100},[],{"intervention":4823,"totalTrials":96,"cells":4824},"OGX-011",{"EARLY_PHASE1":4825,"PHASE1":4827,"PHASE2":4829,"PHASE3":4838,"PHASE4":4840,"NA":4842},{"trials":4826,"activeCount":100},[],{"trials":4828,"activeCount":100},[],{"trials":4830,"activeCount":100},[4831],{"nctId":4832,"briefTitle":4833,"status":394,"phases":4834,"primaryCompletion":4835,"completion":4835,"start":2368,"enrollment":141,"conditions":4836,"interventions":4837},"NCT00138918","Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer",[89],"2008-05-13",[667],[4823],{"trials":4839,"activeCount":100},[],{"trials":4841,"activeCount":100},[],{"trials":4843,"activeCount":100},[],{"intervention":4845,"totalTrials":96,"cells":4846},"Mannitol",{"EARLY_PHASE1":4847,"PHASE1":4849,"PHASE2":4851,"PHASE3":4864,"PHASE4":4866,"NA":4868},{"trials":4848,"activeCount":100},[],{"trials":4850,"activeCount":100},[],{"trials":4852,"activeCount":100},[4853],{"nctId":4854,"briefTitle":4855,"status":394,"phases":4856,"primaryCompletion":4857,"completion":4858,"start":4859,"enrollment":3058,"conditions":4860,"interventions":4862},"NCT02728687","Topical Menthol +\u002F- Mannitol for Painful Diabetic Peripheral Neuropathy",[88,89],"2020-03-30","2020-12-18","2017-03-15",[4861],"Diabetic Peripheral Neuropathy",[4845,4863],"Menthol",{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[],{"intervention":4863,"totalTrials":96,"cells":4871},{"EARLY_PHASE1":4872,"PHASE1":4874,"PHASE2":4876,"PHASE3":4882,"PHASE4":4884,"NA":4886},{"trials":4873,"activeCount":100},[],{"trials":4875,"activeCount":100},[],{"trials":4877,"activeCount":100},[4878],{"nctId":4854,"briefTitle":4855,"status":394,"phases":4879,"primaryCompletion":4857,"completion":4858,"start":4859,"enrollment":3058,"conditions":4880,"interventions":4881},[88,89],[4861],[4845,4863],{"trials":4883,"activeCount":100},[],{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[],{"intervention":4889,"totalTrials":96,"cells":4890},"Fluviral 2010\u002F11 Tri-valent Seasonal Influenza vaccine",{"EARLY_PHASE1":4891,"PHASE1":4893,"PHASE2":4895,"PHASE3":4904,"PHASE4":4906,"NA":4908},{"trials":4892,"activeCount":100},[],{"trials":4894,"activeCount":100},[],{"trials":4896,"activeCount":100},[4897],{"nctId":4898,"briefTitle":4899,"status":394,"phases":4900,"primaryCompletion":2792,"completion":2792,"start":2158,"enrollment":4901,"conditions":4902,"interventions":4903},"NCT01140009","Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011",[89],324,[2489],[4889,4889],{"trials":4905,"activeCount":100},[],{"trials":4907,"activeCount":100},[],{"trials":4909,"activeCount":100},[],{"intervention":4911,"totalTrials":96,"cells":4912},"mifepristone",{"EARLY_PHASE1":4913,"PHASE1":4915,"PHASE2":4917,"PHASE3":4926,"PHASE4":4928,"NA":4930},{"trials":4914,"activeCount":100},[],{"trials":4916,"activeCount":100},[],{"trials":4918,"activeCount":100},[4919],{"nctId":4920,"briefTitle":4921,"status":1458,"phases":4922,"primaryCompletion":2826,"completion":2826,"start":1716,"enrollment":100,"conditions":4923,"interventions":4925},"NCT00359125","RU-486 in the Treatment of Bipolar Depression",[89],[4924],"Bipolar Depression",[4911],{"trials":4927,"activeCount":100},[],{"trials":4929,"activeCount":100},[],{"trials":4931,"activeCount":100},[],{"intervention":4448,"totalTrials":96,"cells":4933},{"EARLY_PHASE1":4934,"PHASE1":4936,"PHASE2":4938,"PHASE3":4953,"PHASE4":4955,"NA":4957},{"trials":4935,"activeCount":100},[],{"trials":4937,"activeCount":100},[],{"trials":4939,"activeCount":100},[4940],{"nctId":4941,"briefTitle":4942,"status":1458,"phases":4943,"primaryCompletion":363,"completion":165,"start":4944,"enrollment":100,"conditions":4945,"interventions":4952},"NCT04944173","SCION: SABR and Checkpoint Inhibition of NSCLC",[89],"2023-08-11",[4946,4947,4948,4027,4949,4950,4951],"Non Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung","Non-small Cell Lung Cancer Stage I","Lung Cancer Stage I","Lung Adenocarcinoma, Stage I","Lung Squamous Cell Carcinoma Stage I",[4448],{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[],{"intervention":4960,"totalTrials":96,"cells":4961},"L-Carnitine",{"EARLY_PHASE1":4962,"PHASE1":4964,"PHASE2":4966,"PHASE3":4975,"PHASE4":4977,"NA":4979},{"trials":4963,"activeCount":100},[],{"trials":4965,"activeCount":100},[],{"trials":4967,"activeCount":100},[4968],{"nctId":4969,"briefTitle":4970,"status":394,"phases":4971,"primaryCompletion":2208,"completion":2208,"start":1347,"enrollment":341,"conditions":4972,"interventions":4974},"NCT01232907","The Effects of L-carnitine on Fatigue in Spinal Cord Injury",[89],[4973],"Spinal Cord Injury (SCI)",[4960],{"trials":4976,"activeCount":100},[],{"trials":4978,"activeCount":100},[],{"trials":4980,"activeCount":100},[],{"intervention":4982,"totalTrials":96,"cells":4983},"Simvastatin",{"EARLY_PHASE1":4984,"PHASE1":4986,"PHASE2":4988,"PHASE3":4997,"PHASE4":4999,"NA":5001},{"trials":4985,"activeCount":100},[],{"trials":4987,"activeCount":100},[],{"trials":4989,"activeCount":100},[4990],{"nctId":4991,"briefTitle":4992,"status":1458,"phases":4993,"primaryCompletion":1838,"completion":1838,"start":1838,"enrollment":100,"conditions":4994,"interventions":4996},"NCT01092572","Statins To Treat Adult Cystic Fibrosis",[88,89],[30,4995],"Systemic Inflammation",[4982],{"trials":4998,"activeCount":100},[],{"trials":5000,"activeCount":100},[],{"trials":5002,"activeCount":100},[],{"intervention":5004,"totalTrials":96,"cells":5005},"Fesoterodine",{"EARLY_PHASE1":5006,"PHASE1":5008,"PHASE2":5010,"PHASE3":5021,"PHASE4":5023,"NA":5025},{"trials":5007,"activeCount":100},[],{"trials":5009,"activeCount":100},[],{"trials":5011,"activeCount":100},[5012],{"nctId":5013,"briefTitle":5014,"status":394,"phases":5015,"primaryCompletion":5016,"completion":5016,"start":5017,"enrollment":36,"conditions":5018,"interventions":5020},"NCT02676154","Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)",[89],"2019-01-31","2016-02-25",[5019],"Autonomic Dysreflexia",[5004],{"trials":5022,"activeCount":100},[],{"trials":5024,"activeCount":100},[],{"trials":5026,"activeCount":100},[],{"intervention":5028,"totalTrials":96,"cells":5029},"Finasteride",{"EARLY_PHASE1":5030,"PHASE1":5032,"PHASE2":5034,"PHASE3":5046,"PHASE4":5048,"NA":5050},{"trials":5031,"activeCount":100},[],{"trials":5033,"activeCount":100},[],{"trials":5035,"activeCount":100},[5036],{"nctId":5037,"briefTitle":5038,"status":1360,"phases":5039,"primaryCompletion":1348,"completion":1348,"start":5040,"enrollment":5041,"conditions":5042,"interventions":5045},"NCT00600691","The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy",[89],"2008-03",29,[5043,5044],"Hematuria","Hematospermia",[5028],{"trials":5047,"activeCount":100},[],{"trials":5049,"activeCount":100},[],{"trials":5051,"activeCount":100},[],{"intervention":5053,"totalTrials":96,"cells":5054},"Lamotrigine",{"EARLY_PHASE1":5055,"PHASE1":5057,"PHASE2":5059,"PHASE3":5069,"PHASE4":5071,"NA":5073},{"trials":5056,"activeCount":100},[],{"trials":5058,"activeCount":100},[],{"trials":5060,"activeCount":100},[5061],{"nctId":5062,"briefTitle":5063,"status":394,"phases":5064,"primaryCompletion":1943,"completion":1943,"start":5065,"enrollment":36,"conditions":5066,"interventions":5068},"NCT00475137","Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression",[89],"2007-12",[5067],"Bipolar II Disorder, Most Recent Episode Major Depressive",[5053,5053],{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[],{"trials":5074,"activeCount":100},[],{"intervention":5076,"totalTrials":96,"cells":5077},"Ketamine Injectable Solution",{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5095,"PHASE4":5097,"NA":5099},{"trials":5079,"activeCount":100},[],{"trials":5081,"activeCount":100},[],{"trials":5083,"activeCount":100},[5084],{"nctId":5085,"briefTitle":5086,"status":1360,"phases":5087,"primaryCompletion":5088,"completion":5089,"start":2961,"enrollment":36,"conditions":5090,"interventions":5092},"NCT04955470","Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics",[88,89],"2023-09-01","2023-10-01",[5091],"Suicidal Ideation",[5076,5093,5094],"Midazolam Injectable Solution","Normal Saline 0.9% Injectable Solution",{"trials":5096,"activeCount":100},[],{"trials":5098,"activeCount":100},[],{"trials":5100,"activeCount":100},[],{"intervention":5093,"totalTrials":96,"cells":5102},{"EARLY_PHASE1":5103,"PHASE1":5105,"PHASE2":5107,"PHASE3":5113,"PHASE4":5115,"NA":5117},{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[5109],{"nctId":5085,"briefTitle":5086,"status":1360,"phases":5110,"primaryCompletion":5088,"completion":5089,"start":2961,"enrollment":36,"conditions":5111,"interventions":5112},[88,89],[5091],[5076,5093,5094],{"trials":5114,"activeCount":100},[],{"trials":5116,"activeCount":100},[],{"trials":5118,"activeCount":100},[],{"intervention":5094,"totalTrials":96,"cells":5120},{"EARLY_PHASE1":5121,"PHASE1":5123,"PHASE2":5125,"PHASE3":5131,"PHASE4":5133,"NA":5135},{"trials":5122,"activeCount":100},[],{"trials":5124,"activeCount":100},[],{"trials":5126,"activeCount":100},[5127],{"nctId":5085,"briefTitle":5086,"status":1360,"phases":5128,"primaryCompletion":5088,"completion":5089,"start":2961,"enrollment":36,"conditions":5129,"interventions":5130},[88,89],[5091],[5076,5093,5094],{"trials":5132,"activeCount":100},[],{"trials":5134,"activeCount":100},[],{"trials":5136,"activeCount":100},[],{"intervention":5138,"totalTrials":96,"cells":5139},"glyburide",{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5144,"PHASE3":5154,"PHASE4":5156,"NA":5158},{"trials":5141,"activeCount":100},[],{"trials":5143,"activeCount":100},[],{"trials":5145,"activeCount":100},[5146],{"nctId":5147,"briefTitle":5148,"status":394,"phases":5149,"primaryCompletion":4282,"completion":4282,"start":5150,"enrollment":279,"conditions":5151,"interventions":5152},"NCT00451620","Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes",[89],"2003-11",[27],[5138,5153],"GlucoNorm",{"trials":5155,"activeCount":100},[],{"trials":5157,"activeCount":100},[],{"trials":5159,"activeCount":100},[],{"intervention":5153,"totalTrials":96,"cells":5161},{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5166,"PHASE3":5172,"PHASE4":5174,"NA":5176},{"trials":5163,"activeCount":100},[],{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[5168],{"nctId":5147,"briefTitle":5148,"status":394,"phases":5169,"primaryCompletion":4282,"completion":4282,"start":5150,"enrollment":279,"conditions":5170,"interventions":5171},[89],[27],[5138,5153],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[],{"intervention":5179,"totalTrials":96,"cells":5180},"Rivaroxaban",{"EARLY_PHASE1":5181,"PHASE1":5183,"PHASE2":5185,"PHASE3":5198,"PHASE4":5200,"NA":5202},{"trials":5182,"activeCount":100},[],{"trials":5184,"activeCount":100},[],{"trials":5186,"activeCount":100},[5187],{"nctId":5188,"briefTitle":5189,"status":394,"phases":5190,"primaryCompletion":5191,"completion":5191,"start":5192,"enrollment":5193,"conditions":5194,"interventions":5196},"NCT03178864","Study of Rivaroxaban for CeREbral Venous Thrombosis",[89],"2022-10-05","2019-03-12",55,[5195],"Cerebral Venous Thrombosis",[5179,5197],"Standard of care",{"trials":5199,"activeCount":100},[],{"trials":5201,"activeCount":100},[],{"trials":5203,"activeCount":100},[],{"intervention":5197,"totalTrials":96,"cells":5205},{"EARLY_PHASE1":5206,"PHASE1":5208,"PHASE2":5210,"PHASE3":5216,"PHASE4":5218,"NA":5220},{"trials":5207,"activeCount":100},[],{"trials":5209,"activeCount":100},[],{"trials":5211,"activeCount":100},[5212],{"nctId":5188,"briefTitle":5189,"status":394,"phases":5213,"primaryCompletion":5191,"completion":5191,"start":5192,"enrollment":5193,"conditions":5214,"interventions":5215},[89],[5195],[5179,5197],{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[],{"trials":5221,"activeCount":100},[],{"intervention":5223,"totalTrials":96,"cells":5224},"blinatumomab",{"EARLY_PHASE1":5225,"PHASE1":5227,"PHASE2":5229,"PHASE3":5242,"PHASE4":5244,"NA":5246},{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[],{"trials":5230,"activeCount":100},[5231],{"nctId":5232,"briefTitle":5233,"status":1360,"phases":5234,"primaryCompletion":5235,"completion":5235,"start":5236,"enrollment":2626,"conditions":5237,"interventions":5241},"NCT04044560","Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant",[89],"2022-02-02","2020-09-08",[5238,5239,5240],"B-cell Adult Acute Lymphoblastic Leukemia","Stem Cell Leukemia","Minimal Residual Disease",[5223],{"trials":5243,"activeCount":100},[],{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"intervention":5249,"totalTrials":96,"cells":5250},"Fibrosis-Inhibiting-Compound-FS2",{"EARLY_PHASE1":5251,"PHASE1":5253,"PHASE2":5255,"PHASE3":5273,"PHASE4":5275,"NA":5277},{"trials":5252,"activeCount":100},[],{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[5257],{"nctId":5258,"briefTitle":5259,"status":431,"phases":5260,"primaryCompletion":5261,"completion":5262,"start":5263,"enrollment":352,"conditions":5264,"interventions":5272},"NCT04186273","Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.",[89],"2021-02-01","2021-03-01","2019-12-05",[5265,5266,5267,5268,5269,5270,5271],"Scar","Cicatrix","Hypertrophic Scar","Skin Graft Scar","Skin Graft Complications","Donor Site Complication","Keloid",[5249],{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[],{"trials":5278,"activeCount":100},[],{"intervention":1354,"totalTrials":96,"cells":5280},{"EARLY_PHASE1":5281,"PHASE1":5283,"PHASE2":5285,"PHASE3":5291,"PHASE4":5293,"NA":5295},{"trials":5282,"activeCount":100},[],{"trials":5284,"activeCount":100},[],{"trials":5286,"activeCount":100},[5287],{"nctId":1344,"briefTitle":1345,"status":394,"phases":5288,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":5289,"interventions":5290},[89],[1352],[1335,1354],{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[],{"intervention":5298,"totalTrials":96,"cells":5299},"resiquimod",{"EARLY_PHASE1":5300,"PHASE1":5302,"PHASE2":5311,"PHASE3":5313,"PHASE4":5315,"NA":5317},{"trials":5301,"activeCount":100},[],{"trials":5303,"activeCount":100},[5304],{"nctId":5305,"briefTitle":5306,"status":394,"phases":5307,"primaryCompletion":4130,"completion":4130,"start":2208,"enrollment":2732,"conditions":5308,"interventions":5310},"NCT01737580","Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists",[88],[5309],"Influenza Vaccination in Seniors",[5298],{"trials":5312,"activeCount":100},[],{"trials":5314,"activeCount":100},[],{"trials":5316,"activeCount":100},[],{"trials":5318,"activeCount":100},[],{"intervention":5320,"totalTrials":96,"cells":5321},"Methylphenidate",{"EARLY_PHASE1":5322,"PHASE1":5324,"PHASE2":5336,"PHASE3":5338,"PHASE4":5340,"NA":5342},{"trials":5323,"activeCount":100},[],{"trials":5325,"activeCount":100},[5326],{"nctId":5327,"briefTitle":5328,"status":431,"phases":5329,"primaryCompletion":3571,"completion":3571,"start":5330,"enrollment":5331,"conditions":5332,"interventions":5334},"NCT04273880","Differences by Sex and Genotype in the Effects of Stress on Executive Functions",[88],"2018-04-28",146,[5333],"Stress",[5320,5335],"Vitamin C",{"trials":5337,"activeCount":100},[],{"trials":5339,"activeCount":100},[],{"trials":5341,"activeCount":100},[],{"trials":5343,"activeCount":100},[],{"intervention":5335,"totalTrials":96,"cells":5345},{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5354,"PHASE3":5356,"PHASE4":5358,"NA":5360},{"trials":5347,"activeCount":100},[],{"trials":5349,"activeCount":100},[5350],{"nctId":5327,"briefTitle":5328,"status":431,"phases":5351,"primaryCompletion":3571,"completion":3571,"start":5330,"enrollment":5331,"conditions":5352,"interventions":5353},[88],[5333],[5320,5335],{"trials":5355,"activeCount":100},[],{"trials":5357,"activeCount":100},[],{"trials":5359,"activeCount":100},[],{"trials":5361,"activeCount":100},[],{"intervention":5363,"totalTrials":96,"cells":5364},"Lidocaine 2% Injectable Solution",{"EARLY_PHASE1":5365,"PHASE1":5367,"PHASE2":5380,"PHASE3":5382,"PHASE4":5384,"NA":5386},{"trials":5366,"activeCount":100},[],{"trials":5368,"activeCount":100},[5369],{"nctId":5370,"briefTitle":5371,"status":394,"phases":5372,"primaryCompletion":5373,"completion":5373,"start":5374,"enrollment":279,"conditions":5375,"interventions":5378},"NCT03806595","A Pilot Study of Intranasal Lidocaine in Acute Management of Pediatric Migraine",[88],"2020-12-03","2019-07-03",[5376,5377],"Migraine in Children","Posttraumatic Headache",[5363,5379],"Normal Saline Flush, 0.9% Injectable Solution",{"trials":5381,"activeCount":100},[],{"trials":5383,"activeCount":100},[],{"trials":5385,"activeCount":100},[],{"trials":5387,"activeCount":100},[],{"intervention":5379,"totalTrials":96,"cells":5389},{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5398,"PHASE3":5400,"PHASE4":5402,"NA":5404},{"trials":5391,"activeCount":100},[],{"trials":5393,"activeCount":100},[5394],{"nctId":5370,"briefTitle":5371,"status":394,"phases":5395,"primaryCompletion":5373,"completion":5373,"start":5374,"enrollment":279,"conditions":5396,"interventions":5397},[88],[5376,5377],[5363,5379],{"trials":5399,"activeCount":100},[],{"trials":5401,"activeCount":100},[],{"trials":5403,"activeCount":100},[],{"trials":5405,"activeCount":100},[],{"intervention":5407,"totalTrials":96,"cells":5408},"Ametop cream",{"EARLY_PHASE1":5409,"PHASE1":5411,"PHASE2":5419,"PHASE3":5421,"PHASE4":5423,"NA":5425},{"trials":5410,"activeCount":100},[],{"trials":5412,"activeCount":100},[5413],{"nctId":5414,"briefTitle":5415,"status":394,"phases":5416,"primaryCompletion":975,"completion":975,"start":878,"enrollment":9,"conditions":5417,"interventions":5418},"NCT01864213","Efficacy of Ametop Cream in Reducing Pain of Local Anesthetic Infiltration",[88],[33],[5407],{"trials":5420,"activeCount":100},[],{"trials":5422,"activeCount":100},[],{"trials":5424,"activeCount":100},[],{"trials":5426,"activeCount":100},[],{"intervention":5428,"totalTrials":96,"cells":5429},"Fluviral 2009\u002F10",{"EARLY_PHASE1":5430,"PHASE1":5432,"PHASE2":5441,"PHASE3":5443,"PHASE4":5445,"NA":5447},{"trials":5431,"activeCount":100},[],{"trials":5433,"activeCount":100},[5434],{"nctId":5435,"briefTitle":5436,"status":1458,"phases":5437,"primaryCompletion":1715,"completion":2486,"start":2769,"enrollment":5438,"conditions":5439,"interventions":5440},"NCT00966342","Rapid Evaluation of Seasonal Influenza Vaccine",[88],300,[2489],[5428],{"trials":5442,"activeCount":100},[],{"trials":5444,"activeCount":100},[],{"trials":5446,"activeCount":100},[],{"trials":5448,"activeCount":100},[],{"intervention":5450,"totalTrials":96,"cells":5451},"Topical TXA",{"EARLY_PHASE1":5452,"PHASE1":5463,"PHASE2":5465,"PHASE3":5467,"PHASE4":5469,"NA":5471},{"trials":5453,"activeCount":100},[5454],{"nctId":5455,"briefTitle":5456,"status":431,"phases":5457,"primaryCompletion":433,"completion":433,"start":965,"enrollment":5458,"conditions":5459,"interventions":5461},"NCT02093988","Topical Tranexamic Acid in Major Paediatric Spine Deformity Surgery: A Randomized Controlled Trial",[87],160,[5460],"Spinal Deformity, Paediatric Surgery, Tranexamic Acid",[5450,5462],"Intravenous TXA",{"trials":5464,"activeCount":100},[],{"trials":5466,"activeCount":100},[],{"trials":5468,"activeCount":100},[],{"trials":5470,"activeCount":100},[],{"trials":5472,"activeCount":100},[],{"intervention":5462,"totalTrials":96,"cells":5474},{"EARLY_PHASE1":5475,"PHASE1":5481,"PHASE2":5483,"PHASE3":5485,"PHASE4":5487,"NA":5489},{"trials":5476,"activeCount":100},[5477],{"nctId":5455,"briefTitle":5456,"status":431,"phases":5478,"primaryCompletion":433,"completion":433,"start":965,"enrollment":5458,"conditions":5479,"interventions":5480},[87],[5460],[5450,5462],{"trials":5482,"activeCount":100},[],{"trials":5484,"activeCount":100},[],{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"intervention":5492,"totalTrials":96,"cells":5493},"Cefazolin",{"EARLY_PHASE1":5494,"PHASE1":5504,"PHASE2":5506,"PHASE3":5508,"PHASE4":5510,"NA":5512},{"trials":5495,"activeCount":100},[5496],{"nctId":5497,"briefTitle":5498,"status":431,"phases":5499,"primaryCompletion":5500,"completion":5500,"start":1691,"enrollment":141,"conditions":5501,"interventions":5503},"NCT03853096","P.Acnes Colony Count Following Subdermal Cefazolin",[87],"2020-04-01",[3350,5502],"Microbial Colonization",[5492],{"trials":5505,"activeCount":100},[],{"trials":5507,"activeCount":100},[],{"trials":5509,"activeCount":100},[],{"trials":5511,"activeCount":100},[],{"trials":5513,"activeCount":100},[],{"intervention":5515,"totalTrials":96,"cells":5516},"Telmisartan 80mg",{"EARLY_PHASE1":5517,"PHASE1":5527,"PHASE2":5529,"PHASE3":5531,"PHASE4":5533,"NA":5535},{"trials":5518,"activeCount":100},[5519],{"nctId":5520,"briefTitle":5521,"status":1458,"phases":5522,"primaryCompletion":363,"completion":363,"start":5523,"enrollment":100,"conditions":5524,"interventions":5526},"NCT04021550","Improving 24-hour Blood Pressure in Obstructive Sleep Apnea",[87],"2023-05",[5525],"Obstructive Sleep Apnea",[5515],{"trials":5528,"activeCount":100},[],{"trials":5530,"activeCount":100},[],{"trials":5532,"activeCount":100},[],{"trials":5534,"activeCount":100},[],{"trials":5536,"activeCount":100},[],{"intervention":5538,"totalTrials":5539,"cells":5540},"Propofol",7,{"EARLY_PHASE1":5541,"PHASE1":5543,"PHASE2":5545,"PHASE3":5557,"PHASE4":5568,"NA":5578},{"trials":5542,"activeCount":100},[],{"trials":5544,"activeCount":100},[],{"trials":5546,"activeCount":100},[5547],{"nctId":5548,"briefTitle":5549,"status":394,"phases":5550,"primaryCompletion":5551,"completion":5551,"start":1347,"enrollment":279,"conditions":5552,"interventions":5554},"NCT01216007","A Pilot Study to Investigate Plasma Bupivacaine Concentrations in Children Receiving Total Intravenous Anaesthesia and Caudal Analgesia",[88,89],"2012-10",[5553],"Anesthesia",[5555,5556],"propofol","sevoflurane",{"trials":5558,"activeCount":100},[5559],{"nctId":5560,"briefTitle":5561,"status":394,"phases":5562,"primaryCompletion":1460,"completion":2791,"start":5563,"enrollment":5564,"conditions":5565,"interventions":5567},"NCT00734383","Propofol Cardioprotection for Type II Diabetics",[89,90],"2005-04",137,[5566],"Myocardial Injury",[5538,5538],{"trials":5569,"activeCount":100},[5570],{"nctId":5571,"briefTitle":5572,"status":431,"phases":5573,"primaryCompletion":5574,"completion":3571,"start":5575,"enrollment":471,"conditions":5576,"interventions":5577},"NCT04164264","Genetic Differences in Propofol Pharmacodynamics in Children",[91],"2023-10-26","2020-03-11",[5553],[5538],{"trials":5579,"activeCount":100},[5580,5591,5599,5606],{"nctId":5581,"briefTitle":5582,"status":431,"phases":5583,"primaryCompletion":5584,"completion":5585,"start":5586,"enrollment":492,"conditions":5587,"interventions":5590},"NCT02699801","Dexmedetomidine Use in ICU Sedation and Postoperative Recovery in Elderly Patients and Post-cardiac Surgery",[92],"2017-10","2018-02","2016-01",[1645,5588,5589],"Cognitive Decline","Post-operative Quality of Recovery",[5555,3577],{"nctId":5592,"briefTitle":5593,"status":394,"phases":5594,"primaryCompletion":3056,"completion":3056,"start":3127,"enrollment":5595,"conditions":5596,"interventions":5598},"NCT00885443","Emergence Delirium in Children: Total Intravenous Anesthesia With Propofol and Remifentanil Versus Inhalational Sevoflurane Anesthesia",[92],112,[5597],"Emergence Delirium",[5538,5556],{"nctId":5600,"briefTitle":5601,"status":394,"phases":5602,"primaryCompletion":2769,"completion":2769,"start":3126,"enrollment":785,"conditions":5603,"interventions":5605},"NCT00358618","The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats",[92],[5604],"Myocardial Repolarization",[5538],{"nctId":5607,"briefTitle":5608,"status":394,"phases":5609,"primaryCompletion":5610,"completion":2769,"start":4726,"enrollment":168,"conditions":5611,"interventions":5613},"NCT00832013","Safe Administration of Propofol for Sedation in Children",[92],"2009-03",[5612],"Sedation",[5538,5538],{"intervention":3577,"totalTrials":5615,"cells":5616},6,{"EARLY_PHASE1":5617,"PHASE1":5619,"PHASE2":5621,"PHASE3":5623,"PHASE4":5629,"NA":5659},{"trials":5618,"activeCount":100},[],{"trials":5620,"activeCount":100},[],{"trials":5622,"activeCount":100},[],{"trials":5624,"activeCount":100},[5625],{"nctId":3567,"briefTitle":3568,"status":431,"phases":5626,"primaryCompletion":3570,"completion":3571,"start":3572,"enrollment":141,"conditions":5627,"interventions":5628},[89,90],[3574,3575],[3577,3556],{"trials":5630,"activeCount":100},[5631,5642,5652],{"nctId":5632,"briefTitle":5633,"status":394,"phases":5634,"primaryCompletion":5635,"completion":5635,"start":5636,"enrollment":5637,"conditions":5638,"interventions":5640},"NCT03422978","The Effects of Dexmedetomidine on Intravenous Anesthetic Requirements for Children Undergoing Dental Procedures",[91],"2021-04-01","2018-03-14",88,[5639],"Anesthetic Sparing",[3577,5641],"Normal saline",{"nctId":5643,"briefTitle":5644,"status":431,"phases":5645,"primaryCompletion":5646,"completion":5647,"start":5648,"enrollment":1422,"conditions":5649,"interventions":5651},"NCT03806777","Intra-nasal Dexmedetomidine for Children Undergoing MRI Imaging",[91],"2020-03","2020-10","2019-02",[5650],"MRI Sedation",[3577],{"nctId":5653,"briefTitle":5654,"status":394,"phases":5655,"primaryCompletion":5656,"completion":1612,"start":1666,"enrollment":904,"conditions":5657,"interventions":5658},"NCT02353169","The Effects of Dexmedetomidine on the Heart Beat During Elective Surgery in Children",[91],"2017-09",[5604,21],[3577,1622],{"trials":5660,"activeCount":100},[5661,5669],{"nctId":5662,"briefTitle":5663,"status":394,"phases":5664,"primaryCompletion":5665,"completion":5665,"start":2393,"enrollment":22,"conditions":5666,"interventions":5668},"NCT01498380","The Bolus Dose of Dexmedetomidine (ED50) That Avoids Hemodynamic Compromise in Children",[92],"2013-09",[5667],"Hemodynamic Instability",[3577],{"nctId":5581,"briefTitle":5582,"status":431,"phases":5670,"primaryCompletion":5584,"completion":5585,"start":5586,"enrollment":492,"conditions":5671,"interventions":5672},[92],[1645,5588,5589],[5555,3577],{"intervention":5674,"totalTrials":860,"cells":5675},"Ondansetron",{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5680,"PHASE3":5689,"PHASE4":5691,"NA":5693},{"trials":5677,"activeCount":100},[],{"trials":5679,"activeCount":100},[],{"trials":5681,"activeCount":100},[5682],{"nctId":5683,"briefTitle":5684,"status":394,"phases":5685,"primaryCompletion":2884,"completion":2884,"start":2367,"enrollment":1488,"conditions":5686,"interventions":5688},"NCT01841606","The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries",[89],[5687],"Cardiac Output",[5674],{"trials":5690,"activeCount":100},[],{"trials":5692,"activeCount":100},[],{"trials":5694,"activeCount":100},[5695,5704,5715],{"nctId":5696,"briefTitle":5697,"status":394,"phases":5698,"primaryCompletion":5699,"completion":5699,"start":3261,"enrollment":5700,"conditions":5701,"interventions":5703},"NCT02436798","5-HT3 Antagonists (Antiemetics) and Cardiac Safety",[],"2020-08",266,[5702],"Adverse Reaction to Other Drugs and Medicines",[5674],{"nctId":5705,"briefTitle":5706,"status":394,"phases":5707,"primaryCompletion":5708,"completion":5708,"start":5709,"enrollment":4352,"conditions":5710,"interventions":5712},"NCT04169828","The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis",[92],"2025-01-17","2019-08-02",[5711],"Juvenile Idiopathic Arthritis",[5713,5674,5714],"Methotrexate","Folic\u002Ffolinic acid",{"nctId":5716,"briefTitle":5717,"status":394,"phases":5718,"primaryCompletion":5719,"completion":5719,"start":5720,"enrollment":5721,"conditions":5722,"interventions":5724},"NCT02966041","Prophylactic Ondansetron in Post-op Cardiac Surgery Patients to Prevent Post-operative Nausea and Vomiting",[92],"2018-07-11","2018-03-06",186,[5723],"Postoperative Nausea and Vomiting",[5674,1622],{"intervention":3204,"totalTrials":860,"cells":5726},{"EARLY_PHASE1":5727,"PHASE1":5729,"PHASE2":5731,"PHASE3":5733,"PHASE4":5739,"NA":5755},{"trials":5728,"activeCount":100},[],{"trials":5730,"activeCount":100},[],{"trials":5732,"activeCount":100},[],{"trials":5734,"activeCount":100},[5735],{"nctId":3196,"briefTitle":3197,"status":394,"phases":5736,"primaryCompletion":3056,"completion":3056,"start":3199,"enrollment":3200,"conditions":5737,"interventions":5738},[90],[2839],[3185,3203,3204,3205],{"trials":5740,"activeCount":100},[5741,5749],{"nctId":5742,"briefTitle":5743,"status":394,"phases":5744,"completion":1839,"start":5745,"enrollment":1445,"conditions":5746,"interventions":5748},"NCT00272584","CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia",[91],"2001-06",[5747],"Psychosis, Schizophrenia",[3204],{"nctId":5750,"briefTitle":5751,"status":394,"phases":5752,"primaryCompletion":1347,"completion":1347,"start":2710,"enrollment":279,"conditions":5753,"interventions":5754},"NCT00272597","Risperidone LA Heathcare Resource Study",[91],[1465,1463],[3204],{"trials":5756,"activeCount":100},[5757],{"nctId":5758,"briefTitle":5759,"status":431,"phases":5760,"primaryCompletion":1486,"completion":1486,"start":3874,"enrollment":785,"conditions":5761,"interventions":5763},"NCT02334904","Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI",[],[5762,473],"First-Episode Psychosis",[5764,3204],"Aripiprazole",{"intervention":1622,"totalTrials":374,"cells":5766},{"EARLY_PHASE1":5767,"PHASE1":5769,"PHASE2":5771,"PHASE3":5773,"PHASE4":5775,"NA":5785},{"trials":5768,"activeCount":100},[],{"trials":5770,"activeCount":100},[],{"trials":5772,"activeCount":100},[],{"trials":5774,"activeCount":100},[],{"trials":5776,"activeCount":100},[5777,5781],{"nctId":1609,"briefTitle":1610,"status":431,"phases":5778,"primaryCompletion":963,"completion":1612,"start":1613,"enrollment":1614,"conditions":5779,"interventions":5780},[91],[1616,1617,1618,1619,1620],[1596,1622],{"nctId":5653,"briefTitle":5654,"status":394,"phases":5782,"primaryCompletion":5656,"completion":1612,"start":1666,"enrollment":904,"conditions":5783,"interventions":5784},[91],[5604,21],[3577,1622],{"trials":5786,"activeCount":100},[5787],{"nctId":5716,"briefTitle":5717,"status":394,"phases":5788,"primaryCompletion":5719,"completion":5719,"start":5720,"enrollment":5721,"conditions":5789,"interventions":5790},[92],[5723],[5674,1622],{"intervention":5792,"totalTrials":374,"cells":5793},"Sildenafil",{"EARLY_PHASE1":5794,"PHASE1":5796,"PHASE2":5798,"PHASE3":5800,"PHASE4":5813,"NA":5815},{"trials":5795,"activeCount":100},[],{"trials":5797,"activeCount":100},[],{"trials":5799,"activeCount":100},[],{"trials":5801,"activeCount":100},[5802],{"nctId":5803,"briefTitle":5804,"status":1360,"phases":5805,"primaryCompletion":5806,"completion":5807,"start":5808,"enrollment":22,"conditions":5809,"interventions":5812},"NCT02442492","Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction",[89,90],"2018-07","2019-04","2017-01",[5810,5811],"Intrauterine Growth Restriction (IUGR)","Fetal Growth Restriction (FGR)",[5792],{"trials":5814,"activeCount":100},[],{"trials":5816,"activeCount":100},[5817,5827],{"nctId":5818,"briefTitle":5819,"status":394,"phases":5820,"primaryCompletion":5821,"completion":5822,"start":5823,"enrollment":599,"conditions":5824,"interventions":5826},"NCT03710369","Endurance Performance at Altitude",[92],"2018-10-01","2018-10-02","2015-11-01",[5825,1387,5792,1040],"Altitude",[5792],{"nctId":5828,"briefTitle":5829,"status":1458,"phases":5830,"primaryCompletion":5831,"completion":5831,"start":5635,"enrollment":100,"conditions":5832,"interventions":5834},"NCT04122105","PDE5i Use in Renal Transplant Recipients",[92],"2023-01-01",[5833],"Renal Transplant Failure",[5792],{"intervention":5836,"totalTrials":374,"cells":5837},"Magnesium Sulfate",{"EARLY_PHASE1":5838,"PHASE1":5840,"PHASE2":5842,"PHASE3":5844,"PHASE4":5846,"NA":5848},{"trials":5839,"activeCount":100},[],{"trials":5841,"activeCount":100},[],{"trials":5843,"activeCount":100},[],{"trials":5845,"activeCount":100},[],{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[5850,5863,5871],{"nctId":5851,"briefTitle":5852,"status":431,"phases":5853,"primaryCompletion":5854,"completion":2251,"start":5855,"enrollment":1445,"conditions":5856,"interventions":5859},"NCT03296579","Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma",[92],"2018-11","2018-06",[5857,5858],"Asthma Acute","Asthma in Children",[5860,5836,5861,5862],"Ipratropium","Aminophylline","Standard steroid dose, hourly salbutamol, oxygen as needed",{"nctId":5864,"briefTitle":5865,"status":1836,"phases":5866,"primaryCompletion":1642,"completion":1642,"start":5867,"enrollment":5868,"conditions":5869,"interventions":5870},"NCT03439358","Magnesium for Shivering in Epidural Lidocaine Deliveries",[92],"2018-06-11",90,[5553],[5836],{"nctId":5872,"briefTitle":5873,"status":394,"phases":5874,"primaryCompletion":5875,"completion":5855,"start":5665,"enrollment":5876,"conditions":5877,"interventions":5880},"NCT01911494","Community Level Interventions for Pre-eclampsia",[92],"2018-05",87500,[5878,5879],"Pre-eclampsia","Hypertension, Pregnancy Induced",[5836,5881],"Methyldopa",{"intervention":1817,"totalTrials":374,"cells":5883},{"EARLY_PHASE1":5884,"PHASE1":5886,"PHASE2":5888,"PHASE3":5890,"PHASE4":5892,"NA":5902},{"trials":5885,"activeCount":100},[],{"trials":5887,"activeCount":100},[],{"trials":5889,"activeCount":100},[],{"trials":5891,"activeCount":100},[],{"trials":5893,"activeCount":100},[5894,5898],{"nctId":5632,"briefTitle":5633,"status":394,"phases":5895,"primaryCompletion":5635,"completion":5635,"start":5636,"enrollment":5637,"conditions":5896,"interventions":5897},[91],[5639],[3577,5641],{"nctId":1809,"briefTitle":1810,"status":394,"phases":5899,"primaryCompletion":1812,"completion":1812,"start":1813,"enrollment":168,"conditions":5900,"interventions":5901},[91],[33,1815],[1796,1817],{"trials":5903,"activeCount":100},[5904],{"nctId":5905,"briefTitle":5906,"status":394,"phases":5907,"primaryCompletion":2689,"completion":2689,"start":4141,"enrollment":279,"conditions":5908,"interventions":5910},"NCT00474162","The Clotting Effects of Pentastarch and Normal Saline in Obstetric Patients",[92],[5909],"Elective Cesarean Section",[5911,1817],"Pentaspan®",{"intervention":5913,"totalTrials":374,"cells":5914},"Botox",{"EARLY_PHASE1":5915,"PHASE1":5917,"PHASE2":5926,"PHASE3":5928,"PHASE4":5930,"NA":5932},{"trials":5916,"activeCount":100},[],{"trials":5918,"activeCount":100},[5919],{"nctId":5920,"briefTitle":5921,"status":1458,"phases":5922,"primaryCompletion":2689,"completion":2689,"start":3418,"enrollment":100,"conditions":5923,"interventions":5925},"NCT00175604","Comparative Trial of Botox in the Management of Children With Congenital Muscular Torticollis",[88],[5924],"Torticollis",[5913],{"trials":5927,"activeCount":100},[],{"trials":5929,"activeCount":100},[],{"trials":5931,"activeCount":100},[],{"trials":5933,"activeCount":100},[5934,5942],{"nctId":5935,"briefTitle":5936,"status":394,"phases":5937,"primaryCompletion":1487,"completion":5938,"start":2710,"enrollment":624,"conditions":5939,"interventions":5941},"NCT00152334","Efficacy of Botox in Patients With Idiopathic Clubfoot",[92],"2018-10",[5940],"Idiopathic Clubfoot (Talipes Equinovarus)",[5913],{"nctId":5943,"briefTitle":5944,"status":394,"phases":5945,"primaryCompletion":4173,"completion":4173,"start":2710,"enrollment":4495,"conditions":5946,"interventions":5947},"NCT00152347","A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot",[92],[5940],[5913],{"intervention":1331,"totalTrials":374,"cells":5949},{"EARLY_PHASE1":5950,"PHASE1":5952,"PHASE2":5954,"PHASE3":5956,"PHASE4":5958,"NA":5968},{"trials":5951,"activeCount":100},[],{"trials":5953,"activeCount":100},[],{"trials":5955,"activeCount":100},[],{"trials":5957,"activeCount":100},[],{"trials":5959,"activeCount":100},[5960,5964],{"nctId":1418,"briefTitle":1419,"status":394,"phases":5961,"primaryCompletion":963,"completion":963,"start":1421,"enrollment":1422,"conditions":5962,"interventions":5963},[91],[1424],[1426,1427,1428,1331,1429,1430,1394],{"nctId":1321,"briefTitle":1322,"status":394,"phases":5965,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":1326,"conditions":5966,"interventions":5967},[91],[1328,1329],[1331,1288],{"trials":5969,"activeCount":100},[5970],{"nctId":5971,"briefTitle":5972,"status":394,"phases":5973,"primaryCompletion":5974,"completion":5974,"start":5975,"enrollment":2160,"conditions":5976,"interventions":5978},"NCT03065569","A Comparison of Epidural Techniques for Labour Analgesia",[92],"2018-05-07","2017-05-07",[5977],"Labour Analgesia",[1331],{"intervention":1317,"totalTrials":374,"cells":5980},{"EARLY_PHASE1":5981,"PHASE1":5983,"PHASE2":5985,"PHASE3":5987,"PHASE4":5997,"NA":5999},{"trials":5982,"activeCount":100},[],{"trials":5984,"activeCount":100},[],{"trials":5986,"activeCount":100},[],{"trials":5988,"activeCount":100},[5989,5993],{"nctId":3339,"briefTitle":3340,"status":431,"phases":5990,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":3345,"conditions":5991,"interventions":5992},[89,90],[3347,3348,3349,3350],[3328,1317],{"nctId":1308,"briefTitle":1309,"status":394,"phases":5994,"primaryCompletion":1311,"completion":1311,"start":1312,"enrollment":11,"conditions":5995,"interventions":5996},[90],[1314,1315],[1288,1317],{"trials":5998,"activeCount":100},[],{"trials":6000,"activeCount":100},[6001],{"nctId":6002,"briefTitle":6003,"status":394,"phases":6004,"primaryCompletion":3057,"completion":2709,"start":3032,"enrollment":2160,"conditions":6005,"interventions":6007},"NCT00257803","Does the Rapid Intravenous Administration of Oxytocin After Delivery of the Baby Decrease the Bleeding During Cesarean Section in Women at Risk of Bleeding During Cesarean Section?",[92],[6006],"Postpartum Hemorrhage",[6008,6009],"Oxytocin","Saline solution",{"intervention":6011,"totalTrials":341,"cells":6012},"Trientine Hydrochloride",{"EARLY_PHASE1":6013,"PHASE1":6015,"PHASE2":6017,"PHASE3":6026,"PHASE4":6028,"NA":6030},{"trials":6014,"activeCount":100},[],{"trials":6016,"activeCount":100},[],{"trials":6018,"activeCount":100},[6019],{"nctId":6020,"briefTitle":6021,"status":1458,"phases":6022,"enrollment":100,"conditions":6023,"interventions":6025},"NCT01295073","Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus",[89],[6024],"Macular Edema Following Cataract Surgery",[6011],{"trials":6027,"activeCount":100},[],{"trials":6029,"activeCount":100},[],{"trials":6031,"activeCount":100},[6032],{"nctId":6033,"briefTitle":6034,"status":1360,"phases":6035,"primaryCompletion":2208,"completion":2208,"start":2836,"enrollment":374,"conditions":6036,"interventions":6038},"NCT01213888","Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy",[92],[6037],"Diabetic Retinopathy",[6011,6039],"Oral placebo",{"intervention":5556,"totalTrials":341,"cells":6041},{"EARLY_PHASE1":6042,"PHASE1":6044,"PHASE2":6046,"PHASE3":6052,"PHASE4":6054,"NA":6056},{"trials":6043,"activeCount":100},[],{"trials":6045,"activeCount":100},[],{"trials":6047,"activeCount":100},[6048],{"nctId":5548,"briefTitle":5549,"status":394,"phases":6049,"primaryCompletion":5551,"completion":5551,"start":1347,"enrollment":279,"conditions":6050,"interventions":6051},[88,89],[5553],[5555,5556],{"trials":6053,"activeCount":100},[],{"trials":6055,"activeCount":100},[],{"trials":6057,"activeCount":100},[6058],{"nctId":5592,"briefTitle":5593,"status":394,"phases":6059,"primaryCompletion":3056,"completion":3056,"start":3127,"enrollment":5595,"conditions":6060,"interventions":6061},[92],[5597],[5538,5556],{"intervention":6063,"totalTrials":341,"cells":6064},"Polysporin ointment",{"EARLY_PHASE1":6065,"PHASE1":6067,"PHASE2":6069,"PHASE3":6071,"PHASE4":6077,"NA":6079},{"trials":6066,"activeCount":100},[],{"trials":6068,"activeCount":100},[],{"trials":6070,"activeCount":100},[],{"trials":6072,"activeCount":100},[6073],{"nctId":3612,"briefTitle":3613,"status":431,"phases":6074,"primaryCompletion":3615,"completion":3615,"start":3616,"enrollment":1445,"conditions":6075,"interventions":6076},[89,90],[3618],[3601,3620],{"trials":6078,"activeCount":100},[],{"trials":6080,"activeCount":100},[6081],{"nctId":6082,"briefTitle":6083,"status":394,"phases":6084,"primaryCompletion":4812,"completion":3261,"start":1586,"enrollment":6085,"conditions":6086,"interventions":6088},"NCT01608880","Effect of Nitroglycerin Ointment on Mastectomy Flap Necrosis",[92],154,[6087],"Mastectomy Flap Necrosis",[6089,6063],"nitroglycerin ointment",{"intervention":1429,"totalTrials":341,"cells":6091},{"EARLY_PHASE1":6092,"PHASE1":6094,"PHASE2":6096,"PHASE3":6098,"PHASE4":6100,"NA":6106},{"trials":6093,"activeCount":100},[],{"trials":6095,"activeCount":100},[],{"trials":6097,"activeCount":100},[],{"trials":6099,"activeCount":100},[],{"trials":6101,"activeCount":100},[6102],{"nctId":1418,"briefTitle":1419,"status":394,"phases":6103,"primaryCompletion":963,"completion":963,"start":1421,"enrollment":1422,"conditions":6104,"interventions":6105},[91],[1424],[1426,1427,1428,1331,1429,1430,1394],{"trials":6107,"activeCount":100},[6108],{"nctId":6109,"briefTitle":6110,"status":431,"phases":6111,"primaryCompletion":2438,"completion":3570,"start":4701,"enrollment":1384,"conditions":6112,"interventions":6115},"NCT05619887","Muscle Reflex Inhibition in Hypoxic Exercise",[92],[6113,6114],"Dyspnea","Muscle Strain",[1429],{"intervention":6117,"totalTrials":341,"cells":6118},"Fecal microbiota transplantation",{"EARLY_PHASE1":6119,"PHASE1":6121,"PHASE2":6123,"PHASE3":6125,"PHASE4":6127,"NA":6129},{"trials":6120,"activeCount":100},[],{"trials":6122,"activeCount":100},[],{"trials":6124,"activeCount":100},[],{"trials":6126,"activeCount":100},[],{"trials":6128,"activeCount":100},[],{"trials":6130,"activeCount":100},[6131,6140],{"nctId":6132,"briefTitle":6133,"status":1360,"phases":6134,"primaryCompletion":6135,"completion":6135,"start":6136,"enrollment":374,"conditions":6137,"interventions":6139},"NCT02906774","Fecal Transplant for MDR Pathogen Decolonization",[],"2019-11","2016-04",[6138],"Multi-antibiotic Resistance",[6117],{"nctId":6141,"briefTitle":6142,"status":431,"phases":6143,"primaryCompletion":6144,"completion":6145,"start":6146,"enrollment":5868,"conditions":6147,"interventions":6148},"NCT04181112","Fecal Transplant for MDRO Decolonization",[92],"2022-11","2023-11","2019-11-04",[6138],[6149],"Fecal Microbiota Transplantation",{"intervention":6151,"totalTrials":341,"cells":6152},"Rosuvastatin",{"EARLY_PHASE1":6153,"PHASE1":6155,"PHASE2":6157,"PHASE3":6159,"PHASE4":6161,"NA":6170},{"trials":6154,"activeCount":100},[],{"trials":6156,"activeCount":100},[],{"trials":6158,"activeCount":100},[],{"trials":6160,"activeCount":100},[],{"trials":6162,"activeCount":100},[6163],{"nctId":6164,"briefTitle":6165,"status":1360,"phases":6166,"primaryCompletion":2709,"completion":2367,"start":1461,"enrollment":2277,"conditions":6167,"interventions":6169},"NCT00673582","Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients",[91],[6168,1719],"Atherosclerosis",[6151],{"trials":6171,"activeCount":100},[6172],{"nctId":6173,"briefTitle":6174,"status":394,"phases":6175,"primaryCompletion":876,"completion":2135,"start":4110,"enrollment":3852,"conditions":6176,"interventions":6178},"NCT00908011","Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets",[92],[6177,1719],"Hypercholesterolemia",[6179,6151],"Ezetimibe",{"intervention":5764,"totalTrials":341,"cells":6181},{"EARLY_PHASE1":6182,"PHASE1":6184,"PHASE2":6186,"PHASE3":6188,"PHASE4":6190,"NA":6192},{"trials":6183,"activeCount":100},[],{"trials":6185,"activeCount":100},[],{"trials":6187,"activeCount":100},[],{"trials":6189,"activeCount":100},[],{"trials":6191,"activeCount":100},[],{"trials":6193,"activeCount":100},[6194,6198],{"nctId":5758,"briefTitle":5759,"status":431,"phases":6195,"primaryCompletion":1486,"completion":1486,"start":3874,"enrollment":785,"conditions":6196,"interventions":6197},[],[5762,473],[5764,3204],{"nctId":6199,"briefTitle":6200,"status":394,"phases":6201,"primaryCompletion":1643,"completion":1643,"start":3851,"enrollment":6202,"conditions":6203,"interventions":6205},"NCT01739127","Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI",[],83,[1971,473,6204],"Metabolic Syndrome X",[5764,6206],"Risperidone\u002FQuetiapine",{"intervention":6208,"totalTrials":341,"cells":6209},"Standard Bowel Prep",{"EARLY_PHASE1":6210,"PHASE1":6212,"PHASE2":6214,"PHASE3":6216,"PHASE4":6218,"NA":6220},{"trials":6211,"activeCount":100},[],{"trials":6213,"activeCount":100},[],{"trials":6215,"activeCount":100},[],{"trials":6217,"activeCount":100},[],{"trials":6219,"activeCount":100},[],{"trials":6221,"activeCount":100},[6222,6233],{"nctId":6223,"briefTitle":6224,"status":394,"phases":6225,"primaryCompletion":6226,"completion":5665,"start":1862,"enrollment":6227,"conditions":6228,"interventions":6231},"NCT01398020","Comparing 2L Bi-Pegyte to 4L PegLyte Regiments for Outpatient Colonic Preparation",[92],"2012-09",318,[6229,6230],"Efficacy of Bowel Preparation","Ease of Bowel Preparation and Patient Tolerability",[6208,6232],"2L Bi-Peglyte Bowel Prep",{"nctId":6234,"briefTitle":6235,"status":1458,"phases":6236,"primaryCompletion":1460,"completion":1460,"start":1444,"enrollment":100,"conditions":6237,"interventions":6238},"NCT01452737","Comparing 4L Golytely to 2L Golytely With 15mg Bisacodyl Regimens for Inpatient Colonic Preparation",[92],[2211],[6208,6239],"2L Golytely\u002Fbisacodyl",{"intervention":6008,"totalTrials":341,"cells":6241},{"EARLY_PHASE1":6242,"PHASE1":6244,"PHASE2":6246,"PHASE3":6248,"PHASE4":6250,"NA":6252},{"trials":6243,"activeCount":100},[],{"trials":6245,"activeCount":100},[],{"trials":6247,"activeCount":100},[],{"trials":6249,"activeCount":100},[],{"trials":6251,"activeCount":100},[],{"trials":6253,"activeCount":100},[6254,6261],{"nctId":6255,"briefTitle":6256,"status":394,"phases":6257,"primaryCompletion":6258,"completion":6258,"start":1813,"enrollment":352,"conditions":6259,"interventions":6260},"NCT02415920","The Influence of Intranasal Oxytocin on Communication",[92],"2018-12-12",[21],[6008],{"nctId":6002,"briefTitle":6003,"status":394,"phases":6262,"primaryCompletion":3057,"completion":2709,"start":3032,"enrollment":2160,"conditions":6263,"interventions":6264},[92],[6006],[6008,6009],{"intervention":6266,"totalTrials":341,"cells":6267},"Triamcinolone acetonide",{"EARLY_PHASE1":6268,"PHASE1":6270,"PHASE2":6272,"PHASE3":6282,"PHASE4":6284,"NA":6286},{"trials":6269,"activeCount":100},[],{"trials":6271,"activeCount":100},[],{"trials":6273,"activeCount":100},[6274],{"nctId":6275,"briefTitle":6276,"status":431,"phases":6277,"primaryCompletion":3371,"completion":5586,"start":4788,"enrollment":28,"conditions":6278,"interventions":6280},"NCT01766609","Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo",[89],[6279],"Vitiligo",[6281],"Triamcinolone Acetonide",{"trials":6283,"activeCount":100},[],{"trials":6285,"activeCount":100},[],{"trials":6287,"activeCount":100},[6288],{"nctId":6289,"briefTitle":6290,"status":394,"phases":6291,"primaryCompletion":3874,"completion":3874,"start":2826,"enrollment":2757,"conditions":6292,"interventions":6294},"NCT01246284","The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata",[92],[6293],"Alopecia Areata",[6266],{"intervention":5860,"totalTrials":96,"cells":6296},{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6301,"PHASE3":6303,"PHASE4":6305,"NA":6307},{"trials":6298,"activeCount":100},[],{"trials":6300,"activeCount":100},[],{"trials":6302,"activeCount":100},[],{"trials":6304,"activeCount":100},[],{"trials":6306,"activeCount":100},[],{"trials":6308,"activeCount":100},[6309],{"nctId":5851,"briefTitle":5852,"status":431,"phases":6310,"primaryCompletion":5854,"completion":2251,"start":5855,"enrollment":1445,"conditions":6311,"interventions":6312},[92],[5857,5858],[5860,5836,5861,5862],{"intervention":5861,"totalTrials":96,"cells":6314},{"EARLY_PHASE1":6315,"PHASE1":6317,"PHASE2":6319,"PHASE3":6321,"PHASE4":6323,"NA":6325},{"trials":6316,"activeCount":100},[],{"trials":6318,"activeCount":100},[],{"trials":6320,"activeCount":100},[],{"trials":6322,"activeCount":100},[],{"trials":6324,"activeCount":100},[],{"trials":6326,"activeCount":100},[6327],{"nctId":5851,"briefTitle":5852,"status":431,"phases":6328,"primaryCompletion":5854,"completion":2251,"start":5855,"enrollment":1445,"conditions":6329,"interventions":6330},[92],[5857,5858],[5860,5836,5861,5862],{"intervention":5862,"totalTrials":96,"cells":6332},{"EARLY_PHASE1":6333,"PHASE1":6335,"PHASE2":6337,"PHASE3":6339,"PHASE4":6341,"NA":6343},{"trials":6334,"activeCount":100},[],{"trials":6336,"activeCount":100},[],{"trials":6338,"activeCount":100},[],{"trials":6340,"activeCount":100},[],{"trials":6342,"activeCount":100},[],{"trials":6344,"activeCount":100},[6345],{"nctId":5851,"briefTitle":5852,"status":431,"phases":6346,"primaryCompletion":5854,"completion":2251,"start":5855,"enrollment":1445,"conditions":6347,"interventions":6348},[92],[5857,5858],[5860,5836,5861,5862],{"intervention":6350,"totalTrials":96,"cells":6351},"Pharmacological agent: Citalopram",{"EARLY_PHASE1":6352,"PHASE1":6354,"PHASE2":6356,"PHASE3":6358,"PHASE4":6360,"NA":6362},{"trials":6353,"activeCount":100},[],{"trials":6355,"activeCount":100},[],{"trials":6357,"activeCount":100},[],{"trials":6359,"activeCount":100},[],{"trials":6361,"activeCount":100},[],{"trials":6363,"activeCount":100},[6364],{"nctId":6365,"briefTitle":6366,"status":431,"phases":6367,"primaryCompletion":2960,"completion":2960,"start":2959,"enrollment":36,"conditions":6368,"interventions":6370},"NCT05957094","Human Cerebral Blood Flow and Serotonin",[92],[35,6369],"Serotonin Deficiency",[6350],{"intervention":198,"totalTrials":96,"cells":6372},{"EARLY_PHASE1":6373,"PHASE1":6375,"PHASE2":6377,"PHASE3":6379,"PHASE4":6381,"NA":6383},{"trials":6374,"activeCount":100},[],{"trials":6376,"activeCount":100},[],{"trials":6378,"activeCount":100},[],{"trials":6380,"activeCount":100},[],{"trials":6382,"activeCount":100},[],{"trials":6384,"activeCount":100},[6385],{"nctId":6386,"briefTitle":6387,"status":394,"phases":6388,"primaryCompletion":6389,"completion":6390,"start":6391,"enrollment":279,"conditions":6392,"interventions":6395},"NCT01265537","A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf",[92],"2019-02-21","2019-10-11","2011-06-24",[6393,6394],"Acute Graft Rejection","Diabetes",[198,198],{"intervention":6397,"totalTrials":96,"cells":6398},"Plasmalyte",{"EARLY_PHASE1":6399,"PHASE1":6401,"PHASE2":6403,"PHASE3":6405,"PHASE4":6407,"NA":6409},{"trials":6400,"activeCount":100},[],{"trials":6402,"activeCount":100},[],{"trials":6404,"activeCount":100},[],{"trials":6406,"activeCount":100},[],{"trials":6408,"activeCount":100},[],{"trials":6410,"activeCount":100},[6411],{"nctId":6412,"briefTitle":6413,"status":1360,"phases":6414,"primaryCompletion":5586,"completion":5586,"start":1943,"enrollment":1384,"conditions":6415,"interventions":6417},"NCT02463175","Effects of Goal-directed Fluid Therapy on Post-operative Outcomes in Children Undergoing Scoliosis Repair",[92],[6416,2913],"Scoliosis",[6397],{"intervention":6419,"totalTrials":96,"cells":6420},"Salbutamol inhalation",{"EARLY_PHASE1":6421,"PHASE1":6423,"PHASE2":6425,"PHASE3":6427,"PHASE4":6429,"NA":6431},{"trials":6422,"activeCount":100},[],{"trials":6424,"activeCount":100},[],{"trials":6426,"activeCount":100},[],{"trials":6428,"activeCount":100},[],{"trials":6430,"activeCount":100},[],{"trials":6432,"activeCount":100},[6433],{"nctId":6434,"briefTitle":6435,"status":394,"phases":6436,"primaryCompletion":877,"completion":2110,"start":2462,"enrollment":141,"conditions":6437,"interventions":6440},"NCT02252302","Exercise in Air Pollution and Lung Health in Asthmatics",[92],[6438,6439],"Exercise-induced Bronchoconstriction","Air Pollution",[6419],{"intervention":6442,"totalTrials":96,"cells":6443},"Botulinum Toxin",{"EARLY_PHASE1":6444,"PHASE1":6446,"PHASE2":6448,"PHASE3":6450,"PHASE4":6452,"NA":6454},{"trials":6445,"activeCount":100},[],{"trials":6447,"activeCount":100},[],{"trials":6449,"activeCount":100},[],{"trials":6451,"activeCount":100},[],{"trials":6453,"activeCount":100},[],{"trials":6455,"activeCount":100},[6456],{"nctId":6457,"briefTitle":6458,"status":431,"phases":6459,"primaryCompletion":3572,"completion":3572,"start":6460,"enrollment":6461,"conditions":6462,"interventions":6464},"NCT00474032","Using Botox to Treat Patients With Idiopathic Clubfoot",[92],"2003-03",2000,[6463],"Clubfoot",[6442],{"intervention":6089,"totalTrials":96,"cells":6466},{"EARLY_PHASE1":6467,"PHASE1":6469,"PHASE2":6471,"PHASE3":6473,"PHASE4":6475,"NA":6477},{"trials":6468,"activeCount":100},[],{"trials":6470,"activeCount":100},[],{"trials":6472,"activeCount":100},[],{"trials":6474,"activeCount":100},[],{"trials":6476,"activeCount":100},[],{"trials":6478,"activeCount":100},[6479],{"nctId":6082,"briefTitle":6083,"status":394,"phases":6480,"primaryCompletion":4812,"completion":3261,"start":1586,"enrollment":6085,"conditions":6481,"interventions":6482},[92],[6087],[6089,6063],{"intervention":6484,"totalTrials":96,"cells":6485},"Choline supplementation",{"EARLY_PHASE1":6486,"PHASE1":6488,"PHASE2":6490,"PHASE3":6492,"PHASE4":6494,"NA":6496},{"trials":6487,"activeCount":100},[],{"trials":6489,"activeCount":100},[],{"trials":6491,"activeCount":100},[],{"trials":6493,"activeCount":100},[],{"trials":6495,"activeCount":100},[],{"trials":6497,"activeCount":100},[6498],{"nctId":6499,"briefTitle":6500,"status":394,"phases":6501,"primaryCompletion":2158,"completion":2158,"start":3417,"enrollment":6502,"conditions":6503,"interventions":6504},"NCT00686361","Choline Nutrition in Children With Cystic Fibrosis (CF)",[92],34,[30],[6484],{"intervention":5911,"totalTrials":96,"cells":6506},{"EARLY_PHASE1":6507,"PHASE1":6509,"PHASE2":6511,"PHASE3":6513,"PHASE4":6515,"NA":6517},{"trials":6508,"activeCount":100},[],{"trials":6510,"activeCount":100},[],{"trials":6512,"activeCount":100},[],{"trials":6514,"activeCount":100},[],{"trials":6516,"activeCount":100},[],{"trials":6518,"activeCount":100},[6519],{"nctId":5905,"briefTitle":5906,"status":394,"phases":6520,"primaryCompletion":2689,"completion":2689,"start":4141,"enrollment":279,"conditions":6521,"interventions":6522},[92],[5909],[5911,1817],{"intervention":6524,"totalTrials":96,"cells":6525},"Povidone-iodine",{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6530,"PHASE3":6532,"PHASE4":6534,"NA":6536},{"trials":6527,"activeCount":100},[],{"trials":6529,"activeCount":100},[],{"trials":6531,"activeCount":100},[],{"trials":6533,"activeCount":100},[],{"trials":6535,"activeCount":100},[],{"trials":6537,"activeCount":100},[6538],{"nctId":6539,"briefTitle":6540,"status":394,"phases":6541,"primaryCompletion":2111,"completion":2111,"start":1715,"enrollment":6542,"conditions":6543,"interventions":6545},"NCT00999427","Prostate Biopsy Antisepsis",[92],865,[6544],"Infective Complications Post-transrectal Prostate Biopsy",[6524],{"intervention":6547,"totalTrials":96,"cells":6548},"Calcipotriol, Betamethasone, Calcipotriol & Betamethasone",{"EARLY_PHASE1":6549,"PHASE1":6551,"PHASE2":6553,"PHASE3":6555,"PHASE4":6557,"NA":6559},{"trials":6550,"activeCount":100},[],{"trials":6552,"activeCount":100},[],{"trials":6554,"activeCount":100},[],{"trials":6556,"activeCount":100},[],{"trials":6558,"activeCount":100},[],{"trials":6560,"activeCount":100},[6561],{"nctId":6562,"briefTitle":6563,"status":431,"phases":6564,"primaryCompletion":1408,"completion":2791,"start":3056,"enrollment":2440,"conditions":6565,"interventions":6567},"NCT01413477","Nickel Desensitization Using Topical Therapy",[92],[6566],"Allergic Contact Dermatitis",[6547],{"intervention":6569,"totalTrials":96,"cells":6570},"Intravenous Infusion of Magnesium Sulfate",{"EARLY_PHASE1":6571,"PHASE1":6573,"PHASE2":6575,"PHASE3":6577,"PHASE4":6579,"NA":6581},{"trials":6572,"activeCount":100},[],{"trials":6574,"activeCount":100},[],{"trials":6576,"activeCount":100},[],{"trials":6578,"activeCount":100},[],{"trials":6580,"activeCount":100},[],{"trials":6582,"activeCount":100},[6583],{"nctId":6584,"briefTitle":6585,"status":394,"phases":6586,"primaryCompletion":6587,"completion":6587,"start":6588,"enrollment":6589,"conditions":6590,"interventions":6592},"NCT00423540","Exploring the Role of Magnesium in Rest Cramps",[92],"2008-11","2007-01",54,[6591],"Rest Cramps",[6569],{"intervention":6594,"totalTrials":96,"cells":6595},"Anti-Arrhythmic Drug Therapy",{"EARLY_PHASE1":6596,"PHASE1":6598,"PHASE2":6600,"PHASE3":6602,"PHASE4":6604,"NA":6606},{"trials":6597,"activeCount":100},[],{"trials":6599,"activeCount":100},[],{"trials":6601,"activeCount":100},[],{"trials":6603,"activeCount":100},[],{"trials":6605,"activeCount":100},[],{"trials":6607,"activeCount":100},[6608],{"nctId":6609,"briefTitle":6610,"status":431,"phases":6611,"primaryCompletion":6612,"completion":6144,"start":5808,"enrollment":6613,"conditions":6614,"interventions":6615},"NCT05514860","The Impact of \"First-Line\" Rhythm Therapy on AF Progression",[92],"2022-09",303,[3530],[6594],{"intervention":6617,"totalTrials":96,"cells":6618},"Hydrochlorothiazide",{"EARLY_PHASE1":6619,"PHASE1":6621,"PHASE2":6623,"PHASE3":6625,"PHASE4":6627,"NA":6629},{"trials":6620,"activeCount":100},[],{"trials":6622,"activeCount":100},[],{"trials":6624,"activeCount":100},[],{"trials":6626,"activeCount":100},[],{"trials":6628,"activeCount":100},[],{"trials":6630,"activeCount":100},[6631],{"nctId":6632,"briefTitle":6633,"status":394,"phases":6634,"primaryCompletion":6635,"completion":6635,"start":6636,"enrollment":2160,"conditions":6637,"interventions":6638},"NCT00247910","Behavioural Treatment of Hypertension",[92],"2006-06","2001-10",[3984],[6617],{"intervention":6640,"totalTrials":96,"cells":6641},"Warfarin",{"EARLY_PHASE1":6642,"PHASE1":6644,"PHASE2":6646,"PHASE3":6648,"PHASE4":6650,"NA":6652},{"trials":6643,"activeCount":100},[],{"trials":6645,"activeCount":100},[],{"trials":6647,"activeCount":100},[],{"trials":6649,"activeCount":100},[],{"trials":6651,"activeCount":100},[],{"trials":6653,"activeCount":100},[6654],{"nctId":6655,"briefTitle":6656,"status":394,"phases":6657,"primaryCompletion":1587,"completion":1587,"start":1944,"enrollment":2369,"conditions":6658,"interventions":6659},"NCT00925028","Warfarin Patient Self-Monitoring",[92],[3530],[6640,6640],{"intervention":6661,"totalTrials":96,"cells":6662},"desvenlafaxine",{"EARLY_PHASE1":6663,"PHASE1":6665,"PHASE2":6667,"PHASE3":6669,"PHASE4":6671,"NA":6673},{"trials":6664,"activeCount":100},[],{"trials":6666,"activeCount":100},[],{"trials":6668,"activeCount":100},[],{"trials":6670,"activeCount":100},[],{"trials":6672,"activeCount":100},[],{"trials":6674,"activeCount":100},[6675],{"nctId":6676,"briefTitle":6677,"status":394,"phases":6678,"primaryCompletion":1969,"completion":876,"start":2393,"enrollment":6679,"conditions":6680,"interventions":6681},"NCT01468610","Neurocognition and Work Productivity in Major Depressive Disorder (MDD)",[92],47,[535],[6661],{"intervention":6683,"totalTrials":96,"cells":6684},"Letrozole",{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6689,"PHASE3":6691,"PHASE4":6693,"NA":6695},{"trials":6686,"activeCount":100},[],{"trials":6688,"activeCount":100},[],{"trials":6690,"activeCount":100},[],{"trials":6692,"activeCount":100},[],{"trials":6694,"activeCount":100},[],{"trials":6696,"activeCount":100},[6697],{"nctId":6698,"briefTitle":6699,"status":431,"phases":6700,"primaryCompletion":6701,"completion":6702,"start":1324,"enrollment":6703,"conditions":6704,"interventions":6705},"NCT02630485","Graceful Lifestyle Changes Study for PCOS and Infertility",[92],"2018-03","2018-08",240,[1668,1669],[6683],{"intervention":3347,"totalTrials":96,"cells":6707},{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6712,"PHASE3":6714,"PHASE4":6716,"NA":6718},{"trials":6709,"activeCount":100},[],{"trials":6711,"activeCount":100},[],{"trials":6713,"activeCount":100},[],{"trials":6715,"activeCount":100},[],{"trials":6717,"activeCount":100},[],{"trials":6719,"activeCount":100},[6720],{"nctId":6721,"briefTitle":6722,"status":394,"phases":6723,"primaryCompletion":5065,"completion":5065,"start":6724,"enrollment":785,"conditions":6725,"interventions":6727},"NCT00175370","Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus",[92],"2000-09",[6726],"Staphylococcal Infections",[3347],{"intervention":6729,"totalTrials":96,"cells":6730},"Prazosin HCL",{"EARLY_PHASE1":6731,"PHASE1":6733,"PHASE2":6735,"PHASE3":6737,"PHASE4":6739,"NA":6741},{"trials":6732,"activeCount":100},[],{"trials":6734,"activeCount":100},[],{"trials":6736,"activeCount":100},[],{"trials":6738,"activeCount":100},[],{"trials":6740,"activeCount":100},[],{"trials":6742,"activeCount":100},[6743],{"nctId":6744,"briefTitle":6745,"status":394,"phases":6746,"primaryCompletion":6747,"completion":6747,"start":2276,"enrollment":5539,"conditions":6748,"interventions":6749},"NCT00175682","Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study",[92],"2011-07-28",[5019],[6729],{"intervention":6751,"totalTrials":96,"cells":6752},"Recombinant human activated protein C or drotrecogin alpha",{"EARLY_PHASE1":6753,"PHASE1":6755,"PHASE2":6757,"PHASE3":6759,"PHASE4":6761,"NA":6763},{"trials":6754,"activeCount":100},[],{"trials":6756,"activeCount":100},[],{"trials":6758,"activeCount":100},[],{"trials":6760,"activeCount":100},[],{"trials":6762,"activeCount":100},[],{"trials":6764,"activeCount":100},[6765],{"nctId":6766,"briefTitle":6767,"status":394,"phases":6768,"primaryCompletion":1347,"completion":1347,"start":2276,"enrollment":279,"conditions":6769,"interventions":6770},"NCT00175695","Disease Modification in Toxaemia of Pregnancy",[],[5878],[6751],{"intervention":6772,"totalTrials":96,"cells":6773},"3-5% acetic acid",{"EARLY_PHASE1":6774,"PHASE1":6776,"PHASE2":6778,"PHASE3":6780,"PHASE4":6782,"NA":6784},{"trials":6775,"activeCount":100},[],{"trials":6777,"activeCount":100},[],{"trials":6779,"activeCount":100},[],{"trials":6781,"activeCount":100},[],{"trials":6783,"activeCount":100},[],{"trials":6785,"activeCount":100},[6786],{"nctId":6787,"briefTitle":6788,"status":394,"phases":6789,"primaryCompletion":6790,"completion":6791,"start":4812,"enrollment":624,"conditions":6792,"interventions":6794},"NCT02029794","ASPIRE Pilot: Comparing Self-collected HPV Testing With Visual Inspection With Acetic Acid Screening for Cervical Cancer",[92],"2014-06-30","2015-12-29",[6793],"Cervical Cancer",[6772],{"intervention":6232,"totalTrials":96,"cells":6796},{"EARLY_PHASE1":6797,"PHASE1":6799,"PHASE2":6801,"PHASE3":6803,"PHASE4":6805,"NA":6807},{"trials":6798,"activeCount":100},[],{"trials":6800,"activeCount":100},[],{"trials":6802,"activeCount":100},[],{"trials":6804,"activeCount":100},[],{"trials":6806,"activeCount":100},[],{"trials":6808,"activeCount":100},[6809],{"nctId":6223,"briefTitle":6224,"status":394,"phases":6810,"primaryCompletion":6226,"completion":5665,"start":1862,"enrollment":6227,"conditions":6811,"interventions":6812},[92],[6229,6230],[6208,6232],{"intervention":6814,"totalTrials":96,"cells":6815},"Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders",{"EARLY_PHASE1":6816,"PHASE1":6818,"PHASE2":6820,"PHASE3":6822,"PHASE4":6824,"NA":6826},{"trials":6817,"activeCount":100},[],{"trials":6819,"activeCount":100},[],{"trials":6821,"activeCount":100},[],{"trials":6823,"activeCount":100},[],{"trials":6825,"activeCount":100},[],{"trials":6827,"activeCount":100},[6828],{"nctId":6829,"briefTitle":6830,"status":394,"phases":6831,"primaryCompletion":6832,"completion":6832,"start":6833,"enrollment":2936,"conditions":6834,"interventions":6837},"NCT00897260","Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders",[92],"2013-01-09","2009-05",[6835,6836],"Hematological Malignancy","Bone Marrow Failure Syndrome",[6814],{"intervention":6839,"totalTrials":96,"cells":6840},"Ametop",{"EARLY_PHASE1":6841,"PHASE1":6843,"PHASE2":6845,"PHASE3":6847,"PHASE4":6849,"NA":6851},{"trials":6842,"activeCount":100},[],{"trials":6844,"activeCount":100},[],{"trials":6846,"activeCount":100},[],{"trials":6848,"activeCount":100},[],{"trials":6850,"activeCount":100},[],{"trials":6852,"activeCount":100},[6853],{"nctId":6854,"briefTitle":6855,"status":431,"phases":6856,"primaryCompletion":6857,"completion":6857,"start":6858,"enrollment":6703,"conditions":6859,"interventions":6862},"NCT03749915","Ametop Compared to Ametop With Pain Ease Spray",[92],"2019-12-31","2018-11-20",[6860,6861],"Analgesia","Topical Anesthetic",[6839],{"intervention":6864,"totalTrials":96,"cells":6865},"Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units",{"EARLY_PHASE1":6866,"PHASE1":6868,"PHASE2":6870,"PHASE3":6872,"PHASE4":6874,"NA":6876},{"trials":6867,"activeCount":100},[],{"trials":6869,"activeCount":100},[],{"trials":6871,"activeCount":100},[],{"trials":6873,"activeCount":100},[],{"trials":6875,"activeCount":100},[],{"trials":6877,"activeCount":100},[6878],{"nctId":6879,"briefTitle":6880,"status":394,"phases":6881,"primaryCompletion":6882,"completion":6882,"start":3417,"enrollment":141,"conditions":6883,"interventions":6884},"NCT00408798","Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin",[92],"2009-10-30",[6293],[6864],{"intervention":6886,"totalTrials":96,"cells":6887},"Skin antisepsis",{"EARLY_PHASE1":6888,"PHASE1":6890,"PHASE2":6892,"PHASE3":6894,"PHASE4":6896,"NA":6898},{"trials":6889,"activeCount":100},[],{"trials":6891,"activeCount":100},[],{"trials":6893,"activeCount":100},[],{"trials":6895,"activeCount":100},[],{"trials":6897,"activeCount":100},[],{"trials":6899,"activeCount":100},[6900],{"nctId":6901,"briefTitle":6902,"status":394,"phases":6903,"primaryCompletion":3417,"completion":3417,"start":3032,"enrollment":6904,"conditions":6905,"interventions":6907},"NCT00247897","Comparing Skin Disinfectants Before Labour Epidural Analgesia",[92],195,[6906],"Skin Bacteria",[6886],{"intervention":6909,"totalTrials":96,"cells":6910},"Synthetic cannabinoids",{"EARLY_PHASE1":6911,"PHASE1":6913,"PHASE2":6915,"PHASE3":6917,"PHASE4":6919,"NA":6921},{"trials":6912,"activeCount":100},[],{"trials":6914,"activeCount":100},[],{"trials":6916,"activeCount":100},[],{"trials":6918,"activeCount":100},[],{"trials":6920,"activeCount":100},[],{"trials":6922,"activeCount":100},[6923],{"nctId":6924,"briefTitle":6925,"status":1458,"phases":6926,"primaryCompletion":2884,"completion":2884,"start":4398,"enrollment":100,"conditions":6927,"interventions":6929},"NCT00397605","Cannabinoids in Bipolar Affective Disorder",[92],[6928],"Bipolar Affective Disorder",[6909],{"intervention":6931,"totalTrials":96,"cells":6932},"Rosiglitazone maleate",{"EARLY_PHASE1":6933,"PHASE1":6935,"PHASE2":6937,"PHASE3":6939,"PHASE4":6941,"NA":6943},{"trials":6934,"activeCount":100},[],{"trials":6936,"activeCount":100},[],{"trials":6938,"activeCount":100},[],{"trials":6940,"activeCount":100},[],{"trials":6942,"activeCount":100},[],{"trials":6944,"activeCount":100},[6945],{"nctId":6946,"briefTitle":6947,"status":394,"phases":6948,"primaryCompletion":6949,"completion":6949,"start":6950,"enrollment":352,"conditions":6951,"interventions":6952},"NCT00143624","Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels",[92],"2009-12","2003-06",[6168,1719],[6931],{"intervention":6954,"totalTrials":96,"cells":6955},"30% Mannitol in vehicle cream",{"EARLY_PHASE1":6956,"PHASE1":6958,"PHASE2":6960,"PHASE3":6962,"PHASE4":6964,"NA":6966},{"trials":6957,"activeCount":100},[],{"trials":6959,"activeCount":100},[],{"trials":6961,"activeCount":100},[],{"trials":6963,"activeCount":100},[],{"trials":6965,"activeCount":100},[],{"trials":6967,"activeCount":100},[6968],{"nctId":6969,"briefTitle":6970,"status":394,"phases":6971,"primaryCompletion":6972,"completion":6972,"start":2884,"enrollment":2369,"conditions":6973,"interventions":6974},"NCT01963910","Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream",[92],"2014-01",[33],[6954,6975],"vehicle cream",{"intervention":6975,"totalTrials":96,"cells":6977},{"EARLY_PHASE1":6978,"PHASE1":6980,"PHASE2":6982,"PHASE3":6984,"PHASE4":6986,"NA":6988},{"trials":6979,"activeCount":100},[],{"trials":6981,"activeCount":100},[],{"trials":6983,"activeCount":100},[],{"trials":6985,"activeCount":100},[],{"trials":6987,"activeCount":100},[],{"trials":6989,"activeCount":100},[6990],{"nctId":6969,"briefTitle":6970,"status":394,"phases":6991,"primaryCompletion":6972,"completion":6972,"start":2884,"enrollment":2369,"conditions":6992,"interventions":6993},[92],[33],[6954,6975],{"intervention":6039,"totalTrials":96,"cells":6995},{"EARLY_PHASE1":6996,"PHASE1":6998,"PHASE2":7000,"PHASE3":7002,"PHASE4":7004,"NA":7006},{"trials":6997,"activeCount":100},[],{"trials":6999,"activeCount":100},[],{"trials":7001,"activeCount":100},[],{"trials":7003,"activeCount":100},[],{"trials":7005,"activeCount":100},[],{"trials":7007,"activeCount":100},[7008],{"nctId":6033,"briefTitle":6034,"status":1360,"phases":7009,"primaryCompletion":2208,"completion":2208,"start":2836,"enrollment":374,"conditions":7010,"interventions":7011},[92],[6037],[6011,6039],{"intervention":7013,"totalTrials":96,"cells":7014},"Midodrine",{"EARLY_PHASE1":7015,"PHASE1":7017,"PHASE2":7019,"PHASE3":7021,"PHASE4":7023,"NA":7025},{"trials":7016,"activeCount":100},[],{"trials":7018,"activeCount":100},[],{"trials":7020,"activeCount":100},[],{"trials":7022,"activeCount":100},[],{"trials":7024,"activeCount":100},[],{"trials":7026,"activeCount":100},[7027],{"nctId":7028,"briefTitle":7029,"status":394,"phases":7030,"primaryCompletion":3527,"completion":3527,"start":7031,"enrollment":19,"conditions":7032,"interventions":7034},"NCT01498809","Blood Pressure and Brain Blood Flow Regulation After Midodrine Administration in Those With Spinal Cord Injury",[],"2012-03",[7033],"Orthostatic Intolerance",[7013],{"intervention":7036,"totalTrials":96,"cells":7037},"Dual Therapy",{"EARLY_PHASE1":7038,"PHASE1":7040,"PHASE2":7042,"PHASE3":7044,"PHASE4":7046,"NA":7048},{"trials":7039,"activeCount":100},[],{"trials":7041,"activeCount":100},[],{"trials":7043,"activeCount":100},[],{"trials":7045,"activeCount":100},[],{"trials":7047,"activeCount":100},[],{"trials":7049,"activeCount":100},[7050],{"nctId":7051,"briefTitle":7052,"status":431,"phases":7053,"primaryCompletion":5938,"completion":2251,"start":396,"enrollment":279,"conditions":7054,"interventions":7055},"NCT03435731","Dual Obstructive Sleep Apnea Therapy",[92],[5525],[7036],{"intervention":6179,"totalTrials":96,"cells":7057},{"EARLY_PHASE1":7058,"PHASE1":7060,"PHASE2":7062,"PHASE3":7064,"PHASE4":7066,"NA":7068},{"trials":7059,"activeCount":100},[],{"trials":7061,"activeCount":100},[],{"trials":7063,"activeCount":100},[],{"trials":7065,"activeCount":100},[],{"trials":7067,"activeCount":100},[],{"trials":7069,"activeCount":100},[7070],{"nctId":6173,"briefTitle":6174,"status":394,"phases":7071,"primaryCompletion":876,"completion":2135,"start":4110,"enrollment":3852,"conditions":7072,"interventions":7073},[92],[6177,1719],[6179,6151],{"intervention":7075,"totalTrials":96,"cells":7076},"Azilect",{"EARLY_PHASE1":7077,"PHASE1":7079,"PHASE2":7081,"PHASE3":7083,"PHASE4":7085,"NA":7087},{"trials":7078,"activeCount":100},[],{"trials":7080,"activeCount":100},[],{"trials":7082,"activeCount":100},[],{"trials":7084,"activeCount":100},[],{"trials":7086,"activeCount":100},[],{"trials":7088,"activeCount":100},[7089],{"nctId":7090,"briefTitle":7091,"status":431,"phases":7092,"primaryCompletion":7093,"completion":7093,"start":975,"enrollment":785,"conditions":7094,"interventions":7096},"NCT02207387","Ambulosono Rasagiline Musical Walking Study",[92],"2017-03",[7095],"Parkinson's Disease",[7075],{"intervention":7098,"totalTrials":96,"cells":7099},"Blood samples for whole genomic\u002Ftranscriptomic sequencing",{"EARLY_PHASE1":7100,"PHASE1":7102,"PHASE2":7104,"PHASE3":7106,"PHASE4":7108,"NA":7110},{"trials":7101,"activeCount":100},[],{"trials":7103,"activeCount":100},[],{"trials":7105,"activeCount":100},[],{"trials":7107,"activeCount":100},[],{"trials":7109,"activeCount":100},[],{"trials":7111,"activeCount":100},[7112],{"nctId":7113,"briefTitle":7114,"status":431,"phases":7115,"primaryCompletion":5806,"completion":5806,"start":3874,"enrollment":7116,"conditions":7117,"interventions":7118},"NCT02322918","The BC Psychosis Program Biobank and Database for Genetic Polymorphisms and Their Associations With Psychosis Disorder",[],200,[1465,1463],[7098],{"intervention":7120,"totalTrials":96,"cells":7121},"Colchicine 0.6 mg",{"EARLY_PHASE1":7122,"PHASE1":7124,"PHASE2":7126,"PHASE3":7128,"PHASE4":7130,"NA":7132},{"trials":7123,"activeCount":100},[],{"trials":7125,"activeCount":100},[],{"trials":7127,"activeCount":100},[],{"trials":7129,"activeCount":100},[],{"trials":7131,"activeCount":100},[],{"trials":7133,"activeCount":100},[7134],{"nctId":7135,"briefTitle":7136,"status":1458,"phases":7137,"primaryCompletion":4444,"completion":7138,"start":7139,"enrollment":100,"conditions":7140,"interventions":7144},"NCT04139655","Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study",[92],"2021-10-01","2020-09-01",[7141,5566,7142,7143],"Myocardial Infarction","Major Adverse Cardiac Events","Infectious Complications",[7120],{"intervention":7146,"totalTrials":96,"cells":7147},"Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS",{"EARLY_PHASE1":7148,"PHASE1":7150,"PHASE2":7152,"PHASE3":7154,"PHASE4":7156,"NA":7158},{"trials":7149,"activeCount":100},[],{"trials":7151,"activeCount":100},[],{"trials":7153,"activeCount":100},[],{"trials":7155,"activeCount":100},[],{"trials":7157,"activeCount":100},[],{"trials":7159,"activeCount":100},[7160],{"nctId":7161,"briefTitle":7162,"status":394,"phases":7163,"primaryCompletion":7164,"completion":7164,"start":7165,"enrollment":7166,"conditions":7167,"interventions":7169},"NCT04472975","Prescription Drug Safety and Effectiveness in Multiple Sclerosis",[],"2018-03-31","1996-01-01",35000,[7168],"Multiple Sclerosis",[7146],{"intervention":7171,"totalTrials":96,"cells":7172},"Thoracic paravertebral block",{"EARLY_PHASE1":7173,"PHASE1":7175,"PHASE2":7177,"PHASE3":7179,"PHASE4":7181,"NA":7183},{"trials":7174,"activeCount":100},[],{"trials":7176,"activeCount":100},[],{"trials":7178,"activeCount":100},[],{"trials":7180,"activeCount":100},[],{"trials":7182,"activeCount":100},[],{"trials":7184,"activeCount":100},[7185],{"nctId":7186,"briefTitle":7187,"status":431,"phases":7188,"primaryCompletion":7189,"completion":2960,"start":7190,"enrollment":279,"conditions":7191,"interventions":7196},"NCT04860843","Nerve Blocks in Alloplastic Breast Reconstruction",[92],"2024-05","2021-05-01",[7192,7193,7194,7195],"Surgery, Plastic","Mastectomy","Nerve Block","Breast Reconstruction",[7171,7197,7198],"Pecs block","Sham Pecs block",{"intervention":7197,"totalTrials":96,"cells":7200},{"EARLY_PHASE1":7201,"PHASE1":7203,"PHASE2":7205,"PHASE3":7207,"PHASE4":7209,"NA":7211},{"trials":7202,"activeCount":100},[],{"trials":7204,"activeCount":100},[],{"trials":7206,"activeCount":100},[],{"trials":7208,"activeCount":100},[],{"trials":7210,"activeCount":100},[],{"trials":7212,"activeCount":100},[7213],{"nctId":7186,"briefTitle":7187,"status":431,"phases":7214,"primaryCompletion":7189,"completion":2960,"start":7190,"enrollment":279,"conditions":7215,"interventions":7216},[92],[7192,7193,7194,7195],[7171,7197,7198],{"intervention":7198,"totalTrials":96,"cells":7218},{"EARLY_PHASE1":7219,"PHASE1":7221,"PHASE2":7223,"PHASE3":7225,"PHASE4":7227,"NA":7229},{"trials":7220,"activeCount":100},[],{"trials":7222,"activeCount":100},[],{"trials":7224,"activeCount":100},[],{"trials":7226,"activeCount":100},[],{"trials":7228,"activeCount":100},[],{"trials":7230,"activeCount":100},[7231],{"nctId":7186,"briefTitle":7187,"status":431,"phases":7232,"primaryCompletion":7189,"completion":2960,"start":7190,"enrollment":279,"conditions":7233,"interventions":7234},[92],[7192,7193,7194,7195],[7171,7197,7198],{"intervention":7236,"totalTrials":96,"cells":7237},"Fingolimod",{"EARLY_PHASE1":7238,"PHASE1":7240,"PHASE2":7242,"PHASE3":7244,"PHASE4":7246,"NA":7248},{"trials":7239,"activeCount":100},[],{"trials":7241,"activeCount":100},[],{"trials":7243,"activeCount":100},[],{"trials":7245,"activeCount":100},[],{"trials":7247,"activeCount":100},[],{"trials":7249,"activeCount":100},[7250],{"nctId":7251,"briefTitle":7252,"status":394,"phases":7253,"primaryCompletion":7254,"completion":7254,"start":7255,"enrollment":7256,"conditions":7257,"interventions":7263},"NCT06705608","Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study",[],"2020-12-31","2003-01-01",4000,[7168,7258,7259,7260,7261,7262],"Skin Cancer","Skin Cancer Melanoma","Skin Cancers - Basal Cell Carcinoma","Skin Cancer, Squamous Cell","Multiple Sclerosis (MS) - Relapsing-remitting",[7236,7264,7265,7266,7267],"Natalizumab","Dimethyl fumarate","Alemtuzumab","Teriflunomide",{"intervention":7264,"totalTrials":96,"cells":7269},{"EARLY_PHASE1":7270,"PHASE1":7272,"PHASE2":7274,"PHASE3":7276,"PHASE4":7278,"NA":7280},{"trials":7271,"activeCount":100},[],{"trials":7273,"activeCount":100},[],{"trials":7275,"activeCount":100},[],{"trials":7277,"activeCount":100},[],{"trials":7279,"activeCount":100},[],{"trials":7281,"activeCount":100},[7282],{"nctId":7251,"briefTitle":7252,"status":394,"phases":7283,"primaryCompletion":7254,"completion":7254,"start":7255,"enrollment":7256,"conditions":7284,"interventions":7285},[],[7168,7258,7259,7260,7261,7262],[7236,7264,7265,7266,7267],{"intervention":7265,"totalTrials":96,"cells":7287},{"EARLY_PHASE1":7288,"PHASE1":7290,"PHASE2":7292,"PHASE3":7294,"PHASE4":7296,"NA":7298},{"trials":7289,"activeCount":100},[],{"trials":7291,"activeCount":100},[],{"trials":7293,"activeCount":100},[],{"trials":7295,"activeCount":100},[],{"trials":7297,"activeCount":100},[],{"trials":7299,"activeCount":100},[7300],{"nctId":7251,"briefTitle":7252,"status":394,"phases":7301,"primaryCompletion":7254,"completion":7254,"start":7255,"enrollment":7256,"conditions":7302,"interventions":7303},[],[7168,7258,7259,7260,7261,7262],[7236,7264,7265,7266,7267],{"intervention":7266,"totalTrials":96,"cells":7305},{"EARLY_PHASE1":7306,"PHASE1":7308,"PHASE2":7310,"PHASE3":7312,"PHASE4":7314,"NA":7316},{"trials":7307,"activeCount":100},[],{"trials":7309,"activeCount":100},[],{"trials":7311,"activeCount":100},[],{"trials":7313,"activeCount":100},[],{"trials":7315,"activeCount":100},[],{"trials":7317,"activeCount":100},[7318],{"nctId":7251,"briefTitle":7252,"status":394,"phases":7319,"primaryCompletion":7254,"completion":7254,"start":7255,"enrollment":7256,"conditions":7320,"interventions":7321},[],[7168,7258,7259,7260,7261,7262],[7236,7264,7265,7266,7267],{"intervention":7267,"totalTrials":96,"cells":7323},{"EARLY_PHASE1":7324,"PHASE1":7326,"PHASE2":7328,"PHASE3":7330,"PHASE4":7332,"NA":7334},{"trials":7325,"activeCount":100},[],{"trials":7327,"activeCount":100},[],{"trials":7329,"activeCount":100},[],{"trials":7331,"activeCount":100},[],{"trials":7333,"activeCount":100},[],{"trials":7335,"activeCount":100},[7336],{"nctId":7251,"briefTitle":7252,"status":394,"phases":7337,"primaryCompletion":7254,"completion":7254,"start":7255,"enrollment":7256,"conditions":7338,"interventions":7339},[],[7168,7258,7259,7260,7261,7262],[7236,7264,7265,7266,7267],{"intervention":7341,"totalTrials":96,"cells":7342},"Megstrol Acetate",{"EARLY_PHASE1":7343,"PHASE1":7345,"PHASE2":7347,"PHASE3":7349,"PHASE4":7351,"NA":7353},{"trials":7344,"activeCount":100},[],{"trials":7346,"activeCount":100},[],{"trials":7348,"activeCount":100},[],{"trials":7350,"activeCount":100},[],{"trials":7352,"activeCount":100},[],{"trials":7354,"activeCount":100},[7355],{"nctId":7356,"briefTitle":7357,"status":394,"phases":7358,"primaryCompletion":1409,"completion":1409,"start":407,"enrollment":7359,"conditions":7360,"interventions":7362},"NCT00439101","A Randomized Clinical Trial of Megestrol Acetate as an Appetite Stimulant in Malnourished Children With Cancer",[92],26,[7361],"Malnourished Children With Cancer",[7341],{"intervention":7364,"totalTrials":96,"cells":7365},"Conversion to Advagraf",{"EARLY_PHASE1":7366,"PHASE1":7368,"PHASE2":7370,"PHASE3":7372,"PHASE4":7374,"NA":7376},{"trials":7367,"activeCount":100},[],{"trials":7369,"activeCount":100},[],{"trials":7371,"activeCount":100},[],{"trials":7373,"activeCount":100},[],{"trials":7375,"activeCount":100},[],{"trials":7377,"activeCount":100},[7378],{"nctId":7379,"briefTitle":7380,"status":431,"phases":7381,"primaryCompletion":7382,"completion":3571,"start":6136,"enrollment":7383,"conditions":7384,"interventions":7386},"NCT02426502","Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients",[92],"2022-08-10",76,[7385],"End-Stage Renal Disease",[7364,7387,7388],"conversion of non-immunosuppressant drugs to once daily","Conversion to once daily MPA",{"intervention":7387,"totalTrials":96,"cells":7390},{"EARLY_PHASE1":7391,"PHASE1":7393,"PHASE2":7395,"PHASE3":7397,"PHASE4":7399,"NA":7401},{"trials":7392,"activeCount":100},[],{"trials":7394,"activeCount":100},[],{"trials":7396,"activeCount":100},[],{"trials":7398,"activeCount":100},[],{"trials":7400,"activeCount":100},[],{"trials":7402,"activeCount":100},[7403],{"nctId":7379,"briefTitle":7380,"status":431,"phases":7404,"primaryCompletion":7382,"completion":3571,"start":6136,"enrollment":7383,"conditions":7405,"interventions":7406},[92],[7385],[7364,7387,7388],{"intervention":7388,"totalTrials":96,"cells":7408},{"EARLY_PHASE1":7409,"PHASE1":7411,"PHASE2":7413,"PHASE3":7415,"PHASE4":7417,"NA":7419},{"trials":7410,"activeCount":100},[],{"trials":7412,"activeCount":100},[],{"trials":7414,"activeCount":100},[],{"trials":7416,"activeCount":100},[],{"trials":7418,"activeCount":100},[],{"trials":7420,"activeCount":100},[7421],{"nctId":7379,"briefTitle":7380,"status":431,"phases":7422,"primaryCompletion":7382,"completion":3571,"start":6136,"enrollment":7383,"conditions":7423,"interventions":7424},[92],[7385],[7364,7387,7388],{"intervention":5713,"totalTrials":96,"cells":7426},{"EARLY_PHASE1":7427,"PHASE1":7429,"PHASE2":7431,"PHASE3":7433,"PHASE4":7435,"NA":7437},{"trials":7428,"activeCount":100},[],{"trials":7430,"activeCount":100},[],{"trials":7432,"activeCount":100},[],{"trials":7434,"activeCount":100},[],{"trials":7436,"activeCount":100},[],{"trials":7438,"activeCount":100},[7439],{"nctId":5705,"briefTitle":5706,"status":394,"phases":7440,"primaryCompletion":5708,"completion":5708,"start":5709,"enrollment":4352,"conditions":7441,"interventions":7442},[92],[5711],[5713,5674,5714],{"intervention":5714,"totalTrials":96,"cells":7444},{"EARLY_PHASE1":7445,"PHASE1":7447,"PHASE2":7449,"PHASE3":7451,"PHASE4":7453,"NA":7455},{"trials":7446,"activeCount":100},[],{"trials":7448,"activeCount":100},[],{"trials":7450,"activeCount":100},[],{"trials":7452,"activeCount":100},[],{"trials":7454,"activeCount":100},[],{"trials":7456,"activeCount":100},[7457],{"nctId":5705,"briefTitle":5706,"status":394,"phases":7458,"primaryCompletion":5708,"completion":5708,"start":5709,"enrollment":4352,"conditions":7459,"interventions":7460},[92],[5711],[5713,5674,5714],{"intervention":6206,"totalTrials":96,"cells":7462},{"EARLY_PHASE1":7463,"PHASE1":7465,"PHASE2":7467,"PHASE3":7469,"PHASE4":7471,"NA":7473},{"trials":7464,"activeCount":100},[],{"trials":7466,"activeCount":100},[],{"trials":7468,"activeCount":100},[],{"trials":7470,"activeCount":100},[],{"trials":7472,"activeCount":100},[],{"trials":7474,"activeCount":100},[7475],{"nctId":6199,"briefTitle":6200,"status":394,"phases":7476,"primaryCompletion":1643,"completion":1643,"start":3851,"enrollment":6202,"conditions":7477,"interventions":7478},[],[1971,473,6204],[5764,6206],{"intervention":7480,"totalTrials":96,"cells":7481},"Pyridoxine",{"EARLY_PHASE1":7482,"PHASE1":7484,"PHASE2":7486,"PHASE3":7488,"PHASE4":7490,"NA":7492},{"trials":7483,"activeCount":100},[],{"trials":7485,"activeCount":100},[],{"trials":7487,"activeCount":100},[],{"trials":7489,"activeCount":100},[],{"trials":7491,"activeCount":100},[],{"trials":7493,"activeCount":100},[7494],{"nctId":7495,"briefTitle":7496,"status":1458,"phases":7497,"primaryCompletion":1532,"completion":1532,"start":2208,"enrollment":100,"conditions":7498,"interventions":7500},"NCT01795170","Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients",[],[7499],"Pyridoxine Dependant Epilepsy",[7480],{"intervention":7502,"totalTrials":96,"cells":7503},"Esp protein",{"EARLY_PHASE1":7504,"PHASE1":7506,"PHASE2":7508,"PHASE3":7510,"PHASE4":7512,"NA":7514},{"trials":7505,"activeCount":100},[],{"trials":7507,"activeCount":100},[],{"trials":7509,"activeCount":100},[],{"trials":7511,"activeCount":100},[],{"trials":7513,"activeCount":100},[],{"trials":7515,"activeCount":100},[7516],{"nctId":7517,"briefTitle":7518,"status":1458,"phases":7519,"primaryCompletion":1324,"completion":1324,"start":3874,"enrollment":100,"conditions":7520,"interventions":7524},"NCT01646502","Treatment of Chronic Wound Biofilms",[92],[7521,7522,7523],"Chronic Wound","Venous Insufficiency","Biofilms",[7502],{"intervention":7526,"totalTrials":96,"cells":7527},"Botulinum toxin A",{"EARLY_PHASE1":7528,"PHASE1":7530,"PHASE2":7532,"PHASE3":7534,"PHASE4":7536,"NA":7538},{"trials":7529,"activeCount":100},[],{"trials":7531,"activeCount":100},[],{"trials":7533,"activeCount":100},[],{"trials":7535,"activeCount":100},[],{"trials":7537,"activeCount":100},[],{"trials":7539,"activeCount":100},[7540],{"nctId":7541,"briefTitle":7542,"status":394,"phases":7543,"primaryCompletion":2135,"completion":2135,"start":5551,"enrollment":2757,"conditions":7544,"interventions":7545},"NCT01635504","HIV Posterior Cheek Enlargement",[92],[7542],[7526],{"intervention":7547,"totalTrials":96,"cells":7548},"droperidol and saline",{"EARLY_PHASE1":7549,"PHASE1":7551,"PHASE2":7553,"PHASE3":7555,"PHASE4":7557,"NA":7559},{"trials":7550,"activeCount":100},[],{"trials":7552,"activeCount":100},[],{"trials":7554,"activeCount":100},[],{"trials":7556,"activeCount":100},[],{"trials":7558,"activeCount":100},[],{"trials":7560,"activeCount":100},[7561],{"nctId":7562,"briefTitle":7563,"status":394,"phases":7564,"primaryCompletion":2769,"completion":2769,"start":2689,"enrollment":2962,"conditions":7565,"interventions":7566},"NCT00624208","The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats",[92],[5604],[7547,7567,7568,7569],"ondansetron and saline","droperidol and ondansetron","saline and saline",{"intervention":7567,"totalTrials":96,"cells":7571},{"EARLY_PHASE1":7572,"PHASE1":7574,"PHASE2":7576,"PHASE3":7578,"PHASE4":7580,"NA":7582},{"trials":7573,"activeCount":100},[],{"trials":7575,"activeCount":100},[],{"trials":7577,"activeCount":100},[],{"trials":7579,"activeCount":100},[],{"trials":7581,"activeCount":100},[],{"trials":7583,"activeCount":100},[7584],{"nctId":7562,"briefTitle":7563,"status":394,"phases":7585,"primaryCompletion":2769,"completion":2769,"start":2689,"enrollment":2962,"conditions":7586,"interventions":7587},[92],[5604],[7547,7567,7568,7569],{"intervention":7568,"totalTrials":96,"cells":7589},{"EARLY_PHASE1":7590,"PHASE1":7592,"PHASE2":7594,"PHASE3":7596,"PHASE4":7598,"NA":7600},{"trials":7591,"activeCount":100},[],{"trials":7593,"activeCount":100},[],{"trials":7595,"activeCount":100},[],{"trials":7597,"activeCount":100},[],{"trials":7599,"activeCount":100},[],{"trials":7601,"activeCount":100},[7602],{"nctId":7562,"briefTitle":7563,"status":394,"phases":7603,"primaryCompletion":2769,"completion":2769,"start":2689,"enrollment":2962,"conditions":7604,"interventions":7605},[92],[5604],[7547,7567,7568,7569],{"intervention":7569,"totalTrials":96,"cells":7607},{"EARLY_PHASE1":7608,"PHASE1":7610,"PHASE2":7612,"PHASE3":7614,"PHASE4":7616,"NA":7618},{"trials":7609,"activeCount":100},[],{"trials":7611,"activeCount":100},[],{"trials":7613,"activeCount":100},[],{"trials":7615,"activeCount":100},[],{"trials":7617,"activeCount":100},[],{"trials":7619,"activeCount":100},[7620],{"nctId":7562,"briefTitle":7563,"status":394,"phases":7621,"primaryCompletion":2769,"completion":2769,"start":2689,"enrollment":2962,"conditions":7622,"interventions":7623},[92],[5604],[7547,7567,7568,7569],{"intervention":7625,"totalTrials":96,"cells":7626},"Chlorhexidine gluconate",{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7631,"PHASE3":7633,"PHASE4":7635,"NA":7637},{"trials":7628,"activeCount":100},[],{"trials":7630,"activeCount":100},[],{"trials":7632,"activeCount":100},[],{"trials":7634,"activeCount":100},[],{"trials":7636,"activeCount":100},[],{"trials":7638,"activeCount":100},[7639],{"nctId":7640,"briefTitle":7641,"status":394,"phases":7642,"primaryCompletion":3261,"completion":3261,"start":3461,"enrollment":141,"conditions":7643,"interventions":7645},"NCT02095535","Chlorhexidine Drying Time",[],[7644],"Drying Time",[7625],{"intervention":5881,"totalTrials":96,"cells":7647},{"EARLY_PHASE1":7648,"PHASE1":7650,"PHASE2":7652,"PHASE3":7654,"PHASE4":7656,"NA":7658},{"trials":7649,"activeCount":100},[],{"trials":7651,"activeCount":100},[],{"trials":7653,"activeCount":100},[],{"trials":7655,"activeCount":100},[],{"trials":7657,"activeCount":100},[],{"trials":7659,"activeCount":100},[7660],{"nctId":5872,"briefTitle":5873,"status":394,"phases":7661,"primaryCompletion":5875,"completion":5855,"start":5665,"enrollment":5876,"conditions":7662,"interventions":7663},[92],[5878,5879],[5836,5881],{"intervention":7665,"totalTrials":96,"cells":7666},"Interferon injections and ribavirin",{"EARLY_PHASE1":7667,"PHASE1":7669,"PHASE2":7671,"PHASE3":7673,"PHASE4":7675,"NA":7677},{"trials":7668,"activeCount":100},[],{"trials":7670,"activeCount":100},[],{"trials":7672,"activeCount":100},[],{"trials":7674,"activeCount":100},[],{"trials":7676,"activeCount":100},[],{"trials":7678,"activeCount":100},[7679],{"nctId":7680,"briefTitle":7681,"status":394,"phases":7682,"primaryCompletion":2158,"completion":2709,"start":4789,"enrollment":7683,"conditions":7684,"interventions":7686},"NCT00399672","Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)",[92],370,[7685],"Hepatitis C Virus Infection",[7665,7665],{"intervention":7688,"totalTrials":96,"cells":7689},"Zoladex ®",{"EARLY_PHASE1":7690,"PHASE1":7692,"PHASE2":7694,"PHASE3":7696,"PHASE4":7698,"NA":7700},{"trials":7691,"activeCount":100},[],{"trials":7693,"activeCount":100},[],{"trials":7695,"activeCount":100},[],{"trials":7697,"activeCount":100},[],{"trials":7699,"activeCount":100},[],{"trials":7701,"activeCount":100},[7702],{"nctId":7703,"briefTitle":7704,"status":431,"phases":7705,"primaryCompletion":3571,"completion":3571,"start":6136,"enrollment":2962,"conditions":7706,"interventions":7707},"NCT02594072","Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)",[92],[667],[7688],{"intervention":6239,"totalTrials":96,"cells":7709},{"EARLY_PHASE1":7710,"PHASE1":7712,"PHASE2":7714,"PHASE3":7716,"PHASE4":7718,"NA":7720},{"trials":7711,"activeCount":100},[],{"trials":7713,"activeCount":100},[],{"trials":7715,"activeCount":100},[],{"trials":7717,"activeCount":100},[],{"trials":7719,"activeCount":100},[],{"trials":7721,"activeCount":100},[7722],{"nctId":6234,"briefTitle":6235,"status":1458,"phases":7723,"primaryCompletion":1460,"completion":1460,"start":1444,"enrollment":100,"conditions":7724,"interventions":7725},[92],[2211],[6208,6239]]